Novel peptides and scaffolds for immunotherapy of head and neck squamous cell carcinoma and other cancers
By developing a new peptide sequence that binds to HLA-I molecules, the problems of large side effects and high cost in the treatment of head and neck squamous cell carcinoma are solved, effective anti-tumor immune response and diagnostic prediction are achieved, and treatment efficiency is improved.
Patent Information
- Application Number
- CN202411183035.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-08-26
- Filing Date
- 2017-08-24
- Publication Date
- 2024-12-03
AI Technical Summary
Existing treatments for head and neck squamous cell carcinoma (HNSCC) have problems with high side effects and high cost, and lack of effective biomarkers for diagnosis and prediction of therapeutic effects.
A series of novel peptide sequences and their variants have been developed that bind to HLA-I molecules or are used to target antibodies, soluble T cell receptors and other binding molecular targets for stimulating anti-tumor immune responses and serve as cancer Active ingredients of vaccines or immunotherapy.
These peptide sequences are able to effectively elicit anti-tumor immune responses, reduce treatment side effects, improve treatment efficiency, and provide potential biomarkers for diagnosis and prediction of the possibility of treatment success.
Smart Images

Figure BDA0005012763760000061 
Figure BDA0005012763760000071 
Figure BDA0005012763760000081
Abstract
Description
Technical Field
[0001] The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapy methods. In particular, the present invention relates to immunotherapy for cancer. The present invention also relates to tumor-associated T cell (CTL) peptide epitopes used alone or in combination with other tumor-associated peptides (active pharmaceutical ingredients of vaccine complexes that stimulate anti-tumor immune responses or stimulate T cells in vitro and are transferred to patients). Peptides that bind to major histocompatibility complex (MHC) molecules or peptides of the same class can also be targets for antibodies, soluble T cell receptors and other binding molecules.
[0002] The present invention relates to several novel peptide sequences and variants thereof, which are derived from HLA class I molecules of human tumor cells and can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for developing pharmaceutical / immunologically active compounds and cells. Background Art
[0003] Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous tumor with differences in epidemiology, etiology, and treatment (Economopoulou et al., 2016). These tumors are classified according to where they begin. They include oral cancer (lips, front two-thirds of tongue, gums, lining of cheeks and lips, floor of mouth, hard palate), pharyngeal cancer (nasopharynx, oropharynx including soft palate, tongue floor, tonsils, hypopharynx), laryngeal cancer, paranasal sinus and nasal cavity cancer, and salivary gland cancer (National Cancer Institute, 2015).
[0004] HNSCC is the sixth most common malignancy in the world, accounting for approximately 6% of all diagnosed cancer cases worldwide (Economopoulou et al., 2016). HNSCC is characterized by wide geographic variation in incidence and anatomical distribution (Vigneswaran and Williams, 2014). High-risk countries are located in South and Southeast Asia (e.g., India, Sri Lanka, Bangladesh, Pakistan). In these regions, oral squamous cell carcinoma (OSCC) is the most common cancer in men and the third most common cancer in women (Vigneswaran and Williams, 2014). In Europe, high incidence rates of OSCC are found in France, Hungary, Slovakia, and Slovenia. In the United States, HNSCC is the eighth most common cancer in men.
[0005] The main risk factors for HNSCC are alcohol consumption and smoking. Other risk factors for HNSCC include drinking yerba mate tea, pickled or salted foods, using betel nut, occupational exposure to wood dust, asbestos, and synthetic fibers, radiation exposure, oncogenic human papillomavirus (HPV) or Epstein-Barr virus (EBV), and genetics (especially nasopharyngeal SCC in Chinese descent) (National Cancer Institute, 2015).
[0006] Although OSCC and laryngeal SCC have declined in developed countries, the incidence of oropharyngeal SCC has increased. This has been attributed to changes in the biological drivers of SCC (HPV-related SCC rather than smoking-related SCC). From 1988 to 2004, HPV-related oropharyngeal cancer increased by 225% (National Cancer Institute, 2015). HPV-positive HNSCC may represent a distinct disease entity. These tumors are associated with significantly improved survival.
[0007] The incidence rate depends on sex: the male-to-female ratio ranges from 2:1 to 4:1 (2014 WHO Essential Medicines List Cancer Medicines Review). The five-year overall survival rate for HNSCC patients is 40-50% (World Health Organization, 2014). Although the cure rate for early-stage cancer (T1, T2) is 70%-95% (Nat Cancer Inst), most HNSCC patients present with locally advanced disease (Bauml et al., 2016).
[0008] Treatment of early-stage HNSCC involves single-modality therapy with surgery or radiation (World Health Organization, 2014). Advanced cancer is treated with chemotherapy combined with surgery and / or radiation therapy.
[0009] Chemotherapy mainly includes cisplatin or a combination of drugs containing cisplatin, including docetaxel, cisplatin, fluorouracil (5-FU) or cisplatin, epirubicin, bleomycin or cisplatin, 5-FU. Isotretinoin (13-cis retinoic acid) is used for oral SCC and laryngeal SCC once a day for 1 year to reduce the incidence of secondary tumors (National Cancer Institute, 2015).
[0010] HNSCC is considered an immunosuppressive disease characterized by dysregulation of immunocompetent cells and impaired cytokine secretion (Economopoulou et al., 2016). Immunotherapeutic strategies for HPV-negative and HPV-positive tumors differ.
[0011] For HPV-positive tumors, the viral oncoproteins E6 and E7 represent good targets because they are continuously expressed by tumor cells and are essential for maintaining the transformed state of HPV-positive cancer cells. Several vaccine therapies are currently being studied in HPV-positive HNSCC, including DNA vaccines, peptide vaccines, and vaccines involving dendritic cells (DCs). In addition, an ongoing phase II clinical trial is investigating the efficacy of lymphocyte depletion followed by autologous infusion of TILs in patients with HPV-positive tumors (Economopoulou et al., 2016).
[0012] In HPV-negative tumors, several immunotherapy strategies are currently being used and studied. The chimeric IgG1 anti-EGFR monoclonal antibody cetuximab has been approved by the FDA for use in combination with chemotherapy as a standard first-line treatment for recurrent / metastatic HNSCC. Other anti-EGFR monoclonal antibodies (including panitumumab, nimotuzumab, and zalutumumab) have been evaluated in HNSCC. Several immune checkpoint inhibitors are being studied in clinical trials for their use in HNSCC. They include the following antibodies: ipilimumab (anti-CTLA-4), tremelimumab (anti-CTLA-4), pembrolizumab (anti-PD-1), nivolumab (anti-PD-1), durvalumab (anti-PD-1), anti-KIR, urelumab (anti-CD137), and anti-LAG-3.
[0013] Two clinical studies in HNSCC patients evaluated the use of DCs loaded with p53 peptide or apoptotic tumor cells. The immune response was satisfactory and the side effects were acceptable.
[0014] Several studies have used adoptive T cell therapy (ACT). T cells were induced to fight against either irradiated autologous tumor cells or Epstein-Barr virus. The results of disease control and overall survival were promising (Economopoulou et al., 2016).
[0015] Given the severe side effects and costs associated with treating cancer, there is a need to identify factors that can be used to treat cancer in general, and head and neck squamous cell carcinoma in particular. There is also a need to identify factors that represent biomarkers for cancer in general, and head and neck squamous cell carcinoma in particular, to better diagnose cancer, assess prognosis, and predict treatment success.
[0016] Cancer immunotherapy represents an option for specific targeting of cancer cells while minimizing side effects. Cancer immunotherapy exploits the presence of tumor-associated antigens.
[0017] The current classification of tumor-associated antigens (TAAs) mainly includes the following groups:
[0018] a) Cancer-testis antigens: The first TAAs recognized by T cells belong to this class of antigens, and were initially called cancer-testis (CT) antigens because their members are expressed in histologically distinct human tumors, in normal tissues, only in spermatocytes / spermatogonia of the testis, and occasionally in the placenta. Since testicular cells do not express HLA class I and II molecules, these antigens cannot be recognized by T cells in normal tissues and can therefore be considered immunologically tumor-specific. Well-known examples of CT antigens are members of the MAGE family and NY-ESO-1.
[0019] b) Differentiation antigens: Both tumors and normal tissues (the tissue from which the tumor originates) contain TAAs. Most known differentiation antigens are found in melanoma and normal melanocytes. Many of these melanocyte lineage-associated proteins are involved in the biosynthesis of melanin, so these proteins are not tumor-specific, but are still widely used in cancer immunotherapy. Examples include, but are not limited to, tyrosinase for melanoma and Melan-A / MART-1 or PSA for prostate cancer.
[0020] c) Overexpressed TAAs: TAAs encoded by genes that are widely expressed have been detected in histologically distinct tumors as well as in many normal tissues, generally at low expression levels. It is possible that many epitopes processed and potentially presented by normal tissues are below the threshold level for T cell recognition, and their overexpression in tumor cells can trigger an anti-cancer response by breaking previously established tolerance. Typical examples of such TAAs are Her-2 / neu, survivin, telomerase or WT1.
[0021] d) Tumor-specific antigens: These unique TAAs arise from mutations in normal genes (e.g., β-catenin, CDK4, etc.). Some of these molecular changes are associated with neoplastic transformation and / or progression. Tumor-specific antigens can generally induce a strong immune response without the risk of autoimmune reactions to normal tissues. On the other hand, these TAAs are in most cases only associated with the exact tumor on which the TAA is identified, and are usually not shared between many individual tumors. In the case of proteins containing tumor-specific (associated) isoforms, peptide tumor specificity (or association) may also occur if the peptide is derived from a tumor (associated) exon.
[0022] e) TAAs resulting from aberrant post-translational modifications: These TAAs may be generated from proteins that are neither specific nor overexpressed in tumors, but are still tumor-associated due to post-translational processing that is primarily active on tumors. These TAAs arise from altered glycosylation patterns that result in tumor production of novel epitopes for MUC1 or events such as protein splicing during degradation, which may or may not be tumor-specific.
[0023] f) Oncovirus proteins: These TTAs are viral proteins that play a key role in the carcinogenesis process and because they are foreign (non-human) proteins, they are able to stimulate T cell responses. Examples of such proteins are the human papillomavirus type 16 proteins, E6 and E7, which are expressed in cervical cancer.
[0024] T cell-based immunotherapy targets peptide epitopes derived from tumor-associated or tumor-specific proteins presented by major histocompatibility complex (MHC) molecules. The antigens recognized by tumor-specific T lymphocytes, i.e., their epitopes, can be molecules derived from all types of proteins, such as enzymes, receptors, transcription factors, etc., which are expressed in cells of the corresponding tumor and their expression is usually upregulated compared with homologous unaltered cells.
[0025] There are two types of MHC molecules: MHC class I and MHC class II. MHC class I molecules consist of an alpha heavy chain and beta-2-microglobulin, while MHC class II molecules consist of an alpha and a beta chain. Its three-dimensional structure forms a binding groove for non-covalent interaction with peptides.
[0026] MHC class I molecules are found on most nucleated cells. They present peptides that are mainly endogenous proteins, defective ribosomal products (DRIPs) and peptides generated by cleavage of larger peptides. However, peptides originating from endosomal structures or exogenous sources are also frequently found on MHC class I molecules. This non-classical presentation of class I molecules is referred to in the literature as cross-presentation (Brossart and Bevan, 1997; Rock et al., 1990). MHC class II molecules are mainly found on professional antigen presenting cells (APCs) and mainly present peptides of exogenous or transmembrane proteins that are taken up by APCs during endocytosis and subsequently processed.
[0027] The complex of peptide and MHC class I is recognized by CD8-positive T cells bearing the corresponding T cell receptor (TCR), while the complex of peptide and MHC class II molecule is recognized by CD4-positive helper T cells bearing the corresponding TCR. Therefore, it is a consensus that TCR, peptide and MHC are presented in a 1:1:1 stoichiometry.
[0028] CD4-positive helper T cells play an important role in inducing and maintaining effective responses of CD8-positive cytotoxic T cells. The identification of CD4-positive T cell epitopes derived from tumor-associated antigens (TAAs) may be very important for the development of drug products that can elicit anti-tumor immune responses (Gnjatic et al., 2003). At the tumor site, T helper cells maintain a cytokine environment that is friendly to cytotoxic T cells (CTLs) (Mortara et al., 2006) and attract effector cells such as CTLs, natural killer (NK) cells, macrophages, and granulocytes (Hwang et al., 2007).
[0029] In the absence of inflammation, the expression of MHC class II molecules is mainly restricted to cells of the immune system, especially professional antigen presenting cells (APCs), such as monocytes, monocyte-derived cells, macrophages, and dendritic cells. MHC class II molecules have been found to be expressed in tumor cells from cancer patients (Dengjel et al., 2006).
[0030] The extended (longer) peptides of the present invention can serve as MHC class II active epitopes.
[0031] Helper T cells activated by MHC class II epitopes play an important role in orchestrating CTL effector functions in antitumor immunity. H1 The cell-reactive helper T cell epitopes support the effector functions of CD8-positive killer T cells, including cytotoxic functions directed against tumor cells displaying the tumor-associated peptide / MHC complex on their surface. Thus, tumor-associated T helper cell epitopes, alone or in combination with other tumor-associated peptides, can serve as active pharmaceutical ingredients of vaccine compounds that stimulate anti-tumor immune responses.
[0032] Mammalian (e.g., mouse) models have shown that even in the absence of CD8-positive T lymphocytes, CD4-positive T cells can be sufficient to suppress tumor manifestation by secreting interferon-γ (IFNγ) to inhibit angiogenesis (Beatty and Paterson, 2001; Mumberg et al., 1999). There is no evidence that CD4 T cells act as direct anti-tumor effectors (Braumuller et al., 2013; Tran et al., 2014).
[0033] Since the constitutive expression of HLA class II molecules is usually limited to immune cells, it was previously considered impossible to isolate class II peptides directly from primary tumors. However, Dengjel et al. successfully identified multiple MHC class II epitopes directly in tumors (WO 2007 / 028574, EP 1 760 088 B1).
[0034] Since both CD8-dependent and CD4-dependent responses contribute jointly and synergistically to antitumor effects, identifying and characterizing tumor-associated antigens recognized by CD8+ T cells (ligands: MHC class I molecules + peptide epitopes) or CD4-positive T helper cells (ligands: MHC class II molecules) is very important for the development of tumor vaccines.
[0035] For an MHC class I peptide to trigger (elicit) a cellular immune response, it must also bind to an MHC molecule. This process depends on the allele of the MHC molecule as well as the specific polymorphism of the peptide's amino acid sequence. MHC class I-binding peptides are typically 8-12 amino acid residues in length and typically contain two conserved residues ("anchors") in their sequence that interact with the corresponding binding groove of the MHC molecule. In this way, each MHC allele has a "binding motif" that determines which peptides can specifically bind to the binding groove.
[0036] In the MHC class I-dependent immune response, peptides must not only bind to certain MHC class I molecules expressed by tumor cells, but they must then be recognized by specific T cell receptors (TCRs) carried by T cells.
[0037] For proteins to be recognized by T lymphocytes as tumor-specific antigens or associated antigens and used for treatment, special conditions must be met. The antigen should be expressed mainly by tumor cells, not by normal healthy tissues, or expressed in relatively small amounts. In a preferred embodiment, the peptide should be over-presented in tumor cells compared to normal healthy tissues. More preferably, the corresponding antigen not only appears in a tumor, but also has a high concentration (i.e., the number of copies of the corresponding peptide per cell). Tumor-specific antigens and tumor-associated antigens are often derived from proteins that are directly involved in the transformation of normal cells into tumor cells due to their functions in cell cycle control or apoptosis inhibition. In addition, the downstream targets of these proteins that directly cause transformation events may be upregulated and may therefore be indirectly associated with tumors. These indirect tumor-associated antigens may also be targets for vaccination methods (Singh-Jasuja et al., 2004). It is crucial that the epitope is present in the antigen amino acid sequence to ensure that such peptides from tumor-associated antigens ("immunogenic peptides") can lead to T cell responses in vitro or in vivo.
[0038] Basically, any peptide that can bind to an MHC molecule can potentially serve as a T cell epitope. The prerequisite for inducing a T cell response in vitro or in vivo is the presence of T cells with the corresponding TCR and the absence of immune tolerance to this specific epitope.
[0039] Therefore, TAAs are the starting point for the development of T cell-based therapies (including but not limited to tumor vaccines). Methods for identifying and characterizing TAAs are usually based on the use of T cells from patients or healthy subjects, or on the generation of differential transcriptional properties or differential expression patterns between tumor and normal tissue peptides. However, the identification of genes that are overexpressed or selectively expressed in tumor tissues or human tumor cell lines does not provide accurate information for the use of antigens transcribed by these genes in immunotherapy. This is because T cells with corresponding TCRs must be present and immune tolerance to this specific epitope must be absent or at a minimal level, so only a part of the epitopes of these antigens are suitable for this application. Therefore, in a very preferred embodiment of the present invention, it is very important to select only those over-presented or selectively presented peptides for which functional and / or proliferative T cells can be found. Such functional T cells are defined as T cells that can be clonally expanded and can perform effector functions ("effector T cells") after stimulation with specific antigens.
[0040] In the case of peptide-MHC targeting by specific TCRs (e.g. soluble TCRs) and antibodies or other binding molecules (scaffolds) according to the invention, the immunogenicity of the underlying peptide is secondary. In these cases, presentation is the determining factor. Summary of the invention
[0041] In the first aspect of the present invention, the present invention relates to a peptide or a pharmaceutically acceptable salt thereof, comprising an amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 91, or a variant sequence of the sequence that is at least 77%, preferably at least 88% homologous (preferably at least 77% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 91, wherein the variant binds to MHC and / or induces T cells to cross-react with the peptide, wherein the peptide is not the basic full-length polypeptide.
[0042] The present invention further relates to a peptide of the present invention, comprising a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 91, or a variant thereof having at least 77%, preferably at least 88% homology (preferably at least 77% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 91, wherein the total length of the peptide or its variant is 8 to 100, preferably 8 to 30, most preferably 8 to 14 amino acids.
[0043] The following table shows peptides according to the present invention, their respective SEQ ID NOs, and possible source (potential) genes of these peptides. All peptides in Tables 1 and 2 bind to HLA-A*02. The peptides in Table 2 were previously disclosed in large lists as a result of high throughput screening with high error rates, or calculated using algorithms, but have not previously been shown to have any association with cancer. The peptides in Table 3 are other peptides that can be used in combination with other peptides of the present invention. The peptides in Tables 4A and B can also be used to diagnose and / or treat various other malignant diseases that involve overexpression or overpresentation of each basic polypeptide.
[0044] Table 1: Peptides of the present invention
[0045] J = phosphoserine
[0046]
[0047]
[0048]
[0049] Table 2: Other peptides of the present invention with no previous known association with cancer.
[0050] Serial ID Number sequence Gene ID Official gene symbol 81 VLAENPDIFAV 6541 SLC7A1 82 VLDINDNPPV 120114,1828,2195 FAT3,DSG1,FAT1 83 QLLQYVYNL 4173 MCM4 84 ALMAGCIQEA 1026 CDKN1A 85 QLIEKITQV 114827 FHAD1 86 SLQERQVFL 9333 TGM5 87 ALPEPSPAA 5339 PLEC 88 LMAPAPSTV 7071 KLF10 89 VLDEGLTSV 25909,285116 AHCTF1,AHCTF1P1 90 TLNDGVVVQV 10146 G3BP1 91 MLFENMGAYTV 4953 ODC1
[0051] Table 3: Peptides of the invention for personalized cancer therapy.
[0052]
[0053]
[0054] The present invention also generally relates to the use of the peptides of the present invention in the treatment of proliferative diseases, such as acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, bladder cancer and uterine cancer.
[0055] Particularly preferred are peptides of the present invention (alone or in combination) selected from SEQ ID NO: 1 to SEQ ID NO: 91. More preferred are peptides (alone or in combination) selected from SEQ ID NO: 1 to SEQ ID NO: 31 (see Table 1) and used for immunotherapy as shown in Table 4A below, where many peptides of the present invention are also found in other tumors and can therefore also be used for immunotherapy of other indications. See also Figure 1 and Example 1.
[0056] As shown in Table 4A below, many of the peptides of the present invention are also found in other tumors and thus can also be used for immunotherapy of other indications. See also FIG. 1 and Example 1.
[0057] Table 4A: Peptides of the invention and their specific use in other proliferative diseases, particularly other cancerous diseases. This table shows selected peptides for other tumor types that were found to be over-presented in more than 5% of the tumor samples tested, or presented in more than 5% of the tumor samples tested with a geometric mean tumor to normal tissue ratio greater than 3. Over-presentation is defined as higher presentation in tumor samples compared to the highest presenting normal sample. The normal tissues tested for over-presentation were: adipose tissue, adrenal glands, bile ducts, blood cells, blood vessels, bone marrow, brain, esophagus, eyes, gallbladder, heart, kidney, large intestine, liver, lung, lymph nodes, nerves, pancreas, parathyroid, peritoneum, pituitary, pleura, salivary glands, skeletal muscle, skin, small intestine, spleen, stomach, thyroid, trachea, ureters, bladder.
[0058]
[0059]
[0060]
[0061] NSCLC = non-small cell lung cancer, SCLC = small cell lung cancer, RCC = renal cancer, CRC = colon or rectal cancer, GC = gastric cancer, HCC = liver cancer, PC = pancreatic cancer, PrC = prostate cancer, leukemia, BRCA = breast cancer, OC = ovarian cancer, MCC = Merkel cell carcinoma, NHL = non-Hodgkin lymphoma, AML = acute myeloid leukemia, CLL = chronic lymphocytic leukemia
[0062] Table 4B: Peptides of the invention and their specific use in other proliferative diseases, particularly other cancerous diseases. This table shows that for selected peptides of other tumor types, they were found to be over-presented (specifically presented) in more than 5% of the tumor samples tested, or presented in more than 5% of the tumor samples tested with a geometric mean tumor to normal tissue ratio greater than 3. Over-presentation is defined as higher presentation in tumor samples compared to the highest presenting normal sample. The normal tissues tested for over-presentation were: adipose tissue, adrenal glands, arteries, bone marrow, brain, central nervous system, colon, duodenum, esophagus, eye, gallbladder, heart, kidney, liver, lung, lymph nodes, blood cells, pancreas, parathyroid glands, peripheral nerves, peritoneum, pituitary, pleura, rectum, salivary glands, skeletal muscle, skin, small intestine, spleen, stomach, thymus, thyroid gland, trachea, ureter, bladder, vein.
[0063] Serial ID Number sequence Other entities 2 PVCPPGGIQEV Esophageal cancer 6 ALYDAELSQM Esophageal cancer 8 AQLNIGNVLPV Bladder cancer 9 STASAITPSV Esophageal cancer 16 ALKDSVQRA HCC 43 AVLGGKLYV RCC, GC, HCC 45 GLIEWLENTV HCC 47 QLLEGELETL OC 50 ALSNVVHKV NSCLC 51 FLIPSIIFA OC 56 FLQLETEQV OC 57 AILGFALSEA HCC 60 SLGNFKDDLL NSCLC 61 FVV HCC 65 ALWGFFPVLL HCC 66 TLLSEIAEL HCC 73 YIDPYKLLPL BRCA, bladder cancer 75 ALASAPTSV HCC 88 LMAPAPSTV Melanoma 89 VLDEGLTSV GC
[0064] NSCLC = non-small cell lung cancer, HCC = liver cancer, BRCA = breast cancer, RCC = renal cell carcinoma, GC = gastric cancer, OC = ovarian cancer.
[0065] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 1, 10, 17, 37, 42, 48, 57, 61, 67, 69, 70, 72, 75, 76, 78 and 87 in the treatment (in a preferred embodiment, in combination therapy) of gallbladder cancer and / or bile duct cancer.
[0066] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 2, 20, 50, 60, 61, 63 and 64 in the treatment (in a preferred embodiment in combination therapy) of NSCLC.
[0067] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 2, 17, 45, 59, 61, 63, 67, 81, 83, 85, 89 and 91 in the treatment (in a preferred embodiment, in combination therapy) of SCLC.
[0068] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 2, 3, 4, 6, 7, 8, 9, 16, 19, 23, 27, 32, 39, 41, 42, 46, 48, 49, 50, 52, 53, 54, 58, 60, 61, 62, 72, 75, 88 and 90 in the treatment (in a preferred embodiment, in combination therapy) of esophageal cancer.
[0069] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 3, 4, 7, 8, 15, 16, 19, 20, 21, 24, 27, 31, 32, 39, 45, 46, 47, 48, 50, 51, 53, 56, 58, 60, 64, 69, 73, 74, 78, 81, 85, 86, 88, 89 and 90 in the treatment of bladder cancer (in a preferred embodiment, in combination therapy).
[0070] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 4, 16, 17, 39, 48, 50, 56, 57, 58, 62, 73, 75, 76, 79 and 89 in the treatment (in a preferred embodiment, in combination therapy) of BRCA.
[0071] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 8, 9, 11, 16, 17, 32, 43, 48, 56, 57, 65, 66, 67, 71, 73, 81, 82, 85, 87, 88 and 89 in the treatment of melanoma (in a preferred embodiment, in combination therapy).
[0072] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 16, 17, 24, 29, 43, 57, 66, 70, 73, 76, 77 and 83 in the treatment (in a preferred embodiment in combination therapy) of AML.
[0073] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 16, 17, 19, 31, 43, 46, 47, 48, 49, 51, 56, 57, 58, 66, 67, 72, 75, 76, 79, 83, 89, 90 and 91 in the treatment (in a preferred embodiment, in combination therapy) of uterine cancer.
[0074] Therefore, another aspect of the present invention relates to the use of at least one peptide of the present invention according to any one of SEQ ID NOs: 18, 58, 61 and 88 in the treatment (in a preferred embodiment in combination therapy) of brain cancer.
[0075] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 32, 43, 48, 59, 60, 61, 63, 66, 73, 76, 79, 83, 85, 86, 87, 89, 90 and 91 in the treatment (in a preferred embodiment, in combination therapy) of NHL.
[0076] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 43, 61, 65, 66, 73, 76, 78, 89, 90 and 91 in the treatment (in a preferred embodiment in combination therapy) of CLL.
[0077] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NOs: 45, 47, 51 , 56, 66 and 67 in the treatment, in a preferred embodiment in combination therapy, of OC.
[0078] Therefore, another aspect of the present invention relates to the use of at least one peptide of the present invention according to any one of SEQ ID NOs: 43, 50, 89 and 61 in the treatment (in a preferred embodiment in combination therapy) of GC.
[0079] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NO: 16, 43, 45, 57, 61, 65, 66 and 75 in the treatment (in a preferred embodiment in combination therapy) of HCC.
[0080] Therefore, another aspect of the invention relates to the use of at least one peptide of the invention according to any one of SEQ ID NOs: 43, 61 , 62, 87, 89 and 90 in the treatment (in a preferred embodiment in combination therapy) of RCC.
[0081] Therefore, another aspect of the present invention relates to the use of the peptides of the present invention in the treatment (preferably combination therapy) of proliferative diseases selected from head and neck squamous cell carcinoma, acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, bladder cancer, and uterine cancer.
[0082] The present invention also relates to the peptides of the present invention, which have the ability to bind to major histocompatibility complex (MHC) class I or MHC class II molecules present in an extended form, for example of varying length.
[0083] The present invention further relates to the peptides of the present invention, wherein the peptide (each peptide) consists or essentially consists of the amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 91.
[0084] The present invention further relates to the peptides of the present invention, wherein the peptides are modified and / or comprise non-peptide bonds.
[0085] The present invention further relates to the peptides of the present invention, wherein the peptides are part of a fusion protein, in particular fused to the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii), or to an antibody (e.g., a dendritic cell-specific antibody), or fused to the sequence of an antibody.
[0086] The present invention further relates to an expression vector capable of expressing and / or expressing the nucleic acid of the present invention.
[0087] The present invention further relates to the use of the peptide of the present invention, the nucleic acid of the present invention or the expression vector of the present invention in medicine, in particular for the treatment of cancer.
[0088] The present invention further relates to antibodies specific for the peptides of the present invention or complexes of the peptides of the present invention (containing MHC) and methods for producing these antibodies.
[0089] The present invention further relates to the T cell receptors (TCRs) of the present invention, in particular soluble TCRs (sTCRs) and cloned TCRs processed into autologous or allogeneic T cells, as well as methods for producing these TCRs, and also to methods for producing NK cells carrying the TCRs or cross-reacting with the TCRs.
[0090] Antibodies and TCRs are additional embodiments of immunotherapeutic uses of the present peptides.
[0091] The present invention further relates to a host cell comprising the nucleic acid or expression vector of the present invention. The present invention further relates to a host cell of the present invention, which is an antigen presenting cell, preferably a dendritic cell.
[0092] The present invention further relates to a method for preparing the peptide of the present invention, said method comprising culturing the host cell of the present invention, and isolating the peptide from said host cell or its culture medium.
[0093] The present invention further relates to the method of the present invention, wherein the antigen is loaded onto a class I or II MHC molecule expressed on the surface of a suitable antigen presenting cell or artificial antigen presenting cell by contacting a sufficient amount of the antigen with the antigen presenting cell.
[0094] The present invention further relates to the method of the present invention, wherein the antigen presenting cell comprises an expression vector capable of expressing a peptide comprising the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 91, preferably comprising the amino acid sequence of SEQ ID NO: 1 to SEQ ID No: 31 or variants thereof.
[0095] The present invention further relates to activated T cells produced by the method of the present invention, wherein the T cells selectively recognize a cell that expresses a polypeptide comprising the amino acid sequence of the present invention.
[0096] The present invention further relates to a method for killing target cells of a patient, wherein the target cells of the patient abnormally express a polypeptide comprising any amino acid sequence of the present invention, the method comprising administering to the patient an effective amount of T cells produced by the method of the present invention.
[0097] The present invention further relates to the use of any of the peptides, nucleic acids of the present invention, expression vectors of the present invention, cells of the present invention, activated T lymphocytes, T cell receptors or antibodies or other peptide- and / or peptide-MHC binding molecules of the present invention as a drug or in the preparation of a drug. The drug preferably has anticancer activity.
[0098] Preferably, the drug is a cell therapy drug, vaccine or protein based on soluble TCR or antibody.
[0099] The present invention further relates to the use of the present invention, wherein the cancer cells are head and neck squamous cell carcinoma, acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, bladder cancer, uterine cancer cells, preferably head and neck squamous cell carcinoma cells.
[0100] The present invention further relates to a biomarker based on a peptide of the present invention, referred to herein as a "target", which can be used to diagnose cancer, preferably head and neck squamous cell carcinoma. The marker can be an over-presentation of the peptide itself, or an over-expression of the corresponding gene. The marker can also be used to predict the likelihood of success of a treatment, preferably an immunotherapy, most preferably an immunotherapy targeting the same target recognized by the biomarker. For example, an antibody or soluble TCR can be used to stain a tumor section to detect the presence of the relevant peptide complexed with MHC.
[0101] Optionally, the antibody has further effector functions, such as an immunostimulatory domain or a toxin.
[0102] The present invention also relates to the use of these novel targets in cancer treatment. DETAILED DESCRIPTION
[0103] ALOX12B is involved in terminal skin differentiation and epidermal barrier function (Furstenberger et al., 2007; Epp et al., 2007). ALOX12B is an immunosuppressive factor amplified in cancer (Rooney et al., 2015). Cisplatin induces and ATM phosphorylates (p)-δNp63α. Subsequently, it upregulates miR-185-5p, which downregulates let7-5p, leading to the regulation of ALOX12B expression in squamous cell carcinoma (Ratovitski, 2013). ALOX12B is associated with breast and lung cancer risk (Lee et al., 2009; Shen et al., 2009).
[0104] ANKRD17 mRNA levels are widely downregulated in colorectal cancer, making this protein a potential marker for multi-target assay panels for colorectal cancer detection (Ioana et al., 2010). ANKRD17 is involved in cell cycle regulation through phosphorylation of cyclin E / CdK2. Overexpression promotes entry into the S phase, while depletion inhibits DNA replication, blocks cell cycle progression, and upregulates the expression of tumor suppressor genes p53 and p21 (Deng et al., 2009).
[0105] ATP5G1 is enriched in the oxidative phosphorylation pathway in gastric cancer (Song et al., 2016). ATP5G1 expression is reduced in head and neck squamous cell carcinoma (Koc et al., 2015). Knockdown of the enhancer of liver regeneration (ALR) leads to accelerated development of fatty liver and hepatocellular carcinoma in mice. In addition, ATP5G1 expression is reduced in ALR knockout mice (Gandhi et al., 2015).
[0106] ATP5G2 is more highly methylated in high-grade bladder cancer tumors compared to low- and intermediate-grade tumors (Kitchen et al., 2016). RIZ1 is a tumor suppressor whose depletion leads to altered ATP5G2 expression (Xie et al., 2016b). TP5G2 is highly expressed after estrogen and progesterone treatment of the endometrial Ishikawa carcinoma cell line (Tamm-Rosenstein et al., 2013). The ATP5G2 promoter is methylated in primary renal cell carcinoma (Morris et al., 2011).
[0107] ATP5G3 is enriched in the oxidative phosphorylation pathway of gastric cancer (Song et al., 2016). ATP5G3 is upregulated when PPARα is activated, which is negatively correlated with tumor progression and inhibits cell migration (Huang and Chang, 2016). ATP5G3 may be a radiation sensitivity gene (Tsuji et al., 2005).
[0108] BTBD11 encodes a BTB domain-containing 11 protein and is located on chromosome 12q23.3 (RefSeq, 2002). BTBD11 is differentially expressed in papillary thyroid carcinoma (Qu et al., 2016). BTBD11 is a TGF-β target gene (Sawada et al., 2016). BTBD11 is mutated in gastric cancer (Leiserson et al., 2015; Leiserson et al., 2016).
[0109] The prognostic association of CD276 differs between smokers and nonsmokers of lung adenocarcinoma. High CD276 expression is associated with smoking (Inamura et al., 2017). CD276 is hypermethylated in prostate cancer (Wang et al., 2016b). CD276 is regulated by miR-124, which is downregulated in osteosarcoma. TGF-β1 upregulates miR-155 through SMAD3 and 4 signaling, leading to attenuation of miR-143 inhibition by CEBPB, which results in the accumulation of CD276. CD276 is regulated by miR-187, which is downregulated in colorectal cancer (Wang et al., 2016e; Trojandt et al., 2016; Zhou et al., 2016; Wang et al., 2016a). CD276 mediates abnormal lipid metabolism in lung cancer by affecting SREBP-1 / FASN signaling. Soluble CD276 mediates pancreatic cancer invasion and metastasis through TLR4 / NF-κB signaling (Xie et al., 2016a; Luo et al., 2016). CD276 is an immune checkpoint that may be a promising target in cancer therapy. It can be targeted during tumor growth to inhibit antitumor immunity, thereby allowing newly emerged tumors to escape immune defenses (Leung and Suh, 2014; Swatler and Kozlowska, 2016; Janakiram et al., 2016). CD276 is expressed by most high-risk neuroblastomas, is overexpressed in tumor vasculature, and plays an important role in tumor survival and invasion (Bottino et al., 2014). CD276 knockdown increases chemosensitivity and reduces metastatic potential. CD276 knockdown leads to increased expression of apoptotic markers and STAT3 phosphorylation. Intravenous astragaloside treatment reduces cell growth and increases chemosensitivity to cisplatin by inhibiting CD276 in non-small cell lung cancer cells (Nygren et al., 2011; He et al., 2016). CD276 is overexpressed in esophageal, breast, gallbladder, prostate, and ovarian cancers (Barach et al., 2011; Janakiram et al., 2012; Fauci et al., 2012; Chen et al., 2016; Liu et al., 2016). CD276 overexpression is associated with poor survival, prognosis, and tumor grade. CD276 can promote cancer invasion and progression. However, CD276 may also have anti-tumor effects.High expression of CD276 is an indicator of lymph node metastasis and advanced TNM stage in non-small cell lung cancer (Yi and Chen, 2009; Loos et al., 2010; Nygren et al., 2011; Fauci et al., 2012; Wang et al., 2014a; Ye et al., 2016; Benzon et al., 2016; Wu et al., 2016). CD276 downregulates the cytotoxicity of natural killer cells and supports cancer immune escape (Bottino et al., 2014).
[0110] CDH23 encodes cadherin-related 23 protein, a member of the cadherin superfamily, whose gene encodes a calcium-dependent cell adhesion glycoprotein. The encoded protein is thought to be involved in capillary structure and hair bundle formation. This gene is located in the region containing the human deafness loci DFNB12 and USH1D. Usher syndrome 1D and non-syndromic autosomal hereditary deafness DFNB12 are caused by allelic mutations in this cadherin-like gene. Upregulation of this gene may also be associated with breast cancer (RefSeq, 2002). TMPRSS3 is a poor prognostic factor for breast cancer and can interact with CDH23 (Rui et al., 2015). CDH23 is upregulated after leptin treatment in ERα-expressing breast cancer cells (Binai et al., 2013). CDH23 is upregulated in breast cancer and may be involved in early metastasis (Apostolopoulou and Ligon, 2012). CDH23 loss can be observed in pancreatic cancer cell lines (Suzuki et al., 2008).
[0111] CDH3 participates in oncogenic signaling and activates integrins, receptor tyrosine kinases, small GTPases, EMT transcription factors, and other cadherin family members. CDH3 signaling induces invasion and metastasis (Albergaria et al., 2011; Paredes et al., 2012; Bryan, 2015; Vieira and Paredes, 2015). Oncogenic activation of CDH3 is involved in gastric carcinogenesis (Resende et al., 2011). CDH3 overexpression promotes breast, bladder, ovarian, prostate, endometrial, skin, gastric, pancreatic, and colon cancers (Albergaria et al., 2011; Paredes et al., 2007; Bryan and Tselepis, 2010; Reyes et al., 2013; Vieira and Paredes, 2015). CDH3 is a basal epithelial marker expressed in basal-like breast cancers. BRCA1 cancers are characterized by the expression of basal markers such as CDH3 and display a high-grade, highly proliferative, ER-negative, and HER3-negative phenotype (Honrado et al., 2006; Palacios et al., 2008; Rastelli et al., 2010; Dewar et al., 2011). CDH3 is a tumor suppressor in melanoma and oral squamous cell carcinoma (Haass et al., 2005; Vieira and Paredes, 2015). CDH3 can be used as an EMT marker. During tumor formation and progression, E-cadherin is converted to N-cadherin and CDH3 expression (Piura et al., 2005; Bonitsis et al., 2006; Bryan and Tselepis, 2010; Ribeiro and Paredes, 2014). Competitive interaction between CDH3 and β-catenin leads to impaired cell-cell interactions and metastasis in gastric cancer (Moskvina and Mal'kov, 2010). CDH3 may be an early marker for carcinogenesis in colon cancer (Alrawi et al., 2006). Dysregulation of CDH3 is a marker for poor prognosis and increased progression (Knudsen and Wheelock, 2005).
[0112] Overexpression of CLCA2 downregulates β-catenin and β-catenin promoter genes (Ramena et al., 2016). CLCA2 strongly interacts with EVA1, which is also induced by p53 and p63, is often downregulated in breast cancers that cause EMT, and is important for epithelial differentiation. Both proteins interact with E-cadherin (Ramena et al., 2016). AML1-CLCA2 and RUNX1-CLCA2 gene fusion products are present in adult acute myeloid leukemia (Giguere and Hebert, 2010; Jiang et al., 2013). Following DNA damage, CLCA2 can be induced by p73, p53, and p63 and acts as a suppressor of proliferation (Walia et al., 2009; Sasaki et al., 2012; Yu et al., 2013; Ramena et al., 2016). CLCA2 expression is elevated in circulating tumor cells of patients with lung adenocarcinoma, and increased detection is associated with shorter patient survival (Hayes et al., 2006; Man et al., 2014). CLCA2 expression is higher in lung squamous cell carcinoma compared to adenocarcinoma, and correlates with histological tumor grade. CLCA2 expression can be used to detect non-small cell lung cancer and small cell lung cancer (Hayes et al., 2006; Shinmura et al., 2014). CLCA2 knockdown leads to epithelial-mesenchymal transition, cancer cell migration and invasion. Under normal conditions, CLCA 2 is thought to inhibit migration and invasion by inhibiting the FAK signaling pathway. CLCA2 mediates lung metastasis associated with β(4) integrin (Abdel-Ghany et al., 2001; Walia et al., 2012; Sasaki et al., 2012; Ramena et al., 2016). CLCA2 is downregulated in breast cancer due to promoter hypermethylation and is downregulated in colorectal cancer. CLCA2 is differentially expressed in bladder cancer and melanoma metastasis during metastasis. CLCA2 copy number loss is present in mantle cell lymphoma (Gruber and Pauli, 1999; Bustin et al., 2001; Li et al., 2004; Balakrishnan et al., 2006; Riker et al., 2008; Walia et al., 2012; Matin et al., 2014; Ramena et al., 2016).
[0113] DSG1 is overexpressed in keratocystic odontogenic tumors and has high expression in oral intraepithelial neoplasms (Aizawa et al., 2014; Heikinheimo et al., 2015). DSG1 expression is lost in acantholytic squamous cell carcinoma and is decreased in chondrosarcoma, oral squamous cell carcinoma, and lung cancer (Xin et al., 2014; Saaber et al., 2015; Galoian et al., 2015; Jurcic et al., 2015). DSG1 expression is regulated by GRHL1, and GRHL1-negative mice treated with standard chemical skin cancer regimens develop fewer papillomas but more squamous cell carcinomas (Mlacki et al., 2014). DSG1 is a downstream target of Rhoda and the GEF Bcr and is a keratinocyte differentiation marker (Dubash et al., 2013). KLK5 cleavage of DSG1 may be involved in the formation of metastatic lesions in oral squamous cell carcinoma. Reduced levels of DSG1 may be associated with pancreatic cancer invasion (Ramani et al., 2008; Jiang et al., 2011). Negative DSG1 staining is associated with improved anal cancer-specific survival, while positive staining is associated with large tumor size and lymph node metastasis. Loss of DSG1 is associated with poor prognosis in head and neck squamous cell carcinoma (Wong et al., 2008; Myklebust et al., 2012). Autoantibodies against DSG1 can be detected in paraneoplastic pemphigus (Seishimaa et al., 2004).
[0114] DSG3 expression in esophageal squamous cell carcinoma was shown to be highly correlated with histological grade and has an impact on the survival of esophageal squamous cell carcinoma, with negative DSG3 expression indicating poor survival. Therefore, DSG3 may be involved in the progression of esophageal squamous cell carcinoma and may serve as a prognostic marker (Fang et al., 2014). In primary lung tumors, higher expression of DSG3 and DSG2 showed correlation with the diagnosis of squamous cell lung cancer, while lower expression of DSG3 showed significant correlation with higher tumor grade. Therefore, DSG3 may serve as a potential diagnostic marker for squamous cell lung cancer and a potential differentiation marker for lung cancer (Saaber et al., 2015). DSG3 has been described as a negative prognostic biomarker in resected pancreatic ductal adenocarcinoma, as high DSG3 expression was associated with poor overall survival and poor tumor-specific survival. Therefore, DSG3 and its downstream signaling pathways may be possible therapeutic targets in pancreatic ductal adenocarcinoma expressing DSG3 (Ormanns et al., 2015).
[0115] Decreased DSP expression is associated with tumor progression in several cancers, including breast, lung, and cervical cancer (Schmitt-Graeff et al., 2007; Davies et al., 1999; Yang et al., 2012b). DSP expression significantly inhibits cell proliferation, anchorage-independent growth, migration, and invasion of lung cancer cells by inhibiting the Wnt / β-catenin signaling pathway (Yang et al., 2012b).
[0116] DST may be associated with breast cancer metastasis (Sun et al., 2006). Autoantibodies against DST can be found in lymphocytic leukemia and follicular lymphoma (Aisa et al., 2005; Taintor et al., 2007). In nasopharyngeal carcinoma, DST is upregulated in 5-8F cells (high tumorigenic and metastatic capacity) compared with 6-10B cells (tumorigenic but not metastatic) (Fang et al., 2005). DST is highly expressed in head and neck squamous cell carcinoma (Lin et al., 2004). Autoantibodies against DST are present in paraneoplastic pemphigus, which is associated with tumors (Yong and Tey, 2013; Wang et al., 2005; Preisz and Karpati, 2007; Zhu and Zhang, 2007). DST expression in prostate cancer is strongly inversely correlated with disease progression (Vanaja et al., 2003). Anti-DST autoantibodies are a promising marker for the diagnosis of melanoma (Shimbo et al., 2010). DST can be found in the urine of cachectic cancer patients (Skipworth et al., 2010). DST is differentially expressed in lung adenocarcinoma and squamous cell carcinoma (McDoniels-Silvers et al., 2002). DST is significantly upregulated and accompanies invasive cell growth (Herold-Mende et al., 2001).
[0117] EMC7 encodes ER membrane protein complex subunit 7 and is located on chromosome 15q14 (RefSeq, 2002). EMC7 may be a novel drug target and diagnostic biomarker in cancer (Delgado et al., 2014). EMC7 is downregulated in bleomycin-inhibited tongue squamous cell carcinoma cell lines (Zheng et al., 2010).
[0118] ESRP2 encodes an epithelial cell type-specific splicing regulator (RefSeq, 2002). ESRP2 inhibits cancer cell motility in different cancer types, including lung and breast cancer cells. ESRP2 is downregulated by TGF-β at the invasive front, leading to increased expression of epithelial-mesenchymal transition-related transcription factors (Gemmill et al., 2011; Horiguchi et al., 2012; Ishii et al., 2014).
[0119] Mutations in the PH domain binding motif of F2RL1 are sufficient to reduce breast tumor growth (Bar-Shavit et al., 2016). F2RL1 is overexpressed in gastric cancer and negatively correlated with overall survival of patients (Sedda et al., 2014). Trypsin is a mediator of angiogenesis released by mast cells, which activates F2RL1, leading to cancer cell proliferation, invasion, and metastasis (Marech et al., 2014; Ammendola et al., 2014). F2RL1 is affected by genes that are differentially expressed and mutated in cancer (D'Asti et al., 2014). F2RL1 is involved in cancer progression, invasion, and metastasis (Wojtukiewicz et al., 2015; Canto et al., 2012; Lima and Monteiro, 2013; Gieseler et al., 2013). F2RL1 is expressed in adenocarcinomas, melanomas, osteosarcomas, glioblastomas, meningiomas, leukemias, and squamous cell carcinomas (Elste and Petersen, 2010). F2RL1 regulates the expression of ALK5, a type 1 receptor for TGF-β. F2RL1 activates MAP kinases (Oikonomopoulou et al., 2010; Witte et al., 2016). Upregulation of tissue factor and integrins mediates F2RL1 signaling that promotes metastasis (Kasthuri et al., 2009; Ruf et al., 2011; Kocaturk and Versteeg, 2012; Ruf, 2012; Kocaturk and Versteeg, 2013). Trypsin and PAR2 form an autocrine loop that promotes proliferation, invasion, and metastasis. Trypsin stimulation may lead to the activation of the MAPK-ERK pathway through MMP- and PAR2-dependent activation of the epidermal growth factor receptor (Soreide et al., 2006).
[0120] FAM160A1 encodes family with sequence similarity 160 member A1 and is located on chromosome 4q31.3 (RefSeq, 2002). FAM160A1 expression is altered following binding of DAM131 to estrogen-related receptor β in prostate cancer (Lu et al., 2015b). NFκB-FAM160A1 gene fusion products are present in prostate cancer (Teles, I et al., 2015). FAM160A1 is upregulated in ovarian cancer compared to benign tumors (Li et al., 2012a). FAM160A1 deletions can be found in familial and early-onset breast cancer (Krepischi et al., 2012). FAM160A1 is downregulated in colorectal cancer (Li et al., 2012b).
[0121] FANCE is associated with the risk of esophageal squamous cell carcinoma (Li et al., 2013). Rare FANCE downregulation can be observed in head and neck squamous cell carcinoma (Wreesmann et al., 2007). Chk1 mediates the phosphorylation of FANCE after DNA crosslinking (Wang et al., 2007). Familial colorectal cancer shows heterozygous FANCE genotype. Fanconi anemia DNA damage repair may be associated with hereditary colorectal cancer. Gain-loss mutations may be involved in hereditary esophageal squamous cell carcinoma. Missense variants of FANCE were found in a family with breast cancer (Akbari et al., 2011; Sealet et al., 2003; Esteban-Jurado et al., 2016). FANCE is involved in the regulation of cisplatin sensitivity (Taniguchi et al., 2003).
[0122] FAT1 has been described as significantly mutated in head and neck squamous cell carcinoma, frequently mutated in endocervical adenocarcinoma, bladder cancer, early T-cell precursor acute lymphoblastic leukemia, fludarabine-refractory chronic lymphocytic leukemia, glioblastoma, and colorectal cancer, and mutated in esophageal squamous cell carcinoma (Gao et al., 2014; Neumann et al., 2013; Morris et al., 2013; Messina et al., 2014; Mountzios et al., 2014; Cazier et al., 2014; Chung et al., 2015). FAT1 has been described as being repressed in oral cancer and preferentially downregulated in invasive breast cancer (Katoh, 2012). FAT1 has been described as being upregulated in leukemias, where it is associated with a poor prognosis in pre-B acute lymphoblastic leukemia (Katoh, 2012). FAT1 has been shown to be upregulated in pancreatic cancer and hepatocellular carcinoma (Valletta et al., 2014; Wojtalewicz et al., 2014). FAT1 has been described to suppress tumor growth through the initiation of Hippo signaling and to promote tumor metastasis through actin polymerization induction (Katoh, 2012). FAT1 has been shown to be a candidate cancer driver gene in cutaneous squamous cell carcinoma (Pickering et al., 2014). FAT1 has been described as a tumor suppressor associated with Wnt signaling and tumorigenesis (Morris et al., 2013).
[0123] FAT3 was shown to be downregulated in paclitaxel-resistant ovarian cancer cell lines upon androgen receptor silencing, resulting in increased sensitivity to paclitaxel in these cell lines. Therefore, FAT3 may be a candidate gene associated with paclitaxel resistance (Sun et al., 2015b). FAT3 was shown to be mutated in esophageal squamous cell carcinoma, leading to dysregulation of the Hippo signaling pathway (Gao et al., 2014). FAT3 was shown to be recurrently mutated in early T-cell precursor acute lymphoblastic leukemia (Neumann et al., 2013). FAT3 was described as a gene with specific features for meningioma and, therefore, is associated with tumorigenesis of this subtype of benign meningioma (Fevre-Montange et al., 2009). FAT3 was described as a tumor suppressor with inhibitory effects on lung cancer development from dysplastic cells (Rohrbeck and Borlak, 2009).
[0124] FHAD1 is downregulated after knockdown of NFE2, which is involved in the oxidative stress response (Williams et al., 2016). CpG methylation of FHAD1 can be used as a biomarker for metastatic and lethal prostate cancer (Zhao et al., 2017). FHAD1 is downregulated in esophageal squamous cell carcinoma and may contribute to promoting cisplatin chemoresistance (Tsutsui et al., 2015). FHAD1 may be a tumor suppressor gene in breast cancer (Iorns et al., 2012).
[0125] G3BP1 encodes G3BP stress granule assembly factor 1, which is one of the DNA depolymerases that prefers partially depolymerized 3'-end substrates and can also depolymerize partially RNA / DNA and RNA / RNA duplexes in an ATP-dependent manner (RefSeq, 2002). G3BP1 can be used as a biomarker for drug response in HER2+ breast cancer (Chien et al., 2016). miR-193a-3p, which inhibits lung cancer progression and metastasis in vitro and in vivo, downregulates G3BP1 (Deng et al., 2015). G3BP1 is a direct target of resveratrol. Depletion of G3BP1 reduces resveratrol-induced p53 expression and apoptosis. G3BP1 is a negative regulator of p53 by interacting with USP10, a p53-specific deubiquitinase (Oi et al., 2015). G3BP1 is recruited to the promoter region of MYCN by MYCNOS to regulate its expression. G3BP1 negatively regulates PMP22 to increase breast cancer proliferation (Winslow et al., 2013; Vadie et al., 2015). G3BP1 may be a target of a bifunctional peptide consisting of a cancer recognition peptide and a pro-apoptotic peptide (Meschenmoser et al., 2013). Advanced oral squamous cell carcinoma is sensitive to G3BP1 knockdown, resulting in increased apoptosis (Xu et al., 2013). G3BP1 is upregulated in breast cancer, oral squamous cell carcinoma, colon cancer, pancreatic cancer, hepatocellular carcinoma, and gastric cancer, and is associated with patient prognosis, tumor size, vascular invasion, T classification, lymph node metastasis, TNM stage, and decreased overall survival (Lo et al., 2012; Winslow et al., 2013; Min et al., 2015; Dou et al., 2016). Y-box binding protein 1 binds to the 5'UTR of G3BP1 mRNA to regulate the availability of G3BP1 stress granule nucleators for granule assembly. Downregulation of YB-1 or G3BP1 results in decreased stress granule formation and tumor invasion (Ward et al., 2011; Annibaldi et al., 2011; Somasekharan et al., 2015). G3BP1 controls the activity of H+-ATPase and the translation of β-F1-ATPase mRNA (Willers and Cuezva, 2011). G3BP1 colocalizes with promyelocytic leukemia nuclear bodies before and after ionizing radiation (Liu et al., 2010). Epigallocatechin gallate is a major compound of green tea that inhibits lung tumorigenesis by binding to G3BP1. G3BP1 expression is affected by lovastatin (Klawitter et al., 2010; Shim et al., 2010).G3BP1 participates in cancer cell growth, apoptosis, motility, migration, invasion, and metastasis by upregulating Slug. Knockdown of G3BP1 reduces Slug expression and increases the epithelial marker E-cadherin. Upregulation of G3BP1 in breast cancer initiates epithelial-mesenchymal transition via the Smad signaling pathway. G3BP1 participates in Ras and NF-κB signaling, the ubiquitin proteasome pathway, and RNA processing (Frenchet et al., 2002; Zhang et al., 2015; Dou et al., 2016). Forced expression of G3BP1 promotes migration of hepatocellular carcinoma cells (Dou et al., 2016).
[0126] GAR1 can activate p53 (Zhang et al., 2012). GAR1 participates in the telomerase complex (Zhu et al., 2004; Rashid et al., 2006; Tomlinson et al., 2008; Pigullo et al., 2009; Low and Tergaonkar, 2013; Heidenreich et al., 2014). GAR1 is important for cell viability (Lubben et al., 1995).
[0127] ITGB4 has been associated with prostate, gastric, breast, oral squamous cell, and ovarian cancers, and has been shown to be upregulated in pancreatic ductal adenocarcinoma (Chen et al., 2014; Xin et al., 2014; Zubor et al., 2015; Masugi et al., 2015; Gao et al., 2015; Kawakami et al., 2015). ITGB4 (also known as CD104) is often associated with the α6 subunit and may play an important role in the biology of several invasive cancers, such as esophageal squamous cell carcinoma, bladder cancer, and ovarian cancer (Kwon et al., 2013; Pereira et al., 2014; Chen et al., 2014). ITGB4 single nucleotide polymorphisms appear to affect tumor aggressiveness and survival and may have prognostic value in breast cancer patients (Brendle et al., 2008).
[0128] KDM5B encodes the protein JARID1B, a lysine-specific histone demethylase that can repress certain tumor suppressor genes by demethylating lysine 4 of histone H3 (RefSeq, 2002). As an epigenetic factor, KDM5B supports the proliferation, migration, and invasion of human OSCC, head and neck squamous cell carcinoma (HNSCC), breast cancer, and lung cancer by inhibiting p53 expression (Shen et al., 2015; Tang et al., 2015a; Zhao and Liu, 2015; Lin et al., 2015). In addition, KDM5B, also known as JARID1B, promotes metastatic epithelial-mesenchymal transition in various tumor types through PTEN / AKT signaling (Tang et al., 2015a).
[0129] KLHL21 is upregulated in hepatocellular carcinoma and can be used as a bioclinical marker (Shi et al., 2016). KLHL21 is a negative regulator of IKKβ. KLHL21 expression is downregulated in macrophages following proinflammatory stimulation. KLHL21 overexpression inhibits IKKβ priming and IκBα degradation (Mei et al., 2016). KLHL21 is overexpressed by the aberrant gene fusion transcription factor ASPSCR1-TFE3, which is found in two different entities: alveolar soft tissue sarcoma and renal cell carcinoma (Kobos et al., 2013). KLHL21 may be involved in carcinogenesis (Martinez et al., 2010). KLHL21 is required for cell division and regulates the transfer of the chromosome passenger complex from chromosomes to the spindle midzone during anaphase. It interacts with Cullin3-based E3 ubiquitin ligases and directly binds to AuroraB, leading to its ubiquitination (Maerki et al., 2009). KLHL21 negatively regulates TNFα-initiated NF-κB signaling by targeting IKKβ (Mei et al., 2016).
[0130] KLK6 encodes kallikrein-related peptidase 6, a member of the kallikrein subfamily of serine proteases of the peptidase S1 family. There is increasing evidence that many kallikreins are involved in carcinogenesis, and some have the potential to serve as novel biomarkers for cancer and other diseases. The expression of this protease is regulated by steroid hormones and may be elevated in a variety of human cancers and in sera from patients with psoriasis. The encoded protease may be involved in the cleavage of amyloid precursor protein and α-synuclein, implicating this protease in Alzheimer's and Parkinson's diseases, respectively. The gene is located in a gene cluster on chromosome 19 (RefSeq, 2002). KLK6 can be induced by p53, and its expression increases autophagy and drug resistance in gastric cancer (Kim et al., 2016). KLK6 downregulation is associated with increased expression of GNA13, which is associated with the aggressiveness of benign breast tumors (Teo et al., 2016). KLK6 is able to up- and down-regulate several miRNAs that may affect the cell cycle, MYC, MAPK, and other signaling pathways (Sidiropoulos et al., 2016). KLK6 belongs to a condition associated with panitumumab resistance in metastatic colorectal cancer (Barry et al., 2016). KLK6 has been implicated in the regulation of axonal growth following spinal cord injury, tumor cell metastasis, and alpha-synuclein aggregation disorders such as Parkinson's disease (Xi et al., 2015). KLK6 is overexpressed in highly aggressive PC3 prostate and ovarian cancers and is dysregulated in cervical precancerous lesions (Tamir et al., 2014; Hwang and Lindholm, 2015). KLK6 can be used as a biomarker for a variety of entities, including hepatocellular carcinoma, breast cancer, colon cancer, gastrointestinal cancer, and astrocytoma (Vakrakou et al., 2014; Yu et al., 2015b; Grin et al., 2015; Schrader et al., 2015; Drucker et al., 2015; Mange et al., 2016). KLK6 is associated with overall survival in advanced serous ovarian cancer, and its expression may be associated with other clinical parameters (Kolin et al., 2014; Dorn et al., 2015; Yang et al., 2016a; Leung et al., 2016; Ahmed et al., 2016).
[0131] CD34 expression in head and neck squamous cell carcinoma is associated with cell cycle progression, and its knockdown upregulates KRT1 expression (Ettlet al., 2016). KRT1 was downregulated in HepG2 cells after platycodin D treatment (Lu et al., 2015a). Immunohistochemical staining of clear cell foci from Bowen's superficial invasive carcinoma showed negative KRT1 (Misago et al., 2016). miR-944 induces KRT1 expression by upregulating p53 and attenuating ERK signaling (Kim et al., 2015). KRT1 expression is upregulated in early and advanced squamous cell carcinoma (Tang et al., 2015b). Nuclear degradation downregulates KRT1 expression (Naeem et al., 2015). KRT1 expression may be a marker of differentiation state. It can be used together with NMP-52 and AFP expression to detect hepatocellular carcinoma (Attalla het al., 2015; Bruna et al., 2017). KRT1 is upregulated after docosahexaenoic acid treatment, which is known to reduce breast cancer invasion (Blanckaert et al., 2015). Proliferating basophils from alpha cell carcinomas fail to express KRT1 (Wang et al., 2015a). Upregulation of KRT1 is indirectly associated with Notch1 receptor stimulation (Vliet-Gregg et al., 2015). S100A7 downregulates KRT1 (Li et al., 2015). KRT1 expression is associated with p21 and hsp70 expression in oral squamous cell carcinoma. Loss of KRT1 is associated with deficiency of Klf4, a transcription factor that inhibits cell proliferation and promotes differentiation (Paparella et al., 2015; Frohwitter et al., 2016).
[0132] KRT13 encodes keratin 13, a member of the keratin gene family. Vitamin D alters KRT 13 expression (Narayanan, 2006). Immunostaining for CK13 is positive in the epidermoid component of mucoepidermoid carcinoma and negative in tubular adenomas and oncolytic carcinomas arising from the mandibular gland (Muramatsu et al., 2003; Matsuzaka et al., 2004; doPrado et al., 2007). Aberrant expression of α6β4 integrin upregulates KRT13, an early event in the development of cutaneous squamous cell carcinoma (Tennenbaum et al., 1996). KRT13 can be used as a biomarker for cervical intraepithelial neoplasia. KRT13 loss is a marker for tumor grade and staging of metastatic urothelial carcinoma. KRT13 expression is a marker for skin cancer progression (Slaga et al., 1995; Southgate et al., 1999; Duggan, 2002; Baake et al., 2006). KRT13 expression is downregulated in oral cancer stem cells and oral squamous cell carcinoma (Morgan and Su, 1994; Sinha et al., 2013).
[0133] KRT14 is highly expressed in various squamous cell carcinomas (e.g., esophageal, lung, laryngeal, cervical) and adenomatous odontogenic tumors. However, it is absent in small cell carcinoma of the bladder and weakly expressed in lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast invasive ductal carcinoma, thyroid papillary carcinoma, and endometrioid adenocarcinoma (Xue et al., 2010; Terada, 2012; Vasca et al., 2014; Hammam et al., 2014; Shruthi et al., 2014). In bladder cancer, KRT14 expression is strongly associated with poor survival (Volkmer et al., 2012).
[0134] Prolonged exposure of MCF-7 breast cancer cells to ethanol upregulates KRT15, a malignancy-associated gene (Gelfand et al., 2017). Basal cell carcinomas with aggressive growth show negative expression of KRT15 (Ziari et al., 2015). KRT15 can be used to differentiate spiradenomas from cylindromas (Sellheyer, 2015). KRT15 is sequentially upregulated in bladder carcinogenesis (Chuang et al., 2014). SIRT2, which is downregulated in skin cancer, inhibits the expression of KRT15 as an epithelial stem cell marker (Wang et al., 2014b). KRT15 is a hair follicle stem cell marker (Bongiovanni et al., 2014; Koba et al., 2015; Narisawa et al., 2015). KRT15 is an undifferentiated basal cell marker that is more strongly expressed in malignant tumors compared to benign ocular surface squamous tumors (Nagata et al., 2014). Spheroid-selected epidermal squamous cell carcinomas have abundant KRT15 expression (Adhikary et al., 2013). KRT15 is upregulated in urothelial carcinoma (Tai et al., 2013). Actinic keratoses associated with head and neck tumors are positive for KRT15 in 7% of cases and in 36% of adenoid cystic carcinomas. Desmoplastic trichoepithelioma has higher staining compared with sclerodermatous forms of basal cell carcinoma and microcystic adnexal carcinoma (Sabeti et al., 2013; Evangelista and North, 2015; North et al., 2015; Solus et al., 2016). KRT15 upregulation affects overall survival in non-small cell lung cancer and can be used as a marker for differential diagnosis of NSCLC (Gomez-Morales et al., 2013; Boyero et al., 2013). KRT15 is regulated by p53 and ER (Lion et al., 2013).
[0135] KRT16 overexpression was found in basal-like breast cancer cell lines as well as in carcinoma in situ. Others have not found significant differences in KRT16 immunohistochemical expression between non-recurrent and recurrent ameloblastoma (Joosse et al., 2012; Ida-Yonemochi et al., 2012; Safadi et al., 2016). In addition, in silico analysis has shown an association between KRT16 expression and shorter recurrence-free survival in metastatic breast cancer (Joosse et al., 2012).
[0136] KRT5 was shown to be upregulated in breast cancer of young women (Johnson et al., 2015). KRT5 was shown to be associated with poor disease-free survival in young women with breast cancer and clinical outcome in premenopausal patients with hormone receptor-positive breast cancer (Johnson et al., 2015; Sato et al., 2014). KRT5 was shown to be regulated by the tumor suppressor BRCA1 in breast cancer cell lines HCC1937 and T47D (Gorski et al., 2010). KRT5 was shown to be dysregulated in malignant pleural mesothelioma (Melaiu et al., 2015). KRT5 was described as a diagnostic mesothelial marker for malignant mesothelioma (Arif and Husain, 2015). KRT5 was shown to be associated with endometrial cancer progression (Zhao et al., 2013). KRT5 was shown to be downregulated in invasive tumor areas in patients with verrucous carcinoma (Schumann et al., 2012). KRT5 was shown to be part of a family of four proteins that were differentially expressed in colorectal cancer biopsies compared to normal tissue samples (Yang et al., 2012a). KRT5 and three other proteins from the family of four proteins were described as novel markers and potential targets for colorectal cancer therapy (Yang et al., 2012a). KRT5 was described as being associated with basal cell carcinoma (Depianto et al., 2010). KRT5 was described as a candidate gene for identifying urothelial cancer stem cells (Hatina and Schulz, 2012).
[0137] KRT6A has been described as part of a seven-gene signature that can be used as a prognostic model to predict long-term recurrence-free survival in patients with triple-negative breast cancer who received adjuvant chemotherapy after surgery (Park et al., 2015b). KRT6A has been shown to be upregulated in zebu horn carcinoma and in gastric cancer (El-Rifai et al., 2002; Koringa et al., 2013). KRT6A was shown to be downregulated in two cases of vulvar sarcomas with morphological and immunohistochemical features of exoskeletal myxoid chondrosarcomas (Dotlic et al., 2014). KRT6A expression was shown to be altered in oral squamous cell carcinoma (Chanthammachat et al., 2013). KRT6A was shown to be associated with negative regulation of proto-oncogene Src kinase activity during wound repair and the migratory potential of skin keratinocytes. This may be important in relevant contexts such as cancer (Rotty and Coulombe, 2012). KRT6A was shown to mark mammary bipotential progenitors that generate a unique mammary tumor model that resembles human normal-like breast cancer (Bu et al., 2011). KRT6A was described as an essential component of a 25-gene transcriptional network signature that can be used to distinguish lung adenocarcinoma from squamous cell carcinoma (Chang et al., 2011).
[0138] KRT6B was shown to be a candidate for downregulated genes in the esophageal cancer cell line KYSE170 (Kan et al., 2006). KRT6B was shown to be upregulated in renal cell carcinoma, sporadic odontogenic keratocystic tumors, and zebu horn carcinoma (Koringa et al., 2013; Hu et al., 2015; Heikinheimo et al., 2007). Loss of KRT6B function was shown to inhibit notch1 expression and induce cell death in renal cell carcinoma cells in vitro. Thus, the interaction of KRT6B with notch1 was described to promote renal cell carcinoma progression (Hu et al., 2015). KRT6B was described as a basal-like breast cancer-associated cytokeratin, and its expression was reduced after the expression of basal-like tumor-associated GABRP was reduced in the cell lines HCC1187 and HCC70 (Sizemore et al., 2014). Selective inhibition of ERK1 / 2 has also been shown to result in decreased expression of basal-like cytokeratins such as KRT6B and decreased migration in basal-like breast cancer (Sizemore et al., 2014). Thus, the GABRP-ERK1 / 2-cytokeratin axis is involved in maintaining the migratory phenotype of basal-like breast cancer (Sizemore et al., 2014). KRT6B has been shown to be involved in negative regulation of proto-oncogene Src kinase activity during wound repair and in the migratory potential of skin keratinocytes. This may be important in relevant contexts such as cancer (Rotty and Coulombe, 2012). KRT6B has been described as an essential component of a 25-gene transcriptional network signature that can be used to distinguish lung adenocarcinoma from squamous cell carcinoma (Chang et al., 2011). KRT6B has been shown to be differentially expressed during benzo(a)pyrene-induced tumorigenesis in immortalized human oral epithelial cells (Li et al., 2008).
[0139] KRT6C was described as an important component of a 25-gene transcriptional network signature that can be used to distinguish lung adenocarcinoma from squamous cell carcinoma (Chang et al., 2011).
[0140] KRT75 encodes keratin 75, a member of the type II keratin family clustered on the long arm of chromosome 12. The encoded protein plays an important role in hair and nail formation. Variants in this gene have been associated with hair disorders such as pseudofolliculitis barbae (PFB) and loose hair follicle syndrome (LAHS) (RefSeq, 2002). KRT75 is downregulated in in vivo passaged and re-derived prostate cell lines compared to the parental cell line (Sivanathan et al., 2014). KRT75 is expressed in onychomacromas, possibly indicating a differentiating role for the nail bed and nail isthmus (Perrin et al., 2011). KRT75 is downregulated in 21T breast cells (Xu et al., 2010). Proteasome inhibitors and dexamethasone alter the expression of KRT75 (Kinyamu et al., 2008).
[0141] Inhibition of LAP3 was shown to lead to invasion inhibition in the ovarian cancer cell line ES-2 through downregulation of fascin and MMP-2 / 9. Therefore, LAP3 may serve as a potential anti-metastatic therapeutic target (Wang et al., 2015b). High expression of LAP3 was shown to be associated with the grade of malignant tumors and poor prognosis of glioma patients (He et al., 2015). LAP3 was shown to promote the progression of gliomas by regulating cell growth, migration, and invasion, and thus may be a new predictor (He et al., 2015). Frameshift mutations in genes involved in amino acid metabolism, including LAP3, were detected in microsatellite instability-high gastric cancer and colorectal cancer (Oh et al., 2014). LAP3 was shown to be upregulated in hepatocellular carcinoma, esophageal squamous cell carcinoma, and prostate cancer (Zhang et al., 2014a; Tian et al., 2014; Lexander et al., 2005). LAP3 has been shown to promote liver cancer cell proliferation by regulating the G1 / S checkpoint of the cell cycle and late cell migration (Tian et al., 2014). LAP3 expression has further been shown to be associated with the prognosis and malignant development of hepatocellular carcinoma (Tian et al., 2014). Silencing of LAP3 in the esophageal squamous cell carcinoma cell line ECA109 has been shown to reduce cell proliferation and colony formation, while LAP3 knockdown leads to cell cycle arrest (Zhang et al., 2014a). Overexpression of LAP3 in the esophageal squamous cell carcinoma cell line TE1 has been shown to favor cell proliferation and invasion (Zhang et al., 2014a). Therefore, LAP3 has been shown to play a role in the malignant development of esophageal squamous cell carcinoma (Zhang et al., 2014a).
[0142] High levels of LGALS7 are associated with an aggressive phenotype of breast cancer with increased cancer invasiveness, growth, and metastasis (Grosset et al., 2016). LGALS7 is differentially expressed in the serum of patients with colorectal cancer, whereas CRC tumors are negative for LGALS7 by immunohistochemical staining (Lim et al., 2016). LGALS7 is downregulated in prostate cancer, cervical cancer, and vulvar squamous cell carcinoma and is associated with advanced clinical stage, poor differentiation, and regional lymph node metastasis. Re-expression leads to increased apoptosis. Increased promoter methylation is associated with advanced clinical stage, poor differentiation, and regional lymph node metastasis in VSCC (Labrie et al., 2015; Jiang et al., 2015; Higareda-Almaraz et al., 2016). Cytoplasmic expression of LGALS7 inhibits p53 and increases chemoresistance in breast cancer (Grosset et al., 2014). LGALS7 is not expressed in normal ovarian tissue but is expressed in epithelial ovarian cancer. Expression is more common in high-grade and metastatic tumors and correlates with overall survival. LGALS7 expression is induced by mutant p53 (Kim et al., 2013; Labrie et al., 2014). LGALS7 can be used as a biomarker for metastatic cutaneous melanoma. It is also associated with clinical parameters in head and neck squamous cell carcinoma and basal cell carcinoma (Timar et al., 2010; Cada et al., 2009). LGALS7 is associated with breast cancer incidence (Tang et al., 2008). LGALS7 expression can be induced by p53 and can promote apoptosis (Ueda et al., 2004).
[0143] LGALS7B enhances the invasiveness of HER2-positive breast cancer (Grosset et al., 2016). LGALS7B regulates molecules involved in apoptosis, tissue morphogenesis, metabolism, transport, chemokine activity, and immune response (Higareda-Almaraz et al., 2016). LGALS7B is downregulated in cervical cancer. High LGALS7B expression associated with low Gal-1 expression is associated with better prognosis (Higareda-Almaraz et al., 2016). LGALS7B is hypermethylated in vulvar squamous cell carcinoma (Jiang et al., 2015). Re-expression of LGALS7B in prostate cancer enhances chemosensitivity to etoposide and cisplatin (Labrie et al., 2015). LGALS7B is downregulated in vulvar squamous cell carcinoma, prostate cancer, and colorectal cancer. Downregulation of LGALS7B is associated with advanced clinical stage, poor tumor differentiation, and regional lymph node metastasis (Labrie et al., 2015; Lim et al., 2016; Jiang et al., 2015). The cytokine LGALS7B inhibits dox-induced PARP-1 cleavage, leading to inhibition of p53 priming and decreased p21 and CDKN1A expression in breast cancer (Grosset et al., 2014). LGALS7B upregulates apoptosis and inhibits IL-2 and IFN-γ expression (Yamaguchi et al., 2013). LGALS7B is overexpressed in ovarian cancer and is associated with older age, high mortality, increased tumor volume, and poor survival (Kim et al., 2013; Labrie et al., 2014). Immunohistochemical staining of LGALS7B can be used to differentiate salivary gland tumor types (Remmelink et al., 2011). LGALS7B is downregulated in basal cell carcinoma of the head and neck. In head and neck squamous cell carcinoma, LGALS7B shows different expression patterns, and different expression levels are associated with keratinization and differentiation (Cada et al., 2009).
[0144] MALL can be used to classify lung cancer subtypes (Watanabe et al., 2010). MALL may be a metastasis suppressor gene in prostate cancer (Yi et al., 2009). MALL mRNA and protein expression is reduced in patients with colon cancer and is associated with vascular invasion, disease recurrence, metastasis, or death. MALL loss is associated with decreased overall survival and disease-free survival. MALL overexpression inhibits cell proliferation and inhibits migration in cell lines (Fan et al., 2011; Kim et al., 2008a; Wang et al., 2016c). MALL can be found on prostate bodies secreted by prostate cancer cell lines, where it interacts with caveolin-1 (Llorente et al., 2004). MALL is downregulated in non-small cell lung cancer and cervical squamous cell carcinoma. It is differentially expressed in glioma cells (Ai et al., 2003; Hatta et al., 2004; Kettunen et al., 2004).
[0145] MCM4 expression is associated with upregulated carbonic anhydrase IX, a transmembrane glycoprotein that has been implicated in survival and cancer progression in several entities, including esophageal cancer (Huber et al., 2015). Has-miR-615-3p may be implicated in nasopharyngeal carcinoma through regulation of MCM4 (Chen et al., 2015). MCM4 may play a role in bladder cancer development (Zekri et al., 2015). p53 gain-of-function mutations increase MCM4 expression in breast cancer (Polotskaia et al., 2015). MCM4 is mutated in human skin cancers and exhibits reduced DNA helicase activity (Ishimi and Irie, 2015). MCM4 overexpression is only weakly associated with shorter survival in breast cancer. Overexpression of all six components of the MCM complex is strongly associated with shorter survival (Kwok et al., 2015). MCM4 is differentially expressed in lung adenocarcinoma and laryngeal squamous cell carcinoma (Lian et al., 2013; Zhang et al., 2014b). MCM4 is significantly overexpressed in cervical cancer (Das et al., 2013; Das et al., 2015). MCM4 can be used as a biomarker for colorectal cancer (Fijneman et al., 2012).
[0146] Antizyme inhibitors inhibit the ubiquitin-independent degradation of ODC1, leading to accelerated polyamine formation and the development of gastric cancer, breast cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma (Qiu et al., 2016). Piroxicam inhibits ODC1-dependent polyamine production involved in the development of non-melanoma skin cancer (Campione et al., 2015). ODC1 regulates putrescine, which is important for cell division regulation, differentiation, maturation, and apoptosis (Ramani et al., 2014; Zdrojewicz and Lachowski, 2014). ODC1 is a Myc and MYCN target gene, and high ODC1 expression is associated with reduced event-free survival in neuroblastoma (Funakoshi-Tago, 2012; Saletta et al., 2014). Blockade of ODC1 could be used for chemopreventive treatment of colorectal cancer (Zhou et al., 2012).
[0147] PARP9 (also known as ARTD9) encodes poly(ADP-ribose) polymerase family member 9 and is located on chromosome 3q21.1 (RefSeq, 2002). DTX3L forms a complex with ARTD8 and PARP9 and promotes proliferation, chemoresistance, and survival of metastatic prostate cancer cells by inhibiting the tumor suppressor IRF1 (Bachmann et al., 2014). PARP9 inhibits IFN-γ-STAT1-IRF1-p53 signaling in diffuse large B-cell lymphoma and initiates the expression of proto-oncogenes IRF2 and BCL-6. This leads to proliferation, survival, and chemoresistance of DLBCL (Camicia et al., 2013). PARP9 expression is IFN-γ-inducible (Juszczynski et al., 2006). PARP9 may be a drug target in diffuse large B-cell lymphoma. PARP9 is an oncogenic survival factor in high-risk chemoresistant DLBCL (Bachmann et al., 2014; Aguiar et al., 2005; Camicia et al., 2015).
[0148] PKP1 has been shown to be downregulated in prostate cancer and esophageal adenocarcinoma (Kaz et al., 2012; Yang et al., 2015). Knockdown of PKP1 in the non-neoplastic, prostate BPH-1 cell line resulted in reduced apoptosis and differential expression of genes such as the prostate cancer-associated SPOCK1 gene (Yang et al., 2015). Overall, altered PKP1 and SPOCK1 expression appear to be frequent and severe events in prostate cancer, suggesting that PKP1 has a tumor suppressor function (Yang et al., 2015). Decreased PKP1 expression has been shown to be associated with a significantly shorter time to distant metastasis in oral squamous cell carcinoma (Harris et al., 2015). Loss of PKP1 through promoter methylation has been described to be associated with the progression of Barrett's esophagus to esophageal adenocarcinoma (Kaz et al., 2012). PKP1 has been shown to be upregulated in non-small cell lung cancer and may be a good marker to distinguish squamous cell carcinoma samples (Sanchez-Palencia et al., 2011). PKP1 has been shown to be upregulated in the well-differentiated liposarcoma cell line GOT3 (Persson et al., 2008). Decreased PKP1 expression has been described to promote increased activity in head and neck squamous cell carcinoma (Sobolik-Delmaire et al., 2007). PKP1 loss has been shown to be associated with cervical carcinogenesis (Schmitt-Graeff et al., 2007). PKP1 has been shown to be associated with local recurrence or metastasis and poor prognosis in patients with oropharyngeal squamous cell carcinoma (Papagerakis et al., 2003).
[0149] PLEC is overexpressed in colorectal adenocarcinoma, head and neck squamous cell carcinoma, and pancreatic cancer (Lee et al., 2004; Katada et al., 2012; Bausch et al., 2011).
[0150] Periplakin is reduced in T24CDDPR bladder cancer cells (Taoka et al., 2015). PPL staining is lower in bladder cancers compared to healthy tissues. PPL loss is associated with pathological stage and survival (Matsumoto et al., 2014). PPL is associated with epithelioid tumor cells (Kohn et al., 2014). EVPL, periplakin, and involucrin-negative mice display a skin cancer-resistant phenotype (Cipolat et al., 2014; Natsuga et al., 2015; Natsuga et al., 2016). PPL is highly expressed in triple-negative breast cancer (Choi et al., 2013). Periplakin is downregulated in esophageal squamous cell carcinoma due to hypermethylation. PPL knockdown in ESCC is associated with decreased cell migration and attachment (Otsubo et al., 2015; Tonoike et al., 2011). Paraneoplastic pemphigus has been shown to harbor autoantibodies against PPL (Yong and Tey, 2013; Li et al., 2009; Probst et al., 2009; Zimmermann et al., 2010).
[0151] PRKDC is a commonly mutated gene in endometriosis-associated ovarian cancer and breast cancer (Er et al., 2016; Wheler et al., 2015). In colorectal cancer, PRKDC is upregulated in cancer tissues compared with normal tissues. Patients with high PRKDC expression show poor overall survival (Sun et al., 2016).
[0152] PRNP encodes a membrane glycosylphosphatidylinositol-anchored glycoprotein that tends to aggregate into rod-like structures and contains a highly unstable region of five tandem repeats of octapeptides. Mutations in the repeat region as well as other regions of the gene have been associated with various prion diseases. The gene has been found to have overlapping open reading frames that encode a smaller, structurally unrelated protein, AltPrp (RefSeq, 2002). Although its physiological role has not been fully determined, PRNP is involved in self-renewal, pluripotency gene expression, proliferation, and differentiation of neural stem cells. PNRP plays a role in human tumors including glioblastoma, breast cancer, prostate cancer, and colorectal cancer (Yang et al., 2016b; Corsaro et al., 2016). In colorectal cancer, PRNP has been shown to promote epithelial-mesenchymal transition (Duet al., 2013). Overexpression of PNRP in combination with MGr1-Ag / 37LRP predicts poor prognosis in gastric cancer (Zhou et al., 2014). PNRP expression is associated with the redox state of cells and may be involved in antioxidant defense. PNRP silencing has been shown to sensitize cancer cells to anticancer drugs in breast and colon cancer (Sauer et al., 1999; Meslin et al., 2007; Park et al., 2015a; Yun et al., 2016).
[0153] PROM2 is specifically upregulated in lung adenocarcinoma (Bao et al., 2016). PROM2 is expressed in elastofibromas and human prostate cancer. PROM2 expression is higher in low-aggressive prostate cancer and lower in high-aggressive prostate cancer (Yamazaki, 2007; Zhang et al., 2002). PROM2 is downregulated in colon cancer (Deng et al., 2013). PROM2 expression can be used to distinguish renal chromophobe cell carcinoma from neoplastic cell carcinoma (Rohan et al., 2006).
[0154] RIPK4 has been shown to be downregulated in cutaneous squamous cell carcinoma (Poligone et al., 2015). RIPK4 is associated with migration and invasion of the tongue squamous cell carcinoma cell line TCA-8113, survival in diffuse large B-cell lymphoma, and overall survival, disease-free survival, progression, and poor prognosis in cervical squamous cell carcinoma (Wang et al., 2014c; Liu et al., 2015; Kim et al., 2008b). RIPK4 is associated with familial pancreatic cancer (Lucito et al., 2007). RIPK4 may be a potential diagnostic and independent prognostic marker for cervical squamous cell carcinoma and a biomarker for prognosis and treatment of tongue cancer (Wang et al., 2014c; Liu et al., 2015).
[0155] RNASE7 expression is decreased in skin cancer (Scola et al., 2012). RNASE7 expression is affected by several leukemogenic protein tyrosine kinases (Pierce et al., 2008).
[0156] RPL8 expression can be affected by MYC-induced nuclear antigen and nucleolar protein 66 (Chowdhury et al., 2014). RPL8 may be involved in osteosarcoma development (Sun et al., 2015a; Yang and Zhang, 2013). RPL8 is regulated by MYC-activated NO-66 (Ge et al., 2012). RPL8 mutations are associated with Diamond-Blackfan anemia (Gazda et al., 2012). RPL8 expression may be associated with chemotherapy response (Salas et al., 2009). RPL8 is dysregulated in hepatocellular carcinoma (Liu et al., 2007). MHCII-dependent expression of RPL8 has been found in melanoma (Swoboda et al., 2007).
[0157] SERPINB5 is a valuable molecular marker and prognostic predictor for many cancer types, including breast, lung, head and neck, oral, and prostate cancers (Marioni et al., 2009; Lonardo et al., 2010; Sager et al., 1996; Sheng, 2004). SERPINB5 acts as an endogenous regulator of HDAC1 activity and interacts with the p53 tumor suppressor pathway (Maass et al., 2000; Kaplun et al., 2012).
[0158] SLC25A3 is deregulated in chronic myeloid leukemia (Oehler et al., 2009). Depletion of SLC25A3 abolishes stress-induced mitochondrial targeting of BAX (Buttner et al., 2011).
[0159] SLC6A11 expression is reduced in rats with paclitaxel-induced neuropathic pain, a phenomenon observed in cancer patients treated with paclitaxel (Yadav et al., 2015). ALA and its methyl ester MAL are prodrugs used in photodynamic therapy of skin cancer. Their uptake is mediated by SLC6A11 (Novak et al., 2011; Schulten et al., 2012; Baglo et al., 2013). Long-term treatment of glioma cells with sodium valproate reduces the expression of SLC6A11 mRNA (Gao et al., 2003).
[0160] SLC6A15 is hypermethylated and thus downregulated in colorectal cancer and may be a candidate biomarker based on stool assays (Kim et al., 2011; Mitchell et al., 2014).
[0161] SLC7A1 is constitutively expressed in acute myeloid leukemia blasts. These blasts are deficient in arginine cycle pathway enzymes, resulting in arginine accumulation and cell proliferation and survival (Mussai et al., 2015). SLC7A1 is overexpressed in colorectal cancer, resulting in arginine accumulation and cell growth. Overexpression of chromosome 13 genes is common in CRC (Camps et al., 2013; Lu et al., 2013). SLC7A1 can be used as a marker of macrophage differentiation. Its expression increases during induction of THP1 monocyte differentiation (Barilli et al., 2011). The MCF-7 breast cancer cell line is dependent on L-arginine for growth. It expresses SLC7A1, and knockdown of SLC7A1 results in reduced arginine uptake, decreased cell viability, and increased apoptosis (Abdelmagid et al., 2011). SLC7A1 expression is strongly correlated with the expression of heme oxygenase-1, which is expressed in many cancers and promotes tumor growth and survival (Tauber et al., 2010). SLC7A1 is a direct target of hepatocyte-specific miR-122 and is downregulated in hepatocellular carcinoma. Downregulation of miR-122 leads to upregulation of SLC7A1 and increased intracellular arginine levels. This pathway is also an important mechanism for colorectal cancer-derived liver metastasis (Kedde and Agami, 2008; Ino et al., 2013; Kishikawa et al., 2015). Activation of protein kinase C leads to internalization of SLC7A1. Stress leads to differential expression of SLC7A1 (Kakuda et al., 1998; Rotmann et al., 2006).
[0162] SUDS3 loss leads to altered cell morphology and increased cell migration (Smith et al., 2012). SUDS3 is involved in thymocyte differentiation (Lee et al., 2012). SUDS3 may have anti-tumor effects (Ramakrishna et al., 2012). USP17 deubiquitinates SUDS3, leading to altered SUDS3-associated HDAC activity in cancer (Ramakrishna et al., 2011). SUDS3 is involved in mitosis (Pondugula et al., 2009). SUDS3 is expressed in breast cancer (Silveira et al., 2009). SUDS3 controls chromosome segregation and can interact with p53 (David et al., 2006).
[0163] TENM2 may be involved in the age of menarche. Early AAM is associated with type 2 diabetes, breast and ovarian cancer, and cardiovascular disease, while late AAM is associated with low bone mineral density and psychological disorders (Yermachenko and Dvornyk, 2016). DOCK2-TENM2 gene fusion transcripts are present in lung cancer patients living in highly polluted areas (Yu et al., 2015a). TENM2 is expressed in most malignant mesothelioma cells (Ziegler et al., 2012). TENM2 may be downregulated in esophageal squamous cell carcinoma (Kan et al., 2006).
[0164] Focal loss of TGM5 in stage II colon cancer may be a driver of this entity (Brosens et al., 2010). TGM5 mutations occurring in non-small cell lung cancer show no difference between smokers and non-smokers (Yongjun Zhang et al., 2013; Broderick et al., 2009; Rafnar et al., 2011; Choi et al., 2016). TGFBR3 loss in prostate cancer also downregulates TGM5 (Sharifi et al., 2007).
[0165] XIRP1 is mutated in metastatic basal-like breast cancer (Hoadley et al., 2016). XIRP1 promoter motif signatures are enriched in triple-negative breast cancer compared with ER+HER2- breast cancer (Willis et al., 2015). XIRP1 is upregulated after vitamin C treatment, which also reduces cancer cell growth (Marshall et al., 2012; Nagappan et al., 2013). XIRP1 is mutated in head and neck squamous cell carcinoma and may be a tumor suppressor gene (Lee et al., 2010). XIRP1 is an oxidative stress-related gene (Baluchamy et al., 2010).
[0166] ZBED6 is a transcriptional repressor of IGF2, which is overexpressed in colorectal cancer and promotes cell proliferation. Knockdown of ZBED6 affects the cell cycle and leads to enhanced cell growth in the RKO cell line and reduced cell growth in HCT116 cells. ZBED6 is a transcriptional repressor of several genes involved in Wnt, Hippo, TGF-β, EGFR, and PI3K signaling, all of which are involved in colorectal carcinogenesis (Markljung et al., 2009; Andersson, 2009; Andersson et al., 2010; Huang et al., 2014; Jiang et al., 2014; Clark et al., 2015; Akhtar et al., 2015).
[0167] Whether an immune response can be stimulated depends on the presence of antigens that are considered foreign by the host immune system. The discovery of tumor-associated antigens has raised the possibility of using the host immune system to intervene in tumor growth. Currently, various mechanisms of using the humoral and cellular aspects of the immune system are being explored for cancer immunotherapy.
[0168] Specific elements of the cellular immune response can specifically recognize and destroy tumor cells. T-cells isolated from tumor-infiltrating cell populations or peripheral blood have shown that these cells play an important role in the innate immune defense against cancer. In particular, CD8+ T cells play an important role in this response, TCD8 + Class I molecules contained in peptides carried by the major histocompatibility complex (MHC) that recognize usually 8 to 10 amino acid residues derived from proteins or defective ribosomal products (DRIPs) located in the cytoplasm. Human MHC molecules are also called human leukocyte antigens (HLA).
[0169] The term "T cell response" refers to the specific proliferation and activation of effector functions induced by a peptide in vitro or in vivo. For MHC class I restricted cytotoxic T cells, the effector function may be lysis of peptide-pulsed, peptide precursor-pulsed or native peptide-presenting target cells, secretion of cytokines, preferably peptide-induced interferon-γ, TNF-α or IL-2, secretion of effector molecules, preferably peptide-induced granzymes or perforins, or degranulation.
[0170] The term "peptide" as used herein refers to a series of amino acid residues, usually linked by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids. These peptides are preferably 9 amino acids in length, but can be as short as 8 amino acids in length, as long as 10, 11, 12 or 13 amino acids or longer, and if they are MHC-II class peptides (extended variants of the peptides of the present invention), they can be as long as 14, 15, 16, 17, 18, 19 or 20 amino acids in length or longer.
[0171] Thus, the term "peptide" shall include salts of a series of amino acid residues, usually linked by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids. Preferably, the salt is a pharmaceutically acceptable salt of the peptide, for example, a chloride or acetate (trifluoroacetate) salt. It must be noted that the salts of the peptides of the present invention are substantially different from the peptides in their in vivo state, since they are not salts in vivo.
[0172] The term "peptide" shall also include "oligopeptide". The term "oligopeptide" as used herein refers to a series of amino acid residues, usually connected by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids. The length of the oligopeptide is not critical to the present invention, as long as the correct epitope is maintained in the oligopeptide. Typically, the oligopeptide length is less than about 30 amino acid residues and is longer than about 15 amino acids.
[0173] The term "polypeptide" refers to a series of amino acid residues, usually connected by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids. The length of the polypeptide is not critical to the present invention as long as the correct epitope is maintained. In contrast to the terms peptide or oligopeptide, the term "polypeptide" refers to a molecule containing more than about 30 amino acid residues.
[0174] A peptide, oligopeptide, protein or nucleotide encoding the molecule is "immunogenic" (and therefore an "immunogen" in the present invention) if it is able to induce an immune response. In the context of the present invention, a more specific definition of immunogenicity is the ability to induce a T cell response. Thus, an "immunogen" is a molecule capable of inducing an immune response, and in the context of the present invention, a molecule capable of inducing a T cell response. In another aspect, the immunogen may be a peptide, a complex of a peptide with MHC, and / or a protein for enhancing specific antibody or TCR resistance.
[0175] A class I T cell "epitope" requires a short peptide that binds to the MHC class I receptor, forming a ternary complex (MHC class I alpha chain, beta-2-microglobulin, and peptide) that can be recognized by a T cell bearing a matching T cell receptor bound to the MHC / peptide complex with appropriate affinity. The typical length of peptides that bind to MHC class I molecules is 8-14 amino acids, with 9 amino acids being the most typical.
[0176] In humans, there are three different gene loci that encode MHC class I molecules (human MHC molecules are also designated human leukocyte antigens (HLA)): HLA-A, HLA-B, and HLA-C. HLA-A*01, HLA-A*02, and HLA-B*07 are examples of different MHC class I alleles that can be expressed from these gene loci.
[0177] Table 5: Expression frequency F of HLA-A*02 and HLA-A*24 and the most common HLA-DR serotypes. Frequencies are based on the Hardy-Weinberg formula F = 1–(1-Gf) used by Mori et al. (Mori et al., 1997) 2 Adapted from U.S. population-wide haplotype frequencies. Due to linkage disequilibrium, some HLA-DR allele combinations may be enriched or at lower frequencies than their expected individual frequencies for A*02 or A*24. For more information, see Chanock et al. (Chanockk et al., 2004).
[0178]
[0179]
[0180]
[0181] The peptides of the invention preferably bind to A*02 when incorporated into the vaccines of the invention as described herein. Vaccines may also include pan-binding MHC class II peptides. Thus, the vaccines of the invention may be used to treat cancer in A*02 positive patients, but do not necessarily select for class II MHC allotypes due to the broad binding properties of these peptides.
[0182] If the A*02 peptide of the present invention is combined with a peptide that binds to another allele, such as A*24, a higher proportion of the patient population can be treated compared to the MHC class I allele alone. Although in most populations, less than 50% of patients can be treated with a single allele, a vaccine containing HLA-A*24 and HLA-A*02 epitopes according to the present invention can treat at least 60% of patients in any relevant population. Specifically, the following proportions of patients in each region have a positive effect on at least one of these alleles: 61% in the United States, 62% in Western Europe, 75% in China, 77% in South Korea, and 86% in Japan (calculated according to www.allelefrequencies.net).
[0183] In a preferred embodiment, the term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides.
[0184] The nucleotide sequence encoding a specific peptide, oligopeptide or polypeptide may be a natural nucleotide sequence or a synthetic nucleotide sequence. In general, the DNA fragment encoding the peptide, polypeptide and protein of the present invention is composed of a cDNA fragment and a short oligonucleotide linker, or a series of oligonucleotides, to provide a synthetic gene that can be expressed in a recombinant transcription unit containing regulatory elements derived from a microorganism or a viral operon.
[0185] As used herein, the term "nucleotide encoding a peptide" refers to a nucleotide sequence encoding a peptide, wherein the peptide includes artificial (man-made) start codon and stop codon compatible with the biological system in which the sequence will be expressed by dendritic cells or another cell system used to produce TCRs.
[0186] The nucleic acid sequences mentioned herein include both single-stranded nucleic acids and double-stranded nucleic acids. Therefore, unless otherwise indicated herein, for example, for DNA, a specific sequence is a single-stranded DNA of the sequence, a duplex (double-stranded DNA) of the sequence and its complementary sequence, and the complementary sequence of the sequence.
[0187] The term "coding region" refers to that portion of a gene that naturally or normally encodes the expression product of the gene in its natural genomic environment, ie, the region that encodes the native expression product of the gene in vivo.
[0188] The coding region can be derived from a non-mutated ("normal") gene, a mutant gene, or an abnormal gene, and can even be derived from a DNA sequence that can be synthesized entirely in the laboratory using DNA synthesis methods well known in the art.
[0189] The term "expression product" refers to a polypeptide or protein which is the product of translation of a gene and any nucleic acid sequence encoding the equivalent resulting from the degeneration of the genetic code and thereby encoding the same amino acids.
[0190] The term "fragment", when referring to a coding sequence, means a portion of DNA that includes a non-complete coding region, the expression product of which has essentially the same biological function or activity as the expression product of the complete coding region.
[0191] The term "DNA fragment" refers to a DNA polymer, either in the form of an individual fragment or as a component of a larger DNA structure, obtained from DNA that has been isolated at least once in a substantially pure form, i.e., free of contaminating endogenous materials, and in quantities or concentrations that allow for the identification, manipulation, and recovery of the fragment and its component nucleotide sequences using standard biochemical methods, such as the use of cloning vectors. Such fragments are present in the form of open reading frames (not interrupted by internal untranslated sequences) or introns (commonly present in eukaryotic genes). Untranslated DNA sequences may be present downstream of the open reading frame, where they do not interfere with the manipulation or expression of the coding region.
[0192] The term "primer" refers to a short nucleic acid sequence that pairs with a DNA strand and provides a free 3'-OH terminus at which DNA polymerase begins to synthesize a deoxyribonucleic acid strand.
[0193] The term "promoter" refers to a region of DNA that is involved in the binding of RNA polymerase, thereby activating transcription.
[0194] The term "isolated" means that a material is removed from its original environment (e.g., its natural environment if naturally occurring). For example, a native nucleotide or polypeptide in a living animal is not isolated, but a nucleotide or polypeptide separated from some or all of the coexisting materials in the natural system is isolated. Such polynucleotides may be part of a vector and / or such polynucleotides and polypeptides may be part of a composition and still be isolated because the vector or composition is not part of its natural environment.
[0195] The polynucleotides and recombinant or immunogenic polypeptides disclosed in the present invention may also exist in a "purified" form. The term "purified" does not require absolute purity; it is only a relative definition and can include highly purified or partially purified preparations, and these terms are understood by technicians in the relevant field. For example, various clones isolated from a cDNA library that have been purified by traditional methods to have an electrophoretic isomorphism. It is explicitly considered that the starting material or natural substance is purified by at least one order of magnitude, preferably two or three orders of magnitude, and more preferably four or five orders of magnitude. In addition, it is explicitly contemplated that the purity of the polypeptide is preferably 99.999%, or at least 99.99% or 99.9%; even preferably 99% or more by weight.
[0196] The nucleic acid and polypeptide expression products disclosed in accordance with the present invention, as well as expression vectors comprising such nucleic acids and / or polypeptides, may be present in a "concentrated form". As used herein, the term "concentrated" refers to a material having a concentration of at least about 2, 5, 10, 100 or 1000 times its natural concentration, advantageously 0.01% by weight, preferably at least 0.1%. Concentrated preparations of about 0.5%, 1%, 5%, 10% and 20% by weight are also expressly contemplated. The sequences, configurations, vectors, clones and other materials comprising the present invention may advantageously be present in a concentrated or isolated form. The term "active fragment" refers to a fragment that produces an immune response (i.e., has immunogenic activity), generally a fragment of a peptide, polypeptide or nucleic acid sequence, whether administered alone or optionally with a suitable adjuvant or in a carrier to an animal, such as a mammal, for example a rabbit or mouse, including a human; the immune response takes the form of stimulating a T cell response in the recipient animal (e.g., a human). Alternatively, the "active fragment" may also be used to induce a T cell response in vitro.
[0197] As used herein, the terms "portion", "segment" and "fragment" when used in relation to polypeptides refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide is treated with any endopeptidase (such as trypsin or chymotrypsin), the oligopeptides obtained by the treatment will represent a portion, segment or fragment of the starting polypeptide. When used in relation to polynucleotides, these terms refer to the products produced by treating the polynucleotide with any endonuclease.
[0198] According to the present invention, the term "percent identity" or "percent equivalence", if referring to a sequence, means that the sequence to be compared ("the compared sequence") is compared with the sequence or sequence of the claim ("the reference sequence") after alignment. The percent identity is then calculated according to the following formula: Percent identity = 100[1-(C / R)]
[0199] Where C is the number of differences between the reference sequence and the compared sequence over the alignment length between the reference sequence and the compared sequence,
[0200] (i) Each base or amino acid sequence in the reference sequence has no corresponding aligned base or amino acid in the compared sequence;
[0201] (ii) each gap in the reference sequence, and
[0202] (iii) each aligned base or amino acid in the reference sequence that differs from an aligned base or amino acid in the compared sequence constitutes a difference; and
[0203] (iiii) Alignment must start at the first position of the alignment sequence;
[0204] And R is the number of bases or amino acids in the reference sequence over the length of the alignment between the reference sequence and the compared sequence, with any gaps in the reference sequence also counted as one base or amino acid.
[0205] If there is an alignment between the "compared sequence" and the "reference sequence" where the percent identity calculated as above is approximately equal to or greater than the specified minimum percent identity, then the compared sequence has the specified minimum percent identity to the reference sequence, although there may be alignments where the percent identity calculated as above in this document is lower than the specified percent identity.
[0206] Therefore, as described above, the present invention provides a peptide comprising a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 91, or a variant thereof having 88% homology with SEQ ID NO: 1 to SEQ ID NO: 91, or a variant thereof inducing a T cell cross-reaction with the peptide. The peptide of the present invention has the ability to bind to a major histocompatibility complex (MHC) class I or a class II molecule of an extended version of the peptide.
[0207] In the present invention, the term "homology" refers to the degree of identity between two amino acid sequences (see the percentage of identity above, such as peptide or polypeptide sequences. The "homology" mentioned above is determined by aligning the two sequences adjusted under ideal conditions with the sequences to be compared. Such sequence homology can be calculated by creating an alignment using algorithms such as ClustalW. General sequence analysis software can also be used, more specifically, VectorNTI, GENETYX or other tools provided by public databases.
[0208] One skilled in the art can assess whether T cells induced by a particular peptide variant can cross-react with the peptide itself (Appay et al., 2006; Colombetti et al., 2006; Fong et al., 2001; Zaremba et al., 1997).
[0209] By "variant" of a given amino acid sequence, the inventors mean that the side chains of one or two amino acid residues, etc., are altered by substitution with the side chains of another naturally occurring amino acid residue or other side chains, such that the peptide is still able to bind to an HLA molecule in substantially the same manner as a peptide containing the given amino acid sequence (consisting of SEQ ID NO: 1 to SEQ ID NO: 91). For example, a peptide may be modified so as to at least maintain (if not improve) its ability to interact with and bind to the binding groove of a suitable MHC molecule, such as HLA-A*02 or -DR, and at least maintain (if not improve) its ability to bind to the TCR of activated T cells.
[0210] Subsequently, these T cells can cross-react with cells and kill cells that express polypeptides (including the natural amino acid sequence of the homologous peptide defined in the present invention). As described in scientific literature and databases (Rammensee et al., 1999; Godkin et al., 1997), certain sites of HLA-A binding peptides are usually anchor residues that can form a core sequence that is commensurate with the binding motif of the HLA binding groove, which is defined by the polarity, electrophysical, hydrophobicity and spatial properties of the polypeptide chain that constitutes the binding groove. Therefore, those skilled in the art can modify the amino acid sequences set forth in SEQ ID No: 1 to SEQ ID NO: 91 by maintaining known anchor residues, and can determine whether these variants retain the ability to bind to MHC class I or II molecules. The variants of the present invention retain the ability to bind to the TCR of activated T cells, and subsequently, these T cells can cross-react with cells expressing a polypeptide containing the natural amino acid sequence of the homologous peptide defined in the present invention and kill such cells.
[0211] If not otherwise stated, the original (unmodified) peptides disclosed herein can be modified by replacing one or more residues at different (possibly selective) sites within the peptide chain. Preferably, these substitutions are located at the termini of the amino acid chain. This substitution may be conservative, for example, where one amino acid is replaced by another amino acid with similar structure and characteristics, such as where one hydrophobic amino acid is replaced by another hydrophobic amino acid. A more conservative substitution is a substitution between amino acids of the same or similar size and chemical properties, for example, leucine is replaced by isoleucine. In studies of sequence variation in natural homologous protein families, substitutions of certain amino acids are often more tolerated than others, and these amino acids often show similarities with the original amino acids in size, charge, polarity, and hydrophobicity, which is the basis for determining "conservative substitutions".
[0212] In this article, conservative substitutions are defined as exchanges within one of the following five groups: Group 1 - small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro, Gly); Group 2 - polar, negatively charged residues and their amides (Asp, Asn, Glu, Gln); Group 3 - polar, positively charged residues (His, Arg, Lys); Group 4 - large aliphatic nonpolar residues (Met, Leu, Ile, Val, Cys) and Group 5 - large aromatic residues (Phe, Tyr, Trp).
[0213] Less conservative substitutions may involve the replacement of one amino acid with another of similar characteristics but different in size, such as the replacement of an alanine with an isoleucine residue. Highly non-conservative substitutions may involve the replacement of an acidic amino acid with another with polar or even basic properties. However, such "radical" substitutions should not be dismissed as ineffective, since chemical reactions are not completely predictable and radical substitutions may bring about unforeseen effects that could not be foreseen in their simple chemical principles.
[0214] Of course, such substitutions may involve other structures besides common L-amino acids. Thus, D-amino acids may be substituted with common L-amino acids in the antigenic peptides of the present invention, and still be within the scope of the present disclosure. In addition, non-standard amino acids (i.e., in addition to common natural proteinogenic amino acids) may also be used for substitution purposes to produce immunogens and immunogenic polypeptides according to the present invention.
[0215] If substitutions at more than one position are found to result in an antigenic activity of the peptide substantially equal to or greater than the value defined below, combinations of these substitutions are tested to determine whether the combined substitutions produce an additive or synergistic effect on the antigenicity of the peptide. No more than 4 positions may be substituted simultaneously within the peptide.
[0216] A peptide consisting essentially of an amino acid sequence as defined herein may have one or two non-anchor amino acids (see below regarding anchor motifs) exchanged, without the situation being such that the ability to bind to human major histocompatibility complex (MHC) class I or II molecules is substantially altered or adversely affected compared to the unmodified peptide. In another embodiment, in a peptide consisting essentially of an amino acid sequence as defined herein, one or two amino acids may be exchanged with their conservative exchange partners (see below), without the situation being such that the ability to bind to human major histocompatibility complex (MHC) class I or II molecules is substantially altered or adversely affected compared to the unmodified peptide.
[0217] These amino acid residues that do not substantially interact with T cell receptors can be modified by replacing other amino acids that have little effect on T cell response and do not hinder binding to relevant MHC. Therefore, except for specific limiting conditions, the peptide of the present invention may be any peptide (the term used by the inventors includes oligopeptides or polypeptides) comprising a given amino acid sequence or a portion or variant thereof.
[0218] Table 6: Variants and motifs of peptides according to SEQ ID NO: 4, 6 and 10
[0219]
[0220]
[0221]
[0222] Longer (extended) peptides may also be suitable. MHC class I epitopes (usually 8 to 11 amino acids in length) may be produced by processing of the peptide from a longer peptide or protein containing the actual epitope. The residues flanking the actual epitope are preferably residues that do not substantially affect the protein cleavage required to expose the actual epitope during processing.
[0223] The peptides of the present invention can be extended by up to four amino acids, i.e. 1, 2, 3 or 4 amino acids, and can be added to either end in any combination between 4:0 and 0:4. The extended combinations of the present invention can be seen in Table 7.
[0224] Table 7: Extended combinations of peptides of the present invention
[0225]
[0226]
[0227] The stretched / elongated amino acids can be the original sequence peptide of the protein or any other amino acids. The extension can be used to enhance the stability or solubility of the peptide.
[0228] Therefore, the epitope described in the present invention may be the same as a natural tumor-associated epitope or tumor-specific epitope, or may include a peptide that differs by no more than four residues from a reference peptide, as long as they have substantially the same antigenic activity.
[0229] In an alternative embodiment, one or both sides of the peptide are extended by more than 4 amino acids, preferably up to a total length of 30 amino acids. This can form an MHC-II class binding peptide. Binding to MHC class II peptides can be tested by methods known in the art.
[0230] Therefore, the present invention provides peptides and variants of MHC class I epitopes, wherein the total length of the peptide or antibody is 8 to 100, preferably 8 to 30, and most preferably 8 to 14 amino acids in length (i.e., 10, 11, 12, 13, 14 amino acids, and if it is an extended class II binding peptide, the length can also be 15, 16, 17, 18, 19, 20, 21 or 22 amino acids).
[0231] Of course, the peptides or variants of the present invention can bind to human major histocompatibility complex (MHC) class I or II molecules. The binding of the peptides or variants to the MHC complex can be tested by methods known in the art.
[0232] Preferably, when the peptide-specific T cells of the present invention are tested in comparison with the substituted peptide, if the substituted peptide has a half-maximal increase in solubility relative to the background peptide, the peptide concentration is no more than about 1 mM, preferably no more than about 1 μM, more preferably no more than about 1 nM, even more preferably no more than about 100 pM, and most preferably no more than about 10 pM. It is also preferred that the substituted peptide is recognized by more than one T cell, at least 2, more preferably 3.
[0233] In a particularly preferred embodiment of the present invention, the peptide consists or essentially consists of an amino acid sequence selected according to SEQ ID NO: 1 to SEQ ID NO:91.
[0234] “Essentially composed of…” means that the peptide of the present invention, in addition to being composed of any one of SEQ ID NO: 1 to SEQ ID NO: 91 or a variant thereof, also contains amino acids located at other N- and / or C-terminal extensions, which may not necessarily form a peptide that serves as an MHC molecule epitope.
[0235] However, these extended regions play an important role in effectively introducing the peptides of the present invention into cells. In one embodiment of the present invention, the peptide is part of a fusion protein, containing 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain (p33, hereinafter referred to as "Ii") from NCBI, GenBank Accession No. X00497. In other fusions, the peptides of the present invention can be fused to the antibodies described herein, or functional parts thereof, in particular, to sequences of antibodies, so that the antibodies perform specific targeting, or, for example, into dendritic cell-specific antibodies described herein.
[0236] In addition, the peptide or variant can be further modified to improve stability and / or binding to MHC molecules, thereby eliciting a stronger immune response. Such optimization methods of peptide sequences are well known in the art, including, for example, the introduction of trans-peptide bonds and non-peptide bonds.
[0237] In the reverse peptide bond amino acid, the peptide (-CO-NH-) is not connected to its residue, but its peptide bond is reversed. Such retro-inversopeptidomimetics can be prepared by methods known in the art, such as the method described by Meziere et al. (Meziere et al., 1997), which is incorporated herein by reference. This method involves preparing mimetic peptides containing changes in the backbone (rather than the side chains). Studies by Meziere et al. (Meziere et al., 1997) showed that these mimetic peptides are beneficial for MHC binding and helper T cell responses. Retro-inversopeptides with NH-CO bonds instead of CO-NH peptide bonds greatly improve resistance to hydrolysis.
[0238] Non-peptide bonds are -CH2-NH, -CH2S-, -CH2CH2-, -CH=CH-, -COCH2-, -CH(OH)CH2- and -CH2SO-, etc. U.S. Patent No. 4897445 proposes a non-solid phase synthesis method for non-peptide bonds (-CH2-NH) in polypeptide chains, which involves polypeptides synthesized according to standard procedures and non-peptide bonds synthesized by the interaction of aminoaldehydes and an amino acid containing NaCNBH3.
[0239] Peptides containing the above sequences can be synthesized with other chemical groups at their amino and / or carboxyl termini to improve the stability, bioavailability, and / or affinity of the peptides. For example, hydrophobic groups such as benzyloxycarbonyl, dansyl, or tert-butyloxycarbonyl groups can be added to the amino terminus of the peptide. Similarly, acetyl or 9-fluorenylmethoxycarbonyl groups may be located at the amino terminus of the peptide. In addition, hydrophobic groups, tert-butyloxycarbonyl groups, or amino groups may be added to the carboxyl terminus of the peptide.
[0240] In addition, all peptides of the present invention may be synthesized to change their spatial configuration. For example, the dextrorotatory form of one or more amino acid residues of these peptides may be used, usually not the levorotatory form. Further, at least one amino acid residue of the peptide of the present invention may be substituted by a well-known non-natural amino acid residue. Such changes may help to increase the stability, bioavailability and / or binding effect of the peptide of the present invention.
[0241] Similarly, the peptides or variants of the present invention can be chemically modified by reaction of specific amino acids before or after peptide synthesis. Examples of such modifications are well known in the art, for example, in R. Lundblad, Chemical Reagents for Protein Modification (3rd ed. CRC Press, 2004) (Lundblad, 2004), which is incorporated herein by reference. Although the chemical modification methods of amino acids are unlimited, they include (but are not limited to) modification by the following methods: acylation, amidination, lysine pyridoxalation, reductive alkylation, trinitrophenylation of amino groups with 2,4,6-trinitrobenzenesulfonic acid (TNBS), amino modification of carboxyl groups and sulfhydryl groups by performing oxidation of cysteine to cysteic acid, formation of labile derivatives, formation of mixed disulfide compounds with other sulfhydryl compounds, reaction with maleimide, carboxymethylation with iodoacetic acid or iodoacetamide, and carbamoylation with cyanate at alkaline pH. In this regard, the skilled person is referred to Chapter 15 of Current Protocols In Protein Science (Eds. Coligan et al. (John Wiley and Sons NY 1995-2000)) (Coligan et al., 1995) for extensive methods related to the chemical modification of proteins.
[0242] In brief, modification of arginyl residues of proteins is often based on the reaction of ortho-dicarbonyl compounds such as phenylglyoxal, 2,3-butanedione and 1,2-hexanedione to form adducts. Another example is the reaction of methylglyoxal with arginine residues. Cysteine can be modified without concomitant modification of nucleophilic sites such as lysine and histidine. Therefore, there are a large number of reagents for the modification of cysteine. The websites of companies such as Sigma-Aldrich (http: / / www.sigma-aldrich.com) contain information on specific reagents.
[0243] Selective reduction of disulfide bonds in proteins is also common. Disulfide bonds can be formed and oxidized during heat treatment of biopharmaceuticals. Woodward's reagent K can be used to modify specific glutamic acid residues. N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide can be used to form intramolecular crosslinks between lysine residues and glutamic acid residues. For example: diethyl pyrocarbonate is a reagent for modifying histidine residues in proteins. Histidine can also be modified using 4-hydroxy-2-nonenal. Reaction of lysine residues with other α-amino groups, for example, facilitates peptide binding to the surface or crosslinking of proteins / peptides. Lysine polysaccharides are the attachment point for poly(ethylene) glycol and are also the major modification site for protein glycosylation. Methionine residues of proteins can be modified by iodoacetamide, bromoethylamine, chloramine T, etc.
[0244] Tetranitromethane and N-acetylimidazole can be used for modification of tyrosine residues. Cross-linking via dityrosine can be accomplished with hydrogen peroxide / copper ions.
[0245] Recent studies on tryptophan modification have used N-bromosuccinimide, 2-hydroxy-5-nitrobenzyl bromide, or 3-bromo-3-methyl-2-(2-nitrophenylthio)-3H-indole (BPNS-skatole).
[0246] Successful modification of therapeutic proteins and peptides containing polyethylene glycol often results in extended circulation half-life when cross-linking of proteins with glutaraldehyde, polyethylene glycol diacrylate, and formaldehyde is used to formulate hydrogels. Chemical modification of allergens for immunotherapy is often achieved by carbamylation with potassium cyanate.
[0247] Another embodiment of the present invention relates to a non-natural peptide, wherein the peptide consists of or consists essentially of an amino acid sequence according to SEQ ID No: 1 to SEQ ID No: 156, and is synthetically produced (i.e., synthesized) as a pharmaceutically acceptable salt. Methods for synthetically producing peptides are well known in the art. Salts of the peptides of the present invention are substantially different from the peptides in their in vivo state, because these peptides produced in vivo are not salts. The non-natural salt form of the peptide mediates the solubility of the peptide, particularly in the case of a pharmaceutical composition comprising the peptide, for example, a peptide vaccine disclosed herein. In order to effectively provide the peptide to a subject in need of treatment, it is necessary that the peptide has sufficient, at least basic, solubility. Preferably, the salt is a pharmaceutically acceptable salt of the peptide. These salts of the present invention include alkali and alkaline earth salts, such as salts of the Hofmeister series, containing anions PO4 3- 、SO4 2- 、CH3COO - , Cl - Br - 、NO3 - 、ClO4 - ,I - 、SCN - and cation NH4+ , Rb + , K + 、Na + , Cs + , Li + 、Zn 2+ Mg 2+ , Ca 2+ , Mn 2+ , Cu 2+ and Ba 2+ In particular, the salt is selected from (NH4)3PO4, (NH4)2HPO4, (NH4)H2PO4, (NH4)2SO4, NH4CH3COO, NH4Cl, NH4Br, NH4NO3, NH4CIO4, NH4I, NH4SCN, Rb3PO4, Rb2HPO4, RbH2PO4, Rb2SO4, Rb4CH3COO, Rb4Cl, Rb4Br, Rb4NO3, Rb4CIO4, Rb4I, Rb4SCN, K3PO4, K2HP O4, KH2PO4, K2SO4, KCH3COO, KCl, KBr, KNO3, KClO4, KI, KSCN, Na3PO4, Na2HPO4, NaH2PO4, Na2SO4, NaCH3COO, NaC l, NaBr, NaNO3, NaCIO4, NaI, NaSCN, ZnCI2Cs3PO4, Cs2HPO4, CsH2PO4, Cs2SO4, CsCH3COO, CsCl, CsBr, CsNO3, CsCI O4, CsI, CsSCN, Li3PO4, Li2HPO4, LiH2PO4, Li2SO4, LiCH3COO, LiCl, LiBr, LiNO3, LiClO4, LiI, LiSCN, Cu2SO4, M g3(PO4)2, Mg2HPO4, Mg(H2PO4)2, Mg2SO4, Mg(CH3COO)2, MgCl2, MgBr2, Mg(NO3)2, Mg(ClO4)2, MgI2, Mg(SCN)2, Mn Cl2, Ca3(PO4), , Ca2HPO4, Ca(H2PO4)2, CaSO4, Ca(CH3COO)2, CaCl2, CaBr2, Ca(NO3)2, Ca(ClO4)2, CaI2, Ca(SCN)2, Ba3(PO4)2, Ba2HPO4, Ba(H2PO4)2, BaSO4, Ba(CH3COO)2, BaCl2, BaBr2, Ba(NO3)2, Ba(ClO4)2, BaI2 and Ba(SCN)2. Particularly preferred are NH3-acetic acid, MgCl2, KH2PO4, Na2SO4, KCl, NaCl and CaCl2, for example chlorides or acetates (trifluoroacetic acid).
[0248] In general, peptides and variants (at least containing peptide linkages between amino acid residues) can be synthesized using the Fmoc-polyamide format for solid phase peptide synthesis as disclosed by Lukas et al. (Lukas et al., 1981) and references cited therein. Temporary protection of the N-amino groups is provided by the fluorenylmethyloxycarbonyl (Fmoc) group. Repeated cleavage of this highly base-labile protecting group is performed using 20% dimethylpiperidinium in N,N-dimethylformamide. Side chain functions may be protected by their butyl ethers (in the case of serine, threonine and tyrosine), butyl esters (in the case of glutamic acid and aspartic acid), tert-butyloxycarbonyl derivatives (in the case of lysine and histidine), trityl derivatives (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulfonyl derivatives (in the case of arginine). Whenever glutamine and asparagine are C-terminal residues, the side chain amino functions are protected by 4,4'-dimethoxydiphenyl groups. The solid support is based on polydimethylacrylamide polymer, which is composed of three monomers dimethylacrylamide (backbone monomer), bisacryloylethylenediamine (crosslinker) and N-acryloylsarcosine methyl ester (functional agent). The peptide-resin linker used is an acid-sensitive 4-hydroxymethylphenoxyacetic acid derivative. All amino acid derivatives were added as their preformed symmetrical anhydride derivatives, except for asparagine and glutamine, which were added using a reversed N,N-dicyclohexylcarbodiimide / 1-hydroxybenzotriazole-mediated coupling procedure. All coupling and deprotection reactions were monitored using ninhydrin, nitrobenzenesulfonic acid or isotin test procedures. After the synthesis is completed, the peptides are cleaved from the resin support with the concomitant removal of the side chain protecting groups using 95% trifluoroacetic acid containing 50% scavenger mixture. Commonly used scavenger mixtures include ethanedithiol, phenol, anisole and water, and the exact choice depends on the amino acid composition of the synthesized peptide. In addition, it is possible to synthesize peptides using a combination of solid and solution phase methods (see, for example, (Bruckdorfer et al., 2004) and references cited therein).
[0249] Trifluoroacetic acid was removed by evaporation in vacuo followed by titration with diethyl ether loaded with crude peptide. Any scavenger compounds present were removed by a simple extraction procedure which yielded scavenger compound-free peptides after lyophilization of the aqueous phase. Peptide synthesis reagents are generally available from Calbiochem-Novabiochem (Nottingham, UK).
[0250] Purification may be performed by any one or a combination of techniques such as recrystallization, size exclusion chromatography, ion exchange chromatography, hydrophobic interaction chromatography and (usually) reverse phase high performance liquid chromatography (eg using an acetonitrile / water gradient separation).
[0251] Peptide analysis can be performed using thin layer chromatography, electrophoresis, especially capillary electrophoresis, solid phase extraction (CSPE), reversed phase high performance liquid chromatography, amino acid analysis after acid hydrolysis, fast atom bombardment (FAB) mass spectrometry, and MALDI and ESI-Q-TOF mass spectrometry.
[0252] To select over-presented peptides, a presentation plot was calculated that shows the median presentation of the sample as well as the replicate variation. This feature juxtaposes samples of the relevant tumor entity with baseline values of normal tissue samples. Each of the above features can be incorporated into the over-presentation score by calculating the p-value of the adjusted linear mixed effects model (Pinheiro et al., 2015), thereby adjusting for multiple tests by the false discovery rate (BenjaminiandHochberg, 1995) (see Example 1, Figure 1).
[0253] For the identification and relative quantification of HLA ligands by mass spectrometry, HLA molecules from shock-frozen tissue samples were purified and HLA-associated peptides were isolated. The isolated peptides were separated and identified by online nano-electrospray-ionization (nanoESI) liquid chromatography-spectroscopy (LC-MS) experiments. The resulting peptide sequences were validated by comparing the fragmentation patterns of natural tumor-associated peptides (TUMAPs) recorded in head and neck squamous cell carcinoma samples (N=17 A*02-positive samples) with the fragmentation patterns of corresponding synthetic reference peptides of the same sequence. Since these peptides were directly identified as ligands of HLA molecules of primary tumors, these results provide direct evidence for the natural processing and presentation of the identified peptides on primary cancer tissues from 14 patients with head and neck squamous cell carcinoma.
[0254] Discovery pipeline v2.1 (e.g., see US2013-0096016, which is hereby incorporated by reference in its entirety) allows for the identification and selection of relevant over-presented candidate peptide vaccines based on direct relative quantification of HLA-restricted peptide levels in cancer or other infected tissues compared to several different non-cancerous tissues and organs. This was achieved by developing a label-free differential quantification method using LC-MS acquisition data processed using a proprietary data analysis pipeline, incorporating sequence recognition algorithms, spectral clustering, counting ions, retention time adjustment, charge state convolution, and normalization.
[0255] Presentation levels, including error estimates, were established for each peptide and sample. Peptides that are abundantly presented by tumor tissues as well as peptides that are over-presented in tumor versus non-tumor tissues and organs have been identified.
[0256] HLA-peptide complexes from head and neck squamous cell carcinoma tissue samples were purified, and HLA-associated peptides were separated and analyzed using LC-MS (see Examples). All TUMAPs included in this application were identified using the method of primary head and neck squamous cell carcinoma samples to confirm their presentation on primary head and neck squamous cell carcinoma.
[0257] TUMAPs identified on multiple head and neck squamous cell carcinomas and normal tissues were quantified using an ion counting method for label-free LC-MS data. This method assumes that the LC-MS signal area of a peptide is related to its abundance in the sample. All quantified signals of peptides from various LC-MS experiments were normalized on the basis of central tendency, averaged per sample, and merged into a histogram (called a presentation plot). The presentation plot integrates different analytical methods such as: protein database search, spectral clustering, charge state deconvolution (decharge) and retention time alignment and normalization.
[0258] In addition to over-presenting peptides, mRNA expression of potential genes was also tested. mRNA data was obtained by RNA sequencing analysis of normal tissues and cancer tissues (see Example 2, Figure 2). An additional source of normal tissue data is a database of RNA expression data publicly available from 3000 normal tissue samples (Lonsdale, 2013). Peptides obtained from proteins show high expression encoding mRNA in cancer tissues, but are very low or absent in important normal tissues, and these peptides are included in the present invention as preferred peptides.
[0259] The present invention provides methods useful for treating cancer / tumors, preferably head and neck squamous cell carcinoma, which over-present or exclusively present the peptides of the present invention. These peptides were directly shown by mass spectrometry to be naturally presented by HLA molecules in primary head and neck squamous cell carcinoma.
[0260] Compared with normal tissues, many source genes / proteins (also designated as "full-length proteins" or "basic proteins") from which the peptides are derived are highly overexpressed in cancer-the "normal tissues" associated with the present invention are healthy breast cells or other normal tissue cells, which indicates a high degree of association between tumors and these source genes (see Example 2). In addition, these peptides themselves are also over-presented in tumor tissues (the "tumor tissues" associated with the present invention refer to samples from patients with head and neck squamous cell carcinoma), but not over-presented in normal tissues (see Example 1).
[0261] HLA-bound peptides can be recognized by the immune system, specifically T lymphocytes, which can then destroy cells presenting the recognized HLA / peptide complex (e.g., head and neck squamous cell carcinoma cells presenting the derived peptide).
[0262] All peptides of the present invention have been shown to have the ability to stimulate T cell responses and are over-presented, and can therefore be used to prepare antibodies and / or TCRs of the present invention, such as soluble TCRs (see Examples 3 and 4). In addition, when the peptides are combined with the corresponding MHC, they can also be used to prepare antibodies and / or TCRs of the present invention, especially sTCRs. Each method is well known to technicians and can be found in various documents. Therefore, the peptides of the present invention can be used to produce an immune response in patients, thereby destroying tumor cells. The patient's immune response can be induced by directly administering the peptide or precursor substance (e.g., extended peptides, proteins, or nucleic acids encoding these peptides) to the patient, preferably in combination with an immunogenicity-enhancing preparation. The immune response derived from the therapeutic vaccine is expected to be highly specific against tumor cells because the target peptide of the present invention is presented in a small number of copies on normal tissues, preventing the patient from having an adverse autoimmune response against normal cells.
[0263] The present specification also relates to a T cell receptor (TCR) comprising an alpha chain and a beta chain ("α / β TCR"). Peptides of the present invention that can bind to TCRs and antibodies when presented by MHC molecules are also provided. The present specification also relates to nucleic acids, vectors, and host cells for expressing TCRs and peptides of the present specification; and methods of using them.
[0264] The term "T cell receptor" (abbreviation TCR) refers to a heterodimeric molecule comprising one alpha polypeptide chain (α chain) and one beta polypeptide chain (β chain), wherein the heterodimeric receptor is capable of binding peptide antigens presented by HLA molecules. The term also includes so-called gamma / delta TCRs.
[0265] In one embodiment, the specification provides a method of producing a TCR as described herein, the method comprising culturing a host cell capable of expressing the TCR under conditions suitable for promoting expression of the TCR.
[0266] In another aspect, the present description relates to a method according to the present description, wherein the antigen is loaded onto a class I or II MHC molecule expressed on the surface of a suitable antigen-presenting cell or an artificial antigen-presenting cell by contacting a sufficient amount of the antigen with the antigen-presenting cell, or the antigen is loaded onto a class I or II MHC tetramer by tetramerizing a class I or II MHC complex monomer.
[0267] The α and β chains of α / βTCR and the γ and δ chains of γ / δTCR are generally considered to have two "domains" each, namely the variable and constant domains. The variable domain consists of a combination of a variable region (V) and a joining region (J). The variable domain may also include a leader region (L). The β and δ chains may also include a diversity region (D). The α and β constant domains may also include a C-terminal transmembrane (TM) domain that anchors the α and β chains to the cell membrane.
[0268] With respect to γ / δ TCR, as used herein, the term "TCRγ variable domain" refers to a combination of the TCRγV (TRGV) region without a leader region (L) and the TCRγ (TRGJ) region, and the term TCRγ constant domain refers to the extracellular TRGC region, or a C-terminal truncated TRGC sequence. Similarly, the "TCRδ variable domain" refers to a combination of the TCRδV (TRDV) region without a leader region (L) and the TCRδD / J (TRDD / TRDJ) region, and the term "TCRδ constant domain" refers to the extracellular TRDC region, or a C-terminal truncated TRDC sequence.
[0269] The TCR of the present specification preferably binds to a peptide HLA molecule complex with a binding affinity (KD) of about 100 μM or less, about 50 μM or less, about 25 μM or less, or about 10 μM or less. A more preferred situation is a high affinity TCR with a binding affinity of about 1 μM or less, about 100 nM or less, about 50 nM or less, or about 25 nM or less. Non-limiting examples of preferred binding affinity ranges of the TCR of the present invention include about 1 nM to about 10 nM; about 10 nM to about 20 nM; about 20 nM to about 30 nM; about 30 nM to about 40 nM; about 40 nM to about 50 nM; about 50 nM to about 60 nM; about 60 nM to about 70 nM; about 70 nM to about 80 nM; about 80 nM to about 90 nM; and about 90 nM to about 100 nM.
[0270] As used herein with respect to the TCR of this specification, "specific binding" and its grammatical variations are used to indicate a TCR that has a binding affinity (KD) for a peptide-HLA molecule complex of 100 μM or less.
[0271] The α / β heterodimeric TCRs of the present specification may have introduced disulfide bonds between their constant domains. Preferred TCRs of this type include those having a TRAC constant domain sequence and a TRBC1 or TRBC2 constant domain sequence, unless threonine 48 of TRAC and serine 57 of TRBC1 or TRBC2 are substituted with cysteine residues that form disulfide bonds between the TRAC constant domain sequence and the TRBC1 or TRBC2 constant domain sequence of the TCR.
[0272] With or without the above-mentioned introduced interchain bond, the α / β heterodimeric TCR of the present specification may have a TRAC constant domain sequence and a TRBC1 or TRBC2 constant domain sequence, and the TRAC constant domain sequence and the TRBC1 or TRBC2 constant domain sequence of the TCR may be connected via a native disulfide bond between Cys4 of TRAC exon 2 and Cys4 of TRBC1 or TRBC2 exon 2.
[0273] The TCR of the present specification may include a detectable label selected from the group consisting of a radionuclide, a fluorophore and biotin. The TCR of the present specification may be bound to a therapeutically active agent, such as a radionuclide, a chemotherapeutic agent or a toxin.
[0274] In one embodiment, the TCR having at least one mutation in the alpha chain and / or having at least one mutation in the beta chain has modified glycosylation compared to the non-mutated TCR.
[0275] In one embodiment, a TCR comprising at least one mutation in a TCR alpha chain and / or a TCR beta chain has a binding affinity and / or a binding half-life for a peptide HLA molecule complex that is at least twice the binding affinity of a TCR comprising an unmutated TCR alpha chain and / or an unmutated TCR beta chain. Tumor-specific TCR affinity enhancement and its development rely on the existence of a window of optimal TCR affinity. The existence of such a window is based on the observation that HLA-A2 restricted pathogen-specific TCRs are generally about 10 times lower in KD value than HLA-A2 restricted tumor-associated self-antigen-specific TCRs. It is now known that although tumor antigens may be immunogenic, because the tumor comes from the individual's own cells, only mutant proteins or proteins with altered translation processing will be considered foreign by the immune system. Antigens that are upregulated or overexpressed (so-called self-antigens) do not necessarily induce a functional immune response against the tumor: T cells expressing TCRs that are highly reactive to these antigens will be unfavorably selected in the thymus in a process called central tolerance, that is, only cells with low affinity TCRs for self-antigens still exist. Therefore, the affinity of the TCR or variant of the present description for the peptide can be enhanced by methods well known in the art.
[0276] The present specification also relates to a method for identifying and isolating the TCR of the present invention, the method comprising: incubating PBMC from HLA-A*02 negative healthy donors with A2 / peptide monomers, incubating PBMC with tetramer-phycoerythrin (PE) and isolating high affinity T cells by fluorescence activated cell sorting (FACS)-Calibur method analysis.
[0277] The present specification also relates to a method for identifying and isolating the TCR of the present invention, the method comprising: obtaining transgenic mice containing the entire human TCRαβ gene locus (1.1 and 0.7 Mb) (whose T cells express diversified human TCRs to compensate for the lack of mouse TCR), immunizing the mice with a peptide, incubating PBMCs obtained from the transgenic mice with tetramer-phycoerythrin (PE), and analyzing and isolating high-affinity T cells by fluorescence-activated cell sorting (FACS)-Calibur method.
[0278] On the one hand, in order to obtain the T cell expressing this specification TCR, the nucleic acid encoding this specification TCR-α and / or TCR-β chain is cloned into an expression vector, such as a gamma retrovirus or a slow virus. Recombinant virus is produced, and then the function is tested, such as antigen specificity and functional affinity. Then, aliquots of the final product are used to transduce target T cell colonies (generally purified from the patient's PBMC), which are launched before the patient is input. On the other hand, in order to obtain the T cell expressing this specification TCR, TCRRNA is synthesized by technology known in the art (e.g., in vitro transcription system). Then, the TCRRNA synthesized in vitro re-expresses tumor-specific TCR-α and / or TCR-β chains by electroporation and is introduced into primary CD8+T cells obtained from healthy donors.
[0279] To increase expression, the nucleic acid encoding the TCR of the present specification can be operably linked to a strong promoter, such as a retroviral long terminal repeat (LTR), cytomegalovirus (CMV), mouse stem cell virus (MSCV) U3, phosphoglycerate kinase (PGK), β-actin, ubiquitin protein and simian virus 40 (SV40) / CD43 composite promoter, elongation factor (EF)-1a and spleen focus forming virus (SFFV) promoter. In a preferred embodiment, the promoter is heterologous to the nucleic acid being expressed. In addition to a strong promoter, the TCR expression cassette of the present specification may contain additional elements that can increase transgene expression, including a central polypurine region (CPPT), which promotes nuclear translocation of lentiviral constructs (Follenzi et al., 2000), and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), which increases transgene expression levels by increasing RNA stability (Zufferey et al., 1999).
[0280] The α and β chains of the TCR of the present invention may be encoded by nucleic acids located on separate vectors, or may be encoded by polynucleotides located on the same vector.
[0281] Achieving high-level TCR surface expression requires the introduction of TCR-α and TCR-β chains of TCR at high levels of transcription. To achieve it, the TCR-α and TCR-β chains of this specification can be cloned into a bicistronic construct in a single vector, which has been shown to overcome this obstacle. The use of TCR-α and TCR-β chains in between viral ribosome entry sites (IRES) leads to the coordinated expression of the two chains, because TCR-α and TCR-β chains are produced by a single transcript that is divided into two proteins during translation, thereby ensuring the production of TCR-α and TCR-β chains in an equal molar ratio. (Schmitt et al. 2009).
[0282] The nucleic acid encoding the TCR of the present specification may be codon optimized to increase expression from a host cell. Genetic code redundancy allows some amino acids to be encoded by more than one codon, but some codons are not "optimized" as other codons because of the relative availability of matching tRNA and other factors (Gustafsson et al., 2004). Modification of the TCR-α and TCR-β gene sequences so that each amino acid is encoded by the optimal codon for mammalian gene expression, as well as elimination of mRNA instability motifs or cryptic splice sites, has been shown to significantly increase TCR-α and TCR-β gene expression (Scholten et al., 2006).
[0283] Furthermore, mispairing between introduced and endogenous TCR chains may result in the acquisition of specificities that pose a significant risk for autoimmunity. For example, the formation of mixed TCR dimers may reduce the number of CD3 molecules available to form correctly paired TCR complexes and, therefore, may significantly reduce the functional avidity of cells expressing the introduced TCR (Kubal et al., 2007).
[0284] To reduce mispairing, the C-terminal domain of the TCR chain introduced in this specification can be modified to promote interchain affinity while reducing the ability of the introduced chain to pair with endogenous TCR. These strategies may include replacing the human TCR-α and TCR-β C-terminal domains with mouse counterparts (murinized C-terminal domains); generating a second interchain disulfide bond in the C-terminal domain by introducing a second cysteine residue into the TCR-α and TCR-β chains introduced into the TCR (cysteine modification); exchanging the interacting residues of the C-terminal domains of the TCR-α and TCR-β chains ("knob-hole structure"); directly fusing the variable domains of the TCR-α and TCR-β chains to CD3ζ (CD3ζ fusion) (Schmittt et al. 2009).
[0285] In one embodiment, the host cell is structurally altered to express the TCR of this specification. In a preferred embodiment, the host cell is a human T cell or a T cell progenitor cell. In some embodiments, the T cell or T cell progenitor cell is obtained from a cancer patient. In other embodiments, the T cell or T cell progenitor cell is obtained from a healthy donor. The host cell of this specification can be allogeneic or autologous relative to the patient to be treated. In one embodiment, the host is a γ / δ T cell transformed to express an α / β TCR.
[0286] A "pharmaceutical composition" refers to a composition suitable for administration to humans in a medical setting. Preferably, the pharmaceutical composition is sterile and manufactured according to GMP guidelines.
[0287] Pharmaceutical compositions include the peptides in free form or in the form of a pharmaceutically acceptable salt (see also above). As used herein, "pharmaceutically acceptable salt" refers to a derivative of the disclosed peptides wherein the peptide is modified by making an acid or base salt of the agent. For example, acid salts are prepared using a free base (generally where the neutral drug has a neutral -NH2 group) reacted with a suitable acid. Suitable acids for preparing acid salts include organic acids such as acetic acid, propionic acid, hydroxy acids, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, salicylic acid, and the like, and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Conversely, base salt preparations of acidic groups present on a peptide are prepared using pharmaceutically acceptable bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine, and the like.
[0288] In particularly preferred embodiments, the pharmaceutical composition comprises the peptide in the form of acetic acid (acetate), trifluoroacetate or hydrochloric acid (chloride).
[0289] The agent of the present invention is preferably an immunotherapeutic agent, for example, a vaccine. The vaccine may be administered directly to the affected organ of the patient, or systemically by injection, id, im, sc, ip and iv, or applied in vitro to cells from the patient or his cell line (which are then injected into the patient), or applied in vitro to a subset of cells from the patient's immune cells (which are then re-administered to the patient). If the nucleic acid is injected into the cells in vitro, it may be beneficial to transfect the cells to co-express immunostimulatory cytokines (such as interleukin-2). The peptide may be administered completely alone, or in combination with an immunostimulatory adjuvant (see below), or in combination with an immunostimulatory cytokine, or in an appropriate delivery system (such as liposomes). The peptide may also be combined to form a suitable carrier (such as keyhole limpet hemocyanin (KLH) or mannan) to a suitable carrier (see WO95 / 18145 and (Longenecker et al., 1993)). The peptide may also be labeled, may be a fusion protein, or may be a hybrid molecule. The peptides given in the present invention are expected to stimulate CD4 or CD8 T cells. However, CD8 T cell stimulation is more effective with the help of CD4 T-helper cells. Therefore, for MHC class I epitopes that stimulate CD8 T cells, a fusion partner or fragment of a hybrid molecule provides an appropriate epitope for stimulating CD4 positive T cells. CD4- and CD8 stimulatory epitopes are well known in the art and include those identified in the present invention.
[0290] In one aspect, the vaccine comprises at least one peptide set forth in SEQ ID NO: 1 to SEQ ID NO: 91 and at least one additional peptide, preferably 2 to 50, more preferably 2 to 25, even more preferably 2 to 20, most preferably 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 peptides. The peptides may be derived from one or more specific TAAs and may bind to MHC class I molecules.
[0291] In another aspect, the present invention provides a nucleic acid (e.g., a polynucleotide) encoding a peptide or peptide variant of the present invention. The polynucleotide may be, for example, DNA, cDNA, PNA, RNA, or a combination thereof, which may be single-stranded and / or double-stranded, or a native or stable form of a polynucleotide (e.g., a polynucleotide having a thiophosphate backbone), and may or may not contain introns as long as it encodes a peptide. Of course, a polynucleotide can only encode a peptide that incorporates a natural peptide bond and contains natural amino acid residues. In another aspect, the present invention provides an expression vector that can express a polypeptide according to the present invention.
[0292] A variety of methods have been developed for joining polynucleotides, especially for DNA, by methods such as adding ligatable ends to a vector. For example, complementary homopolymer tracks can be added to a DNA fragment, which is then inserted into the vector DNA. The vector and DNA fragment are then joined by hydrogen bonding of the complementary homopolymer tails, thereby forming a recombinant DNA molecule.
[0293] Synthetic linkers containing one or more restriction sites provide another method for connecting DNA fragments to vectors. Synthetic linkers containing various restriction endonucleases can be purchased from a variety of channels, including International Biotechnologies Inc, New Haven, Connecticut, USA.
[0294] The DNA encoding the polypeptide of the present invention is preferably modified by the polymerase chain reaction method used by Saiki et al. (Saiki et al., 1988). This method can be used to introduce DNA into a suitable vector (for example, by designing suitable restriction sites), and can also be used to modify DNA by other useful methods known in the art. If a viral vector is used, a poxvirus vector or an adenovirus vector is preferred.
[0295] Afterwards, the DNA (or in the case of a retroviral vector, RNA) may be expressed in a suitable host, thereby producing a polypeptide containing the peptide or variant of the present invention. Thus, the DNA encoding the peptide or variant of the present invention may be used according to known techniques, after appropriate modification using the methods described herein, to construct an expression vector, which is then used to transform a suitable host cell, thereby expressing and producing the polypeptide of the present invention. Such techniques include those disclosed in, for example, U.S. Patents 4,440,859, 4,530,901, 4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006, 4,766,075, and 4,810,648.
[0296] The DNA (or RNA in the case of retroviral vectors) encoding the polypeptide containing the compound of the invention may be added to a variety of other DNA sequences and introduced into a suitable host. The companion DNA will depend on the nature of the host, the manner in which the DNA is introduced into the host, and whether it is necessary to maintain it as an episome or to be combined with each other.
[0297] In general, the DNA can be attached to an expression vector (such as a plasmid) in the proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the corresponding transcriptional and translational regulatory control nucleotide sequences recognized by the desired host, although such control functions are generally present in the expression vector. The vector is then introduced into the host by standard methods. In general, not all hosts will be transformed by the vector. Therefore, it is necessary to select transformed host cells. The selection method includes inserting a DNA sequence into the expression vector with any necessary control elements, which encodes a selectable attribute (such as antibiotic resistance) in the transformed cell.
[0298] Alternatively, the gene conferring such a selectable trait may be on another vector which is used to co-transform the desired host cell.
[0299] The host cells transformed with the recombinant DNA of the present invention are then cultured under appropriate conditions familiar to those skilled in the art as described herein and for a sufficient period of time to express the peptide which can then be recovered.
[0300] There are many known expression systems, including bacteria (such as Escherichia coli and Bacillus subtilis), yeast (such as Saccharomyces cerevisiae), filamentous fungi (such as Aspergillus), plant cells, animal cells and insect cells. The system can be preferably mammalian cells, such as CHO cells from ATCC Cell Biology Collection.
[0301] Typical mammalian cell constitutive expression vector plasmids include CMV or SV40 promoters containing a suitable poly A tail and resistance markers (such as neomycin). An example is pSVL obtained from Pharmacia (Piscataway, New Jersey, USA). An example of an inducible mammalian expression vector is pMSG, which can also be obtained from Pharmacia. Useful yeast plasmid vectors are pRS403-406 and pRS413-416, which are generally available from Stratagene Cloning Systems (LaJol la, California 92037, USA). Plasmids pRS403, pRS404, pRS405 and pRS406 are yeast integration plasmids (YIp), and yeast selectable markers HIS3, TRP1, LEU2 and URA3 are inserted. pRS413-416 plasmids are yeast centromere plasmids (Ycp). Vectors based on the CMV promoter (e.g., from Sigma-Aldrich) provide transient or stable expression, cytoplasmic expression or secretion, and N-terminal or C-terminal tags in different compositions of FLAG, 3xFLAG, c-myc or MATN. These fusion proteins can be used to detect, purify and analyze recombinant proteins. Dual-label fusion provides flexibility for detection.
[0302] The strong human cytomegalovirus (CMV) promoter regulatory region allows the expression of constitutive proteins in COS cells at levels as high as 1 mg / L. For weaker cell lines, protein levels are generally less than 0.1 mg / L. The presence of the SV40 replication origin will result in high-level replication of DNA in SV40 replication-tolerant COS cells. For example, CMV vectors can contain the pMB1 (derivative of pBR322) replication origin in bacterial cells, the calcium-lactamase gene for ampicillin resistance selection in bacteria, the origin of hGHpolyA and f1. Vectors containing the preproinsulin leader (PPT) sequence can use anti-FLAG antibodies, resins and plates to guide the secretion of FLAG fusion proteins into the culture medium for purification. Other vectors and expression systems used with various host cells are well known in the art.
[0303] In another embodiment, two or more peptides or peptide variants of the present invention are encoded and thus expressed in a continuous order (similar to a "beads on a string" construct). Upon reaching the target, the peptides or peptide variants may be linked or fused together by a stretch of linker amino acids (e.g., LLLLLL) or they may be linked without any additional peptides between them. These constructs may also be used in cancer therapy and may induce immune responses involving MHC I and MHC II class molecules.
[0304] The present invention also relates to a host cell, which is transformed with the polynucleotide vector construction of the present invention. The host cell can be a prokaryotic cell or a eukaryotic cell. In some cases, bacterial cells are preferred prokaryotic host cells, typically Escherichia coli strains, for example, Escherichia coli strain DH5 (obtained from Bethesda Research Laboratories, Bethesda, Maryland, USA) and RR1 (obtained from the American Type Culture Collection (ATCC, Rockville, Maryland, USA), ATCC No. 31343). Preferred eukaryotic host cells include yeast, insect and mammalian cells, preferably vertebrate cells, such as cells in mouse, rat, monkey or human fibroblasts and colon cancer cell lines. Yeast host cells include YPH499, YPH500 and YPH501, which are generally available from Stratagene Cloning Systems, La Jolla, CA92037, USA. Preferred mammalian host cells include Chinese hamster ovary (CHO) cells, CCL61 cells in ATCC, NIH Swiss mouse embryonic cells NIH / 3T3, CRL 1658 cells in ATCC, monkey kidney-derived COS-1 cells, CRL 1650 cells in ATCC, and human embryonic kidney cells No. 293 cells. Preferred insect cells are Sf9 cells, which can be transfected with baculovirus expression vectors. An overview of the selection of appropriate host cells for expression can be found in textbooks (Paulina Balbás and Argelia Lorence "Methods in Molecular Biology Recombinant t Gene Expression, Reviews and Protocols" Part One, Second Edition, ISBN 978-1-58829-262-9) and other literature known to the skilled person.
[0305] Transformation of appropriate host cells containing the DNA structure of the present invention can be accomplished using well-known methods, generally depending on the type of vector used. For transformation of prokaryotic host cells, see, for example, Cohen et al. (Cohen et al., 1972) and (Green and Sambrook, 2012). Transformation of yeast cells is described in Sherman et al. (Sherman et al., 1986). The method described in Beggs (Beggs, 1978) is also useful. For vertebrate cells, reagents for transfecting these cells, such as calcium phosphate and DEAE-dextran or liposome formulations, can be obtained from Stratagene Cloning Systems or Life Technologies (Gaithersburg, MD20877, USA). Electroporation can also be used to transform and / or transfect cells, which is a well-known method in the art for transforming yeast cells, bacterial cells, insect cells, and vertebrate cells.
[0306] Successfully transformed cells (i.e. cells containing the DNA construct of the present invention) can be identified by well-known methods (e.g. PCR). In addition, proteins present in the supernatant can be detected using antibodies.
[0307] It should be understood that certain host cells of the present invention are used to prepare the peptides of the present invention, such as bacterial cells, yeast cells and insect cells. However, other host cells may be useful for certain therapeutic methods. For example, antigen presenting cells (such as dendritic cells) can be used to express the peptides of the present invention so that they can be loaded with corresponding MHC molecules. Therefore, the present invention provides a host cell containing a nucleic acid or expression vector of the present invention.
[0308] In a preferred embodiment, the host cell is an antigen presenting cell, in particular a dendritic cell or an antigen presenting cell. On April 29, 2010, the U.S. Food and Drug Administration (FDA) approved a recombinant fusion protein containing proteolytic adenocarcinoma (PAP) for the treatment of asymptomatic or mildly symptomatic metastatic HRPC (Rini et al., 2006; Small et al., 2006).
[0309] In another aspect, the present invention provides a method for preparing a peptide and a variant thereof, the method comprising culturing a host cell and isolating the peptide from the host cell or its culture medium.
[0310] In another embodiment, the peptide, nucleic acid or expression vector of the present invention is used in medicine. For example, the peptide or its variant can be prepared as an intravenous (iv) injection, a subcutaneous (sc) injection, an intradermal (id) injection, an intraperitoneal (ip) injection, or an intramuscular (im) injection. Preferred methods for peptide injection include sc, id, ip, im and iv injection. Preferred methods for DNA injection are id, im, sc, ip and iv injection. For example, 50 μg to 1.5 mg, preferably 125 μg to 500 μg of peptide or DNA is administered, depending on the specific peptide or DNA. The above dosage range has been successfully used in previous experiments (Walter et al., 2012).
[0311] The polynucleotides used for active immunization can be in a substantially purified form or can be encapsulated in a carrier or delivery system. The nucleic acid may be DNA, cDNA, PNA, RNA, or a combination thereof. The design and introduction of such nucleic acids are well known in the art. For example, there is an overview in the literature (Teufer et al., 2005). Polynucleotide vaccines are easy to prepare, but the mode of action of these vectors in inducing immune responses is not yet fully understood. Suitable vectors and delivery systems include viral DNA and / or RNA, such as systems based on adenovirus, vaccinia virus, retrovirus, herpes virus, adeno-associated virus, or mixed viruses containing more than one viral element. Non-viral delivery systems include cationic liposomes and cationic polymers, which are well known systems in the art of DNA delivery. Physical delivery systems can also be used, such as by "gene guns". The peptide or peptide encoded by the nucleic acid can be a fusion protein, for example, containing epitopes that stimulate T cells to carry out the above-mentioned CDR.
[0312] The medicaments of the present invention may also include one or more adjuvants. Adjuvants are substances that non-specifically enhance or strengthen the immune response (e.g., by CD8-positive T cells and helper T (T H ) cell-mediated immune response to an antigen, and therefore is considered useful for the medicament of the present invention. Suitable adjuvants include (but are not limited to) 1018ISS, aluminum salts, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or flagellin-derived TLR5 ligand, FLT3 ligand, GM-CSF, IC30, IC31, imiquimod resiquimod, ImuFactIMP321, interleukin IL-2, IL-13, IL-21, interferon α or β, or their PEGylated derivatives, IS Patch, ISS, ISCOMATRIX, ISCOMs, LipoVac, MALP2, MF59, monophosphoryl lipid A, Montanide IMS1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, oil-in-water and water-in-oil emulsions, OK-432, OM-174, OM-197-MP-EC, ONTAK, OspA, Delivery systems, poly(lactide-co-glycolide) [PLG]- and dextran-based microparticles, recombinant human lactoferrin SRL172, virosomes and other virus-like particles, YF-17D, VEGFtrap, R848, β-glucan, Pam3Cys, Aquila's QS21 stimulators derived from saponins, mycobacterial extracts, and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox, Quil, or Superfos. Preferred adjuvants are Freund's adjuvant or GM-CSF. Several dendritic cell-specific immunoadjuvants (e.g., MF59) and methods for their preparation have been described previously (Allison and Krummel, 1995). Cytokines may also be used. Some cytokines directly affect the migration of dendritic cells to lymphoid tissues (e.g., TNF-), accelerate the maturation of dendritic cells into effective antigen-presenting cells of T lymphocytes (e.g., GM-CSF, IL-1 and IL-4) (U.S. Patent No. 5,849,589, specifically incorporated herein by reference in its entirety), and act as immune adjuvants (e.g., IL-12, IL-15, IL-23, IL-7, IFN-α, IFN-β) (Gabrilovich et al., 1996).
[0313] CpG immunostimulatory oligonucleotides have been reported to enhance the effects of adjuvants in vaccines. Without being bound by theory, CpG oligonucleotides act by activating the innate (non-adaptive) immune system through Toll-like receptors (TLRs), primarily TLR9. CpG-induced TLR9 activation enhances antigen-specific humoral and cellular responses to a variety of antigens, including peptide or protein antigens, live or killed viruses, dendritic cell vaccines, autologous cell vaccines, and polysaccharide conjugates in prophylactic and therapeutic vaccines. More importantly, it enhances the maturation and differentiation of dendritic cells, leading to T H1 The activation of TLR9-induced T cells and the generation of cytotoxic T lymphocytes (CTLs) were enhanced, even in the absence of CD4 T cells. H1 Offset, these adjuvants such as: Normal promotion of T H2CpG oligonucleotides exhibit stronger adjuvant activity when prepared or co-administered with other adjuvants or formulations, such as microparticles, nanoparticles, fat emulsions or similar preparations, which are particularly necessary to induce strong responses when the antigen is relatively weak. They can also accelerate immune responses, reduce antigen doses by about two orders of magnitude, and in some experiments, produce similar antibody responses to full-dose vaccines without CpG (Krieg, 2006). U.S. Patent No. 6406705B1 describes the use of CpG oligonucleotides, non-nucleic acid adjuvants and antigens in combination to promote antigen-specific immune responses. A CpG TLR9 antagonist is dSLIM (double stem loop immunomodulator) from Mologen (Berlin, Germany), which is a preferred component of the pharmaceutical composition of the present invention. Other TLR binding molecules, such as RNA binding TLR7, TLR8 and / or TLR9, can also be used.
[0314] Other useful adjuvant examples include (but are not limited to) chemically modified CpG (e.g., CpR, Idera), dsRNA mimics, such as Poly(I:C) and its derivatives (e.g., AmpliGen, Hiltonol, poly-(ICLC), poly(IC-R), poly(I:C12U)), non-CpG bacterial DNA or RNA, and immunologically active small molecules and antibodies, such as cyclophosphamide, sunitinib, Celebrex, NCX-4016, sildenafil, tadalafil, vardenafil, sorafenib, temozolomide, temsirolimus, XL-999, CP-547632, pazopanib, VEGF Trap, ZD2171, AZD2171, anti-CTLA4, other antibodies targeting major structures of the immune system (e.g., anti-CD40, anti-TGFβ, anti-TNFα receptors), and SC58175, all of which may have therapeutic effects and / or act as adjuvants. The amounts and concentrations of adjuvants and additives useful in the present invention can be readily determined by the skilled artisan without undue experimentation.
[0315] The preferred adjuvants are anti-CD40, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon α, CpG oligonucleotides and derivatives, poly (I:C) and derivatives, RNA, sildenafil, and microparticle preparations of PLG or virosomes.
[0316] In a preferred embodiment of the pharmaceutical composition of the present invention, the adjuvant is selected from a preparation containing colony stimulating factors, such as granulocyte macrophage colony stimulating factor (GM-CSF, sargramostim), cyclophosphamide, imiquimod, resiquimod and interferon-α.
[0317] In a preferred embodiment of the pharmaceutical composition of the present invention, the adjuvant is selected from a preparation containing colony stimulating factors, such as granulocyte macrophage colony stimulating factor (GM-C SF, sargramostim), cyclophosphamide, imiquimod and resiquimod. In a preferred embodiment of the pharmaceutical composition of the present invention, the adjuvant is cyclophosphamide, imiquimod or resiquimod. More preferred adjuvants are Montanide IMS1312, MontanideISA 206, Montanide ISA50V, Montanide ISA-51, poly-ICLC and anti-CD40 mAb or a combination thereof.
[0318] This combination drug is used for parenteral injection, such as subcutaneous, intradermal, intramuscular injection, and can also be taken orally. For this reason, the peptide and other selective molecules are decomposed or suspended in a pharmaceutical carrier, preferably an aqueous carrier. In addition, the composition may contain excipients, such as buffers, binders, shock agents, diluents, spices, lubricants, etc. These peptides can also be used in combination with immunostimulants, such as cytokines. More excipients that can be used for such compositions can be found in books such as Handbook of Pharmaceutical Excipients (Kibbe, 2000) written by A.Kibbe. This combination drug can be used to prevent, prevent and / or treat adenomas or cancerous diseases. For example, there are example preparations in EP2112253.
[0319] It is important to recognize that the immune response elicited by the vaccine of the present invention attacks cancer at different cellular stages and at different stages of development. And different cancer-related signaling pathways are attacked. This is an advantage over other vaccines, which target only one or a few targets, which may cause tumors to easily adapt to attacks (tumor escape). In addition, not all individual tumors express the same pattern of antigens. Therefore, the combination of several tumor-associated peptides ensures that each tumor bears at least some targets. The composition is designed in such a way that it is expected that each tumor can express several antigens and cover several independent pathways required for tumor growth and maintenance. Therefore, the vaccine can be easily "ready-made" for a larger patient population. This means that patients who are pre-selected for vaccine treatment can be limited to HLA typing, without any additional biomarker assessment of antigen expression, but still ensure that multiple targets are attacked by the induced immune response at the same time, which is important for efficacy (Banchereau et al., 2001; Walter et al., 2012).
[0320] The term "scaffold" as used herein refers to a molecule that specifically binds to a (e.g., antigen) determinant. In one embodiment, the scaffold is capable of guiding the entity to which it is attached (e.g., a (second) antigen binding moiety) to a target of interest, for example, to a specific type of tumor cell or a tumor stroma bearing an antigenic determinant (e.g., a complex of a peptide and MHC according to the current application). In another embodiment, the scaffold is capable of activating a signaling pathway through its target antigen (e.g., a T cell receptor complex antigen). Scaffolds include, but are not limited to, antibodies and fragments thereof, antigen binding regions of antibodies comprising an antibody heavy chain variable region and an antibody light chain variable region, bound proteins comprising at least one ankyrin repeat motif and a single domain antigen binding (SDAB) molecule, an aptamer, a (soluble) TCR, and (modified) cells, such as allogeneic or autologous T cells. In order to assess whether a molecule is a scaffold that binds to a target, a binding assay may be performed.
[0321] "Specific" binding means that the scaffold binds better to the peptide-MHC complex of interest than to other natural peptide-MHC complexes, to the extent that a scaffold with active molecules capable of killing cells bearing a specific target is not able to kill another cell without a specific target but presenting one or more other peptide-MHC complexes. If the peptide of the cross-reactive peptide-MHC is not natural, i.e., not from the human HLA-peptide group, binding to other peptide-MHC complexes is irrelevant. Tests to assess target cell killing are well known in the art. They should be performed with target cells (primary cells or cell lines) presenting unaltered peptide-MHC or with cells loaded with the peptide so as to reach the level of natural peptide-MHC.
[0322] Each scaffold may include a label that can detect the presence or absence of a signal provided by the label. For example, the scaffold can be labeled with a fluorescent dye or any other suitable cell marker molecule. Such marker molecules are well known in the art. For example, fluorescent labeling by fluorescent dyes can provide visualization of bound aptamers by fluorescence or laser scanning microscopy or flow cytometry.
[0323] Each scaffold can be conjugated to a second active molecule (eg, IL-21, anti-CD3, anti-CD28).
[0324] For further information on polypeptide scaffolds, see, for example, the background section of WO 2014 / 071978 A1, which is incorporated herein by reference.
[0325] The present invention also relates to aptamers. Aptamers (e.g., see WO 2014 / 191359 and references cited therein) are short single-stranded nucleic acid molecules that can fold into a defined three-dimensional structure and recognize a specific target structure. They appear to be a suitable alternative for developing targeted therapies. Aptamers have been shown to selectively bind to complex targets with high affinity and specificity.
[0326] Aptamers that recognize cell surface molecules have been identified over the past decade and provide a means for developing diagnostic and therapeutic approaches. Aptamers have been shown to be virtually non-toxic and immunogenic, and therefore, are promising candidates for biomedical applications. In fact, aptamers, such as prostate-specific membrane antigen recognition aptamers, have been successfully used for targeted therapy and have shown functionality in xenografts in in vivo models. In addition, aptamers that recognize specific tumor cell lines have also been identified.
[0327] DNA aptamers can be selected to reveal broad-spectrum signature properties of various cancer cells, especially those derived from solid tumors, while non-tumorigenic and predominantly healthy cells are not recognized. If the identified aptamers not only recognize tumor-specific subtypes but also interact with a range of tumors, this makes aptamers suitable as so-called broad-spectrum diagnostics and therapeutics.
[0328] Furthermore, investigation of the cell binding behavior using flow cytometry revealed that the aptamers displayed good affinity in the nanomolar range.
[0329] Aptamers are used for diagnostic and therapeutic purposes. Furthermore, it could also be shown that some aptamers are taken up by tumor cells and thus can serve as molecular vehicles for the targeted delivery of anticancer agents, such as siRNA into tumor cells.
[0330] Aptamers can be selected against complex targets such as cells and tissues and complexes of peptides according to the current invention comprising, preferably including, a sequence according to any of SEQ ID NO 1 to SEQ ID NO 91 and MHC molecules using the cell SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technique.
[0331] The peptides of the present invention can be used to generate and develop specific antibodies against MHC / peptide complexes. These antibodies can be used therapeutically to target toxins or radioactive substances to diseased tissue. Another use of these antibodies is to target radionuclides to diseased tissue for imaging purposes (such as PET). This can help detect small metastases or determine the size and exact location of diseased tissue.
[0332] Therefore, another aspect of the present invention is to propose a method for producing a recombinant antibody that specifically binds to class I or II human major histocompatibility complex (MHC) complexed with an HLA-restricted antigen, the method comprising: immunizing a genetically engineered non-human mammal containing cells expressing the major histocompatibility complex (MHC) class I or II with a soluble form of the (MHC) class I or II molecule complexed with the HLA-restricted antigen; separating mRNA molecules from antibody-producing cells of the non-human mammal; producing a phage display library that displays protein molecules encoded by the mRNA molecules; and separating at least one phage from the phage display library, the at least one phage displaying that the antibody specifically binds to the human major histocompatibility complex (MHC) class I or II complexed with the HLA-restricted antigen.
[0333] Another aspect of the present invention provides an antibody that specifically binds to a class I or II human major histocompatibility complex (MHC) complexed with an HLA-restricted antigen, wherein the antibody is preferably a polyclonal antibody, a monoclonal antibody, a bispecific antibody and / or a chimeric antibody.
[0334] Corresponding methods for producing such antibodies and single-chain class I major histocompatibility complexes, as well as other tools for producing these antibodies are disclosed in WO03 / 068201, WO2004 / 084798, WO01 / 72768, WO03 / 070752 and publications (Cohen et al., 2003a; Cohen et al., 2003b; Denkberg et al., 2003), all of which are incorporated herein by reference in their entirety for the purposes of the present invention.
[0335] Preferably, the antibody binds to the complex with an affinity of less than 20 nanomolar, preferably less than 10 nanomolar, which is also considered "specific" in the context of the present invention.
[0336] The present invention relates to a peptide comprising a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 91 or a variant thereof having 88% homology (preferably identical) to SEQ ID NO: 1 to SEQ ID NO: 91, or a variant thereof inducing T cells to cross-react therewith, wherein the peptide is not a basic full-length polypeptide.
[0337] The present invention further relates to a peptide comprising a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 91, or a variant having at least 88% homology (preferably identical) to SEQ ID NO: 1 to SEQ ID NO: 91, wherein the total length of the peptide or variant is 8 to 100, preferably 8 to 30, most preferably 8 to 14 amino acids.
[0338] The present invention further relates to the peptides of the present invention, which have the ability to bind to major histocompatibility complex (MHC) class I or II molecules.
[0339] The present invention further relates to the peptides of the present invention, wherein the peptide consists or essentially consists of the amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 91.
[0340] The present invention further relates to the peptides of the present invention, wherein the peptide is (chemically) modified and / or comprises non-peptide bonds.
[0341] The invention further relates to the peptides of the invention, wherein the peptide is part of a fusion protein, in particular comprising the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii), or wherein the peptide is fused to an antibody (eg, a dendritic cell-specific antibody).
[0342] The present invention further relates to a nucleic acid encoding a peptide according to the present invention, with the proviso that the peptide is not a complete (full) human protein.
[0343] The present invention further relates to a nucleic acid of the present invention, which is DNA, cDNA, PNA, RNA or a combination thereof.
[0344] The present invention further relates to an expression vector capable of expressing or expressing the nucleic acid of the present invention.
[0345] The present invention further relates to the use of the peptide of the present invention, the nucleic acid of the present invention or the expression vector of the present invention in medicine, in particular for the treatment of head and neck squamous cell carcinoma.
[0346] The invention further relates to a host cell comprising a nucleic acid according to the invention or an expression vector according to the invention.
[0347] The present invention further relates to the host cell of the present invention, which is an antigen presenting cell, preferably a dendritic cell.
[0348] The present invention further relates to a method for preparing the peptide of the present invention, said method comprising culturing the host cell of the present invention and isolating the peptide from said host cell or its culture medium.
[0349] The present invention further relates to the method of the present invention, wherein the antigen is loaded onto a class I or II MHC molecule expressed on the surface of a suitable antigen presenting cell or artificial antigen presenting cell by contacting a sufficient amount of the antigen with the antigen presenting cell.
[0350] The present invention further relates to the method of the present invention, wherein the antigen presenting cell comprises an expression vector capable of expressing a peptide comprising the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 91 or a variant thereof.
[0351] The present invention further relates to activated T cells produced by the method of the present invention, wherein the T cells selectively recognize a cell that abnormally expresses a polypeptide comprising the amino acid sequence of the present invention.
[0352] The present invention further relates to a method for killing target cells of a patient, wherein the target cells of the patient abnormally express a polypeptide comprising any amino acid sequence of the present invention, the method comprising administering an effective amount of T cells of the present invention to the patient.
[0353] The present invention further relates to the use of any peptide of the present invention, the nucleic acid of the present invention, the expression vector of the present invention, the cell of the present invention, the activated cytotoxic T lymphocyte of the present invention as a medicament or in the manufacture of a medicament. The present invention further relates to the use of the present invention, wherein the medicament is effective against cancer.
[0354] The present invention further relates to a use of the present invention, wherein the medicament is a vaccine. The present invention further relates to a use of the present invention, wherein the medicament is effective against cancer.
[0355] The present invention further relates to the use of the present invention, wherein the cancer cells are head and neck squamous cell cancer cells or other solid or blood tumor cells, such as acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, bladder cancer, and uterine cancer cells.
[0356] The present invention further relates to a specific marker protein and biomarker based on the peptides of the present invention, referred to herein as a "target", which can be used to diagnose and / or determine the prognosis of head and neck squamous cell carcinoma. The present invention also relates to the use of these new targets in cancer treatment.
[0357] The term "antibody" herein is defined in a broad sense, including both polyclonal and monoclonal antibodies. In addition to complete or "whole" immunoglobulin molecules, the term "antibody" also includes fragments (e.g., CDR, Fv, Fab and Fc fragments) or polymers of these immunoglobulin molecules and humanized immunoglobulin molecules, as long as they exhibit any desired attributes of the present invention (e.g., specific binding of head and neck squamous cell carcinoma marker (poly) peptides, delivering toxins to head and neck squamous cell carcinoma cells when the expression level of cancer marker genes increases, and / or inhibiting the activity of head and neck squamous cell carcinoma marker polypeptides).
[0358] Whenever possible, the antibodies of the present invention may be purchased from commercial sources. The antibodies of the present invention may also be made using known methods. The skilled artisan will appreciate that full-length head and neck squamous cell carcinoma marker polypeptides or fragments thereof may be used to prepare the antibodies of the present invention. The polypeptides used to generate the antibodies of the present invention may be partially or completely purified from natural sources or may be produced using recombinant DNA technology.
[0359] For example, a cDNA encoding a peptide of the invention, e.g., a peptide according to SEQ ID NO: 1 to SEQ ID NO: 91, or a variant or fragment thereof, can be expressed in prokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast, insect or mammalian cells), after which the recombinant protein can be purified and used to produce a monoclonal or polyclonal antibody preparation that specifically binds to a head and neck squamous cell carcinoma marker polypeptide used to produce the antibody of the invention.
[0360] Those skilled in the art will recognize that two or more different sets of monoclonal antibodies or polyclonal antibodies can maximize the possibility of obtaining an antibody with the specificity and affinity required for the intended use (e.g., ELISA, immunohistochemistry, in vivo imaging, immunotoxin therapy). Depending on the use of the antibody, its desired activity is tested using known methods (e.g., ELISA, immunohistochemistry, immunotherapy, etc.; for further guidance on generating and testing antibodies, see, for example, Greenfield, 2014 (Greenfield, 2014)). For example, the antibody can be tested using ELISA or immunoblotting, immunohistochemical staining of formalin-fixed cancer tissue or frozen tissue sections. After initial in vitro characterization, antibodies for therapeutic or in vivo diagnostic use are tested according to known clinical testing methods.
[0361] The term "monoclonal antibody" as used herein refers to an antibody obtained from a large number of homogeneous antibodies, i.e., a population of antibodies consisting of identical antibodies, except for natural mutations that may be present in small amounts. The monoclonal antibodies described herein specifically include chimeric "antibodies, in which a portion of the heavy chain and / or light chain is identical (homogeneous) to the corresponding sequence of antibodies obtained from a specific species or belonging to a specific antibody type and subtype, while the remaining chain is identical (homogeneous) to the corresponding sequence of antibodies obtained from other species or belonging to a specific antibody type and subtype, as well as fragments of these antibodies, as long as they exhibit the expected antagonistic activity (U.S. Patent No. 4,816,567, which is incorporated herein in its entirety).
[0362] The monoclonal antibodies of the invention may be prepared using a hybridoma method. In the hybridoma method, mice or other appropriate host animals are typically immunized with an immunizing agent to elicit or produce antibodies that will specifically bind to the immunizing agent. Alternatively, lymphocytes may be immunized in vitro.
[0363] Monoclonal antibodies can also be made by recombinant DNA methods, such as described in U.S. Patent No. 4816567. DNA encoding the monoclonal antibodies of the invention can be easily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that specifically bind to genes encoding mouse antibody heavy and light chains).
[0364] In vitro methods are also applicable to the preparation of monovalent antibodies. Antibody digestion can be accomplished by using conventional techniques known in the art to produce fragments of antibodies, especially Fab fragments. For example, digestion can be accomplished by using papain. Examples of papain digestion are described in WO 94 / 29348 and U.S. Patent No. 4,342,566. Papain digestion of antibodies generally produces two identical antigen-binding fragments, called Fab fragments (each fragment has an antigen binding site) and residual Fc fragments. Pepsin treatment produces a F(ab')2 fragment and a pFc' fragment.
[0365] Antibody fragments, whether or not attached to other sequences, may include insertions, deletions, substitutions, or other selective modifications of specific regions or specific amino acid residues, provided that the activity of the fragment is not significantly altered or impaired compared to the non-modified antibody or antibody fragment. These modifications may provide additional properties, such as deletion / addition of amino acids that can bind to disulfide bonds to increase their biological lifespan, change their secretion properties, etc. In any case, antibody fragments must possess biologically active properties, such as binding activity, modulation of the binding force of the binding domain, etc. The functional or active regions of antibodies can be determined by genetic mutations in specific regions of the protein, followed by expression and testing of the expressed polypeptides. These methods are well known to those skilled in the art and may include specific site genetic mutations of nucleic acids encoding antibody fragments.
[0366] The antibodies of the present invention may further include humanized antibodies or human antibodies. The humanized form of non-human (such as mouse) antibodies is a chimeric antibody immunoglobulin, immunoglobulin chain or fragment thereof (such as Fv, Fab, Fab' or other antigen binding sequences of antibodies), which contains the minimum sequence obtained from non-human immunoglobulins. Humanized antibodies include human immunoglobulins (receptor antibodies), in which residues from the complementary determining region (CDR) of the receptor are replaced by residues from the CDR of non-human species (donor antibodies) (such as mice, rats or rabbits with specificity, affinity and ability). In some cases, the Fv framework (FR) residues of human immunoglobulins are replaced by corresponding non-human residues. Humanized antibodies may also include residues found in neither the receptor antibody nor the imported CDR or framework sequence. In general, humanized antibodies will include almost all of at least one, usually two variable domains, wherein all or almost all of the CDR regions correspond to the regions of non-human immunoglobulins and all or almost all of the FR regions are regions of the same sequence of human immunoglobulins. Ideally, the humanized antibody will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
[0367] The method of humanizing non-human antibodies is well known in the industry. In general, humanized antibodies have one or more amino acid residues introduced from non-human sources. These non-human amino acid residues are often referred to as "import" residues, which are usually obtained from "import" variable domains. Humanization can be basically completed by replacing rodent CDR or CDR sequence with corresponding human antibody sequence. Therefore, this "humanized" antibody is a chimeric antibody (U.S. Patent No. 4816567), in which much less than complete human variable domains are replaced by corresponding sequences from non-human species. In practice, humanized antibodies are usually human antibodies, in which some CDR residues and possible FR residues are replaced by residues from similar sites in rodent antibodies.
[0368] Transgenic animals (e.g., mice) that can produce fully human antibodies in the absence of endogenous immunoglobulin production after immunization can be used. For example, it has been described that homozygous deletion of the antibody heavy chain joining region gene in chimeric and germline mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germline immunoglobulin gene array in this germline mutant mouse will result in the production of human antibodies after antigen challenge. Human antibodies can also be produced in phage display libraries.
[0369] The antibodies of the present invention are preferably administered to a subject in the form of a pharmaceutical carrier. Typically, an appropriate amount of a pharmaceutical salt is used in the formulation to make the formulation isotonic. Examples of pharmaceutical carriers include physiological saline, Ringer's solution, and glucose solution. The pH of the solution is preferably about 5 to 8, more preferably about 7 to 7.5. In addition, carriers also include sustained-release preparations, such as a solid hydrophobic polymer semipermeable matrix containing the antibody, wherein the matrix is in the form of a tangible article, such as a film, liposome, or microparticle. It is well known to those skilled in the art that certain carriers may be more preferred, depending on, for example, the route of administration and concentration of the antibody.
[0370] The antibodies can be administered to subjects, patients or cells by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular) or by other methods such as infusion to ensure that they are delivered to the blood in an effective form. These antibodies can also be administered intratumorally or peritumorally to exert local and systemic therapeutic effects. Local or intravenous injection is preferred.
[0371] The effective dose and schedule for administration of the antibody can be determined empirically, and making such decisions is within the skill of the industry. Those skilled in the art will appreciate that the dose of antibody that must be administered will vary depending on factors such as the subject receiving the antibody, the route of administration, the antibody used, and the specific type of other drugs being used. The usual daily dose of an antibody used alone may be from about 1 μg / kg to a maximum of 100 mg / kg body weight or more, depending on the above factors. After administration of the antibody, preferably for the treatment of head and neck squamous cell carcinoma, the efficacy of the therapeutic antibody can be assessed by different methods well known to the technician. For example, the size, number, and / or distribution of cancer in a subject receiving treatment can be monitored using standard tumor imaging techniques. Antibodies administered for treatment can prevent tumor growth, cause tumor shrinkage, and / or prevent the development of new tumors compared to the course of the disease when the antibody is not administered, and such antibodies are antibodies that are effective in treating cancer.
[0372] Another aspect of the present invention proposes a method for preparing a soluble T cell receptor (sTCR) that recognizes a specific peptide-MHC complex. Such soluble T cell receptors can be produced from specific T cell clones, and their affinity can be increased by targeted mutagenesis of the complementary determining region. For the purpose of T cell receptor selection, phage display can be used (U.S. 2010 / 0113300, (Liddy et al., 2012)). For the purpose of stabilizing T cell receptors during phage display and when actually used as drugs, α and β chains can be connected by non-natural disulfide bonds, other covalent bonds (single-chain T cell receptors) or by dimerization domains (Boulter et al., 2003; Card et al., 2004; Willcox et al., 1999). T cell receptors can be connected to toxins, drugs, cytokines (see US2013 / 0115191), domains recruit effector cells, such as anti-CD3 domains, etc., so as to perform specific functions on target cells. Furthermore, it may be expressed in T cells for adoptive transfer. Further information can be found in WO2004 / 033685A1 and WO2004 / 074322A1. Combinations of sTCRs are described in WO2012 / 056407A1. Further methods of preparation are disclosed in WO2013 / 057586A1.
[0373] Furthermore, the peptides and / or TCRs or antibodies or other binding molecules of the invention can be used to confirm a pathologist's diagnosis of cancer based on a biopsy sample.
[0374] The antibody or TCR can also be used in in vivo diagnostic experiments. Generally, the antibody is labeled with a radionuclide (e.g. 111 In, 99 Tc, 14 C. 131 I. 3 H. 32 P or 35 S), thereby localizing the tumor by immunoscintigraphy. In one embodiment, the antibody or fragment thereof binds to two or more protein target extracellular domains selected from the group including the above proteins, and the affinity value (Kd) is less than 1x10 μM.
[0375] Diagnostic antibodies can be labeled with probes suitable for detection by various imaging methods. Probe detection methods include, but are not limited to, fluorescence, light, confocal and electron microscopy methods; magnetic resonance imaging and spectroscopy techniques; perspective, computer tomography and positron emission tomography. Suitable probes include, but are not limited to, fluorescein, rhodamine, eosin and other fluorophores, radioisotopes, gold, gadolinium and other rare earths, paramagnetic magnets, fluorine-18 and other positron-emitting radionuclides. In addition, the probe may be bifunctional or multifunctional and can be detected by more than one of the above methods. These antibodies can be directly or indirectly labeled with the probes. The connection of antibody probes includes covalent connection of probes, fusion of probes into antibodies, and covalent connection of chelating compounds to bind probes, as well as other methods well known in the industry. For immunohistochemical methods, disease tissue samples may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin. Fixed or embedded sections include samples contacted with labeled primary and secondary antibodies, wherein the antibodies are used to detect the expression of in situ proteins.
[0376] Another aspect of the present invention includes a method for preparing activated T cells in vitro, the method comprising contacting T cells with human MHC molecules loaded with antigens for a sufficient period of time in vitro, these molecules are expressed on the surface of suitable antigen presenting cells, thereby activating T cells in an antigen-specific manner, wherein the antigen is a peptide according to the present invention. Preferably, a sufficient amount of antigen is used together with the antigen presenting cells.
[0377] Preferably, the mammalian cell lacks or has a reduced level or reduced function of the TAP peptide transporter. Suitable cells lacking the TAP peptide transporter include T2, RMA-S and Drosophila cells. TAP is a transporter associated with antigen processing.
[0378] The human peptide loading-deficient cell line T2 is from the American Type Culture Collection (ATCC, 12301 Parklawn Drive, Rockville, Maryland 20852, USA) catalog number CRL1992; the Drosophila cell line Schneider strain 2 is from ATCC catalog number CRL19863; the mouse RMA-S cell line was described by Ljunggren et al. (Ljunggren and Karre, 1985).
[0379] Preferably, the host cells do not substantially express MHC class I molecules prior to transfection. Stimulatory factor cells also preferably express molecules that play an important role in T cell co-stimulatory signals, such as any of B7.1, B7.2, ICAM-1 and LFA3. Nucleic acid sequences of a large number of MHC class I molecules and co-stimulatory molecules are publicly available from GenBank and EMBL databases.
[0380] When an MHC class I epitope is used as an antigen, the T cell is a CD8 positive T cell.
[0381] If an antigen presenting cell is transfected to express such an epitope, preferably the cell comprises an expression vector capable of expressing a peptide or variant amino acid sequence comprising SEQ ID NO: 1 to SEQ ID NO: 91.
[0382] Other methods can be used to generate T cells in vitro. For example, autologous tumor-infiltrating lymphocytes can be used to generate CTLs. Plebanski et al. (Plebanski et al., 1995) used autologous peripheral blood lymphocytes (PLB) to generate T cells. In addition, it is also possible to pulse dendritic cells with peptides or polypeptides or to generate autologous T cells by infection with recombinant viruses. In addition, B cells can be used to prepare autologous T cells. In addition, macrophages pulsed with peptides or polypeptides or infected with recombinant viruses can be used to prepare autologous T cells. S. Walter et al. (Walter et al., 2003) described the in vitro activation of T cells by using artificial antigen presenting cells (aAPC), which is also a suitable method for generating T cells that act on selected peptides. In the present invention, aAPCs are generated by coupling preformed MHC:peptide complexes to polystyrene particles (microspheres) according to the biotin:streptavidin biochemical method. This system enables precise regulation of the MHC density on aAPCs, which allows for the selective induction of high- or low-avidity, efficient antigen-specific T-cell responses in blood samples. In addition to the MHC:peptide complexes, aAPCs should also carry other proteins with co-stimulatory activity, such as anti-CD28 antibodies coupled to their surface. In addition, such aAPC-based systems often require the addition of appropriate soluble factors, for example, cytokines such as interleukin 12.
[0383] T cells can also be made from allogeneic cells, a method described in detail in WO97 / 26328, which is incorporated herein by reference. For example, in addition to Drosophila cells and T2 cells, other cells can be used to present peptides, such as CHO cells, baculovirus-infected insect cells, bacteria, yeast, and vaccinia-infected target cells. In addition, plant viruses can also be used (for example, see Porta et al. (Porta et al., 1994) which describes the development of cowpea mosaic virus as a high-yield system for presenting foreign peptides.
[0384] The activated T cells directly target the peptides of the present invention, which is helpful for treatment. Therefore, another aspect of the present invention provides activated T cells prepared by the aforementioned method of the present invention.
[0385] The activated T cells prepared by the above method will selectively recognize the abnormally expressed polypeptide containing the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 91.
[0386] Preferably, the T cell recognizes the cell by interacting (e.g., binding) with its TCR containing the HLA / peptide complex. T cells are useful cells in a method of killing a patient's target cells, whose target cells abnormally express a polypeptide containing the amino acid sequence of the present invention. Such patients are given an effective amount of activated T cells. The T cells administered to the patient may be derived from the patient and activated as described above (i.e., they are autologous T cells). Alternatively, the T cells are not derived from the patient, but from another person. Of course, it is preferred that the donor is a healthy person. The inventor uses "healthy individual" to refer to a person who is generally in good condition, preferably has a competent immune system, and more preferably does not have any disease that can be easily tested or detected.
[0387] According to the present invention, the in vivo target cells of CD8-positive T cells may be tumor cells (sometimes expressing MHC class II antigens) and / or stromal cells (tumor cells) surrounding the tumor (sometimes also expressing MHC class II antigens; (Dengjel et al., 2006)).
[0388] The T cells of the present invention can be used as an active ingredient in a therapeutic composition. Therefore, the present invention also provides a method for killing a patient's target cells, wherein the patient's target cells abnormally express a polypeptide containing the amino acid sequence of the present invention, the method comprising administering to the patient an effective amount of the T cells.
[0389] The term "abnormal expression" used by the inventors also includes overexpression of a polypeptide compared to the expression level in normal tissues, or expression of the gene in tumors while it is not expressed in the tissues of tumor origin. "Overexpression" means that the level of the polypeptide is at least 1.2 times that in normal tissues; preferably at least 2 times that in normal tissues, and more preferably at least 5 or 10 times that in normal tissues.
[0390] T cells can be prepared by methods known in the art (eg, as described above).
[0391] T cell adoptive transfer protocols are well known in the art. Reviews can be found in: Gattioni et al. and Morgan et al. (Gattinoni et al., 2006; Morgan et al., 2006).
[0392] Another aspect of the invention includes the use of peptides complexed with MHC to generate T cell receptors, the nucleic acid of which is cloned and introduced into a host cell, preferably a T cell. The genetically engineered T cell can then be transferred to a patient for cancer treatment.
[0393] Any molecule of the present invention (i.e., peptide, nucleic acid, antibody, expression vector, cell, activated T cell, T cell receptor or encoding nucleic acid) is useful for treating a disease, and its characteristic is that the cell escapes the attack of the immune response. Therefore, any molecule of the present invention can be used as a medicament or used to manufacture a medicament. Such a molecule can be used alone or in combination with other molecules of the present invention or known molecules.
[0394] The present invention also relates to a kit comprising:
[0395] (a) a container comprising the pharmaceutical composition in the form of a solution or lyophilized powder;
[0396] (b) an optional second container containing a diluent or reconstitution fluid for the lyophilized dosage form; and
[0397] (c) optionally, instructions for (i) use of the solution or (ii) reconstitution and / or use of the lyophilized formulation.
[0398] The kit may further include one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe. The container is preferably a bottle, a vial, a syringe or a test tube, and may be a multi-purpose container. The pharmaceutical composition is preferably lyophilized.
[0399] The kit of the present invention preferably comprises a lyophilized formulation placed in a suitable container and instructions for reconstitution and / or use. Suitable containers include, for example, bottles, vials (such as double chamber bottles), syringes (such as double chamber syringes) and test tubes. The container may be made of a variety of materials, such as glass or plastic. The kit and / or container preferably has instructions on or about the container indicating directions for reconstitution and / or use. For example, the label may indicate that the lyophilized dosage form will be reconstituted into the above-mentioned peptide concentration. The label may further indicate that the formulation is for subcutaneous injection.
[0400] The container for storing the preparation may be a multi-use vial, so that the reconstituted dosage form can be administered repeatedly (for example, 2-6 times). The kit may further include a second container containing a suitable diluent (such as sodium bicarbonate solution).
[0401] After the diluent and the lyophilized preparation are mixed, the final peptide concentration in the reconstituted preparation is preferably at least 0.15 mg / mL / peptide (=75 μg) and no more than 3 mg / mL / peptide (=1500 μg). The kit may also include other materials desirable from a commercial and user perspective, including other buffers, diluents, filtrates, needles, syringes, and package inserts with instructions for use.
[0402] The kit of the present invention may have a single container containing the pharmaceutical composition preparation of the present invention, which may have other ingredients (e.g., other compounds or pharmaceutical compositions thereof), or may have no other ingredients, or each ingredient may have its own different container.
[0403] Preferably, the kit of the invention comprises a formulation of the invention packaged for use in combination with a second compound such as an adjuvant (e.g., GM-CSF), a chemotherapeutic drug, a natural product, a hormone or antagonist, an anti-angiogenic agent or inhibitor, an apoptosis inducer or a chelating agent, or a pharmaceutical combination thereof. The components of the kit may be pre-complexed or each component may be placed in a separate container prior to administration to a patient. The components of the kit may be one or more solutions, preferably aqueous solutions, more preferably sterile aqueous solutions. The components of the kit may also be in solid form, converted to liquids upon addition of a suitable solvent, preferably placed in another separate container.
[0404] The container of the treatment kit may be a vial, test tube, flask, bottle, syringe, or any other tool for holding solids or liquids. Typically, when there is more than one component, the kit will contain a second vial or other container so that it can be quantified separately. The kit may also contain another container for loading a medicinal liquid. Preferably, the treatment kit will contain a device (e.g., one or more needles, syringes, eye droppers, pipettes, etc.) that allows the injection of the drug of the present invention (the composition of the present kit).
[0405] The pharmaceutical formulation of the present invention is suitable for peptide administration by any acceptable route, such as oral (enteral), intranasal, intraocular, subcutaneous, intradermal, intramuscular, intravenous or transdermal administration. Preferably, it is administered subcutaneously, most preferably intradermally, and can also be administered by an infusion pump.
[0406] Since the peptide of the present invention is isolated from head and neck squamous cell carcinoma, the agent of the present invention is preferably used for treating head and neck squamous cell carcinoma.
[0407] The present invention further relates to a method for preparing a personalized medicine for an individual patient, comprising: manufacturing a pharmaceutical composition comprising at least one peptide selected from a pre-screened TUMAP library, wherein the at least one peptide used in the pharmaceutical composition is selected to be suitable for the individual patient. In one embodiment, the pharmaceutical composition is a vaccine. The method can also be modified to produce T cell clones for downstream applications, such as: TCR isolates or soluble antibodies and other therapeutic options.
[0408] “Personalized medicine” refers to treatments that are tailored to an individual patient and will be used only for that individual patient, including personalized active cancer vaccines and adoptive cell therapy using autologous tissue.
[0409] As used herein, a "repository" shall refer to a group or series of peptides that have been pre-screened for immunogenicity and / or are over-presented in a specific tumor type. The term "repository" does not imply that the specific peptides included in the vaccine have been pre-manufactured and stored in a physical device, although this possibility is expected. It is clearly expected that the peptides can be used to newly manufacture each personalized vaccine, and may also be pre-manufactured and stored. The repository (e.g., in the form of a database) consists of tumor-associated peptides that are highly over-expressed in tumor tissues of patients with head and neck squamous cell carcinoma of various HLA-A HLA-B and HLA-C alleles. It may contain MHC I class and MHC II class peptides or extended MHC I class peptides. In addition to tumor-associated peptides collected from several head and neck squamous cell carcinoma tissues, the repository may also contain HLA-A*02 and HLA-A*24 marker peptides. These peptides can be used to quantify and compare T cell immunity induced by TUMAP, thereby drawing important conclusions about the ability of the vaccine to respond to tumors. Second, they serve as important positive control peptides from "non-self" antigens when no vaccine-induced T cell responses are observed from TUMAPs derived from the patient's "self" antigens. Third, it also allows conclusions to be drawn about the patient's immune function status.
[0410] The repository's TUMAPs were identified by using a functional genomics approach that combines gene expression analysis, mass spectrometry, and T cell immunology. This approach ensures that only TUMAPs that are truly present in a high percentage of tumors but are not expressed or only expressed at very low levels in normal tissues are selected for further analysis. For the initial peptide selection, head and neck squamous cell carcinoma samples from patients and blood from healthy donors were analyzed in a step-by-step approach:
[0411] 1. HLA ligands of tumor material were determined by mass spectrometry;
[0412] 2. Use whole genome messenger RNA (mRNA) expression analysis to identify genes that are overexpressed in malignant tumor tissue (small cell lung cancer) compared with a range of normal organs and tissues;
[0413] 3. Comparing the determined HLA ligands with the gene expression data. Peptides that are over- or selectively presented on tumor tissues, preferably those encoded by the selectively expressed or over-expressed genes detected in step 2, are considered to be suitable candidate TUMAPs for peptide vaccines;
[0414] 4. Literature search to identify additional evidence to support the relevance of the peptides identified as TUMPs;
[0415] 5. The relevance of overexpression at the mRNA level was determined by re-detection of the TUMAPs selected from step 3 on tumor tissues and their absence (or low frequency) on healthy tissues;
[0416] 6. To evaluate whether it is feasible to induce T cell responses in vivo by the selected peptides, in vitro immunogenicity assays were performed using human T cells from healthy donors as well as from patients with small cell lung cancer.
[0417] In one aspect, the peptides are screened for immunogenicity before being added to the library. For example, but not limited to, the immunogenicity of the peptides included in the library is determined by in vitro T cell activation, specifically, repeated stimulation of CD8+ T cells from healthy donors with artificial antigen presenting cells loaded with peptide / MHC complexes and anti-CD28 antibodies.
[0418] This approach is preferred for rare cancers and patients with rare expression profiles. In contrast to the peptide cocktails currently developed as fixed components, the library allows a higher degree of matching of the actual expression of antigens in the tumor to the vaccine. In a multi-target approach, each patient will use a selected single peptide or a combination of several "off-the-shelf" peptides. Theoretically, an approach based on the selection of, for example, 5 different antigenic peptides from a library of 50 antigenic peptides could provide approximately 1.7 million possible drug product (DP) components.
[0419] In one aspect, the peptides are selected for inclusion in a vaccine based on suitability for an individual patient using the methods of the invention described herein or hereinafter.
[0420] HLA phenotype, transcriptional and peptidomic profiles are collected from patient tumor material and blood samples to identify peptides that are most appropriate for each patient and contain both the "reservoir" and patient-unique (i.e., mutation) TUMAPs. Those peptides selected will be selectively or overexpressed in the patient's tumor and, where possible, demonstrate strong in vitro immunogenicity when tested with the patient's individual PBMCs.
[0421] Preferably, a method for determining the peptides included in the vaccine comprises: (a) identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from an individual patient; (b) comparing the peptides identified in (a) with a repository (database) of the peptides; and (c) selecting at least one peptide from the repository (database) that is associated with the tumor-associated peptides identified in the patient. For example, the method for identifying TUMAPs presented by a tumor sample comprises: (a1) comparing expression data from a tumor sample with expression data from a normal tissue sample corresponding to the tissue type of the tumor sample to identify proteins that are overexpressed or abnormally expressed in the tumor tissue; and (a2) correlating the expression data with the sequence of MHC ligands bound to class I MHC and / or class II molecules in the tumor sample to determine the MHC ligands derived from proteins that are overexpressed or abnormally expressed in the tumor. Preferably, the sequence of the MHC ligand is determined by eluting MHC molecule-bound peptides separated from the tumor sample and sequencing the eluted ligands. Preferably, the tumor sample and the normal tissue are obtained from the same patient.
[0422] In addition to or as an alternative to using a repository (database) model to select peptides, TUMAPs may be identified in new patients and then included in vaccines. As an example, candidate TUMAPs in patients can be identified by: (a1) comparing expression data from a tumor sample with expression data from a normal tissue sample corresponding to the tissue type of the tumor sample to identify proteins that are overexpressed or abnormally expressed in the tumor tissue; and (a2) associating the expression data with the MHC ligand sequences that bind to class I MHC and / or class II molecules in the tumor sample to determine the MHC ligands derived from proteins that are overexpressed or abnormally expressed in the tumor. As another example, the protein identification method may contain mutations that are unique to the tumor sample relative to the corresponding normal tissue of the individual patient, and the TUMAP can be identified by specifically targeting the mutation. For example, the genome of the tumor and the corresponding normal tissue can be sequenced by a whole genome sequencing method: in order to discover non-synonymous mutations in the protein coding region of the gene, genomic DNA and RNA are extracted from the tumor tissue, and normal non-mutated genomic germline DNA is extracted from peripheral blood mononuclear cells (PBMC). The NGS method used is limited to the resequencing of protein coding regions (exome resequencing). For this purpose, the target sequence enrichment kit provided by the supplier is used to capture exon DNA from human samples, followed by sequencing using HiSeq2000 (Illumina). In addition, the mRNA of the tumor is sequenced to directly quantify gene expression and confirm that the mutant gene is expressed in the patient's tumor. The millions of sequence reads obtained are processed by software algorithms. The output list contains mutations and gene expression. Tumor-specific somatic mutations are determined by comparison with PBMC-derived germline changes and optimized. Then, the newly determined peptides may be tested for immunogenicity as described above for the library, and candidate TUMAPs with suitable immunogenicity are selected for vaccines.
[0423] In one exemplary embodiment, the peptides included in the vaccine are determined by the following method: (a) identifying tumor-associated peptides (TUMAP) presented by an individual patient's tumor sample using the above method; (b) comparing the peptides identified in (a) with a peptide library that has been pre-screened for immunogenicity and over-presentation in tumors (compared to corresponding normal tissues); (c) selecting at least one peptide from the library that is related to the tumor-associated peptides identified in the patient; and (d) optionally selecting at least one peptide newly identified in (a) and confirming its immunogenicity.
[0424] In one exemplary embodiment, the peptides included in the vaccine are identified by: (a) identifying tumor-associated peptides (TUMAPs) presented by tumor samples from individual patients; and (b) selecting at least one newly identified peptide in (a) and confirming its immunogenicity.
[0425] Once the peptides for the personalized peptide vaccine are selected, the vaccine is produced. The vaccine is preferably a liquid formulation comprising the individual peptides dissolved in between 20-40% DMSO, preferably about 30-35% DMSO, for example about 33% DMSO.
[0426] Each peptide included in the product is dissolved in DMSO. The choice of the concentration of the single peptide solution depends on the number of peptides to be included in the product. The single peptide-DMSO solutions are mixed equally to achieve a solution containing all peptides at a concentration of ~2.5 mg / ml per peptide. The mixed solution is then diluted with water for injection at a ratio of 1:3 to achieve a concentration of 0.826 mg / ml per peptide in 33% DMSO. The diluted solution is filtered through a 0.22 μm sterile screening procedure. The final bulk solution is obtained.
[0427] The final bulk solution was filled into vials and stored at -20°C before use. One vial contained 700 μL of solution, containing 0.578 mg of each peptide, of which 500 μL (about 400 μg of each peptide) would be used for intradermal injection.
[0428] In addition to being used to treat cancer, the peptides of the present invention can also be used for diagnosis. Since the peptides are produced by head and neck squamous cell carcinoma cells and it has been determined that these peptides are absent or present at low levels in normal tissues, these peptides can be used to diagnose the presence or absence of cancer.
[0429] Tissue biopsies in blood samples containing the claimed peptides can help pathologists diagnose cancer. Detection of certain peptides using antibodies, mass spectrometry or other methods known in the art can enable pathologists to determine whether the tissue sample is malignant or inflammatory or generally diseased, and can also be used as biomarkers for head and neck squamous cell carcinoma. Presentation of peptide groups allows the classification or further subdivision of diseased tissues.
[0430] Detection of peptides in disease specimens allows the benefit of immune system therapeutic approaches to be determined, especially if T-lymphocytes are known or expected to be involved in the mechanism of action. Loss of MHC expression is a well-characterized mechanism by which infected malignant cells escape immune surveillance. Therefore, presentation of peptides indicates that the analyzed cells do not utilize this mechanism.
[0431] The peptides of the present invention can be used to analyze lymphocyte responses to peptides (such as T cell responses), or antibody responses to peptides or peptides complexed with MHC molecules. These lymphocyte responses can be used as prognostic indicators to determine whether further treatment should be taken. These responses can also be used as alternative response indicators in immunotherapy, which aims to induce lymphocyte responses in different ways, such as protein vaccines, nucleic acids, autologous materials, and adoptive transfer of lymphocytes. In gene therapy, the response of lymphocytes to peptides can be considered in the assessment of side effects. Lymphocyte response monitoring may also become a valuable tool in follow-up examinations of transplantation therapy, such as for detecting graft-versus-host and host-versus-graft diseases.
[0432] The invention will be illustrated by the following examples which describe preferred embodiments, and with reference to (but not limited to) the accompanying drawings. For the purposes of the present invention, all references cited herein are incorporated herein by reference. BRIEF DESCRIPTION OF THE DRAWINGS
[0433] Figures 1A to 1D Over-presentation of various peptides in normal tissue (white bars) and head and neck squamous cell carcinoma (black bars) is shown. Figure 1A )Gene symbol: KRT6C, KRT6A, KRT6B, peptide: GLAGGFGGPGFPV (SEQ ID NO.: 1); tissues from left to right: 6 adipose tissue, 8 adrenal glands, 1 bile duct, 24 blood cells, 15 blood vessels, 10 bone marrow, 15 brain, 7 breast, 11 esophagus, 2 eyes, 6 gallbladder, 16 heart, 17 kidney, 27 large intestine, 24 liver, 49 lung, 7 lymph nodes, 12 nerves, 5 ovaries, 15 pancreas, 6 parathyroid glands, 3 peritoneum, 7 pituitary gland, 10 placenta, 3 pleura, 11 prostate, 9 skeletal muscle, 11 skin, 16 small intestine, 13 spleen, 9 stomach, 8 testicles, 3 thymus, 8 thyroid, 18 trachea, 7 ureters, 8 bladder, 6 uterus, 12 head and neck, 17 HNSCC. Figure 1B )Gene symbol: KRT, KRT6A, KRT6B, peptide: SLYGLGGSKRISI (SEQ ID NO.: 3); Tissues from left to right: 6 adipose tissue, 8 adrenal glands, 1 bile duct, 24 blood cells, 15 blood vessels, 10 bone marrow, 15 brain, 7 breast, 11 esophagus, 2 eyes, 6 gallbladder, 16 heart, 17 kidney, 27 large intestine, 24 liver, 49 lung, 7 lymph nodes, 12 nerves, 5 ovaries, 15 pancreas, 6 parathyroid glands, 3 peritoneum, 7 pituitary gland, 10 placenta, 3 pleura, 11 prostate, 9 skeletal muscle, 11 skin, 16 small intestine, 13 spleen, 9 stomach, 8 testicles, 3 thymus, 8 thyroid, 18 trachea, 7 ureters, 8 bladder, 6 uterus, 12 head and neck, 17 HNSCC. Figure 1C)Gene symbol: KRT5, peptide: STASAITPSV (SEQ ID NO.: 9); Tissues from left to right: 6 adipose tissue, 8 adrenal glands, 1 bile duct, 24 blood cells, 15 blood vessels, 10 bone marrow, 15 brain, 7 breast, 11 esophagus, 2 eyes, 6 gallbladder, 16 heart, 17 kidney, 27 large intestine, 24 liver, 49 lung, 7 lymph nodes, 12 nerves, 5 ovaries, 15 pancreas, 6 parathyroid glands, 3 peritoneum, 7 pituitary gland, 10 placenta, 3 pleura, 11 prostate, 9 skeletal muscle, 11 skin, 16 small intestine, 13 spleen, 9 stomach, 8 testicles, 3 thymus, 8 thyroid, 18 trachea, 7 ureters, 8 bladder, 6 uterus, 12 head and neck, 17 HNSCC. Figure 1D )Gene symbol: SLC25A3, peptide: FVAGYIAGV (SEQ ID NO.: 61); Tissues from left to right: 3 cell lines (2 kidneys, 1 pancreas), 7 normal tissues (1 adrenal gland, 1 colon, 2 lymph nodes, 1 placenta, 2 spleens), 36 cancer tissues (5 white blood cell leukemias, 3 brain cancers, 1 esophageal cancer, 1 gallbladder cancer, 5 head and neck cancers, 1 kidney cancer, 1 liver cancer, 8 lung cancers, 4 lymph node cancers, 3 ovarian cancers, 2 gastric cancers). Figures 1E to 1QThe over-presentation of various peptides in different cancer tissues is shown (black dots). Upper part: The median MS signal intensity according to the technical replicate measurements is plotted as dots, the single HLA-A*02-positive normal tissue is gray dots, and the tumor samples where the peptide was detected are black dots. Tumor and normal samples are grouped according to organ origin, and the box-whisker plot represents the median, 25th and 75th percentiles (boxes) and minimum and maximum values (whiskers) of the normalized signal intensity of multiple samples. Normal organs are ranked according to the risk category (blood cells, blood vessels, brain, liver, lung: high risk, gray dots; reproductive organs, breast, prostate: low risk, gray dots; all other organs: medium risk; gray dots). Lower part: The relative peptide detection frequency of each organ is shown as a spine plot. The numbers below the graphs indicate the number of samples where the peptide was detected out of the total number of samples analyzed for each organ (normal samples N = 526, tumor samples N = 562). If a peptide was detected on a sample but could not be quantified for technical reasons, the sample was included in the detection frequency plot, but no point was shown in the upper part of the graph. Tissues (from left to right): Normal sample: blood cells; bloodvess (blood vessels); brain; heart; liver; lung; adipose (adipose tissue); adren.gl. (adrenal gland); bile duct; bladder; BM (bone marrow); cartilage; esoph (esophagus); eye; gallb (gall bladder); head and neck; kidney; large_int (large intestine); LN (lymph node); nerve; pancreas; parathyr (parathyroid gland); perit (peritoneum); pituit (pituitary gland); pleura; skel.mus (skeletal muscle); skin; small_int (small intestine); spleen; stomach; thyroid gland; trachea; ureter; breast; ovary; placenta; prostate; testis; thymus; uterus. Tumor samples: AML: acute myeloid leukemia; BRCA: breast cancer; CCC: cholangiocarcinoma; CLL: chronic lymphocytic leukemia; CRC: colorectal cancer; GBC: gallbladder cancer; GBM: glioblastoma; GC: gastric cancer; GEJC: gastric cardia-esophageal cancer; HCC: hepatocellular carcinoma; HNSCC: head and neck cancer; MEL: melanoma; NHL: non-Hodgkin lymphoma; NSCLC: non-small cell lung cancer; OC: ovarian cancer; OSCAR: esophageal cancer; PACA: pancreatic cancer; PRCA: prostate cancer; RCC: renal cell carcinoma; SCLC: small cell lung cancer; UBC: bladder cancer; UEC: endometrial cancer. Figure 1E )Gene symbols: KRT6C, KRT6A, KRT1, KRT6B, KRT75, KRT5, peptide: PVCPPGGIQEV (SEQ ID NO: 2), Figure 1F )Gene symbol: PKP1, peptide: SMLNNIINL (SEQ ID NO: 15), Figure 1G )Gene symbol: PRKDC, peptide: GLIEWLENTV (SEQ ID NO: 45), Figure 1H )Gene symbols: ATP5G2, ATP5G1, ATP5G3, peptide: AILGFALSEA (SEQ ID NO: 57), Fig. 1I ) Gene symbol: ITGB4, Peptide: SLSDIQPCL (SEQ ID NO: 58), Figure 1J )Gene symbol: KRT5, peptide: ALMDEINFMKM (SEQ ID NO: 63), Figure 1K )Gene symbol: ESRP2, peptide: ALASAPTSV (SEQ ID NO: 75), Figure 1L )Gene symbol: PARP9, peptide: ILFDEVLTFA (SEQ ID NO: 76), Figure 1M )Gene symbol: MCM4, peptide: QLLQYVYNL (SEQ ID NO: 83), Figure 1N )Gene symbol: FHAD1, peptide: QLIEKITQV (SEQ ID NO: 85), Fig.1O )Gene symbol: PLEC, peptide: ALPEPSPAA (SEQ ID NO: 87), Figure 1P )Gene symbol: G3BP1, peptide: TLNDGVVVQV (SEQ ID NO: 90), Figure 1Q ) Gene symbol: ODC1, peptide: MLFENMGAYTV (SEQ ID NO.: 91).
[0434] Figure 2A Figures 4 to 5 show representative expression signatures of source genes of the present invention that are highly overexpressed or exclusively expressed in head and neck squamous cell carcinomas of a range of normal tissues (white bars) and 15 head and neck squamous cell carcinoma samples (black bars). Figure 2A ) Gene symbol: PGLYRP4, peptide: AIYEGVGWNV (SEQ ID NO: 33); Figure 2B ) Gene symbol: PAPL, peptide: KLLPGVQYV (SEQ ID NO: 38); Figure 2C ) Gene symbol: LGALS7, LGALS7B, peptide: RLVEVGGDVQL (SEQ ID NO.: 53).
[0435] Figure 3 Exemplary immunogenicity data are shown: flow cytometry results after peptide-specific multimer staining.
[0436] Figure 4Exemplary results of peptide-specific CD8+ T cell responses in vitro from healthy HLA-A*02+ donors are shown. CD8+ T cells were prepared using anti-CD28 mAb and HLA-A*02 coated artificial APCs synthesized with Seq ID NO.:17 peptide (A, left), Seq ID NO.:28 peptide (B, left), and Seq ID NO.:29 peptide (C, left). After 12 cycles of stimulation, peptide-reactive cells were detected by 2D multimer staining of A*02 / Seq ID NO.:17 (A), A*02 / Seq ID NO.:28 (B), or A*02 / Seq ID NO.:29 (C). The right panels (A, B, and C) show control staining of cells stimulated with irrelevant A*02 / peptide complexes. Live single cells were gated on CD8+ lymphocytes. Boolean gating helps exclude false positive events detected with multimers specific for different peptides. The frequencies of specific multimer+ cells and CD8+ lymphocytes are indicated.
[0437] Example
[0438] Example 1 Identification and Quantification of Tumor-Associated Peptides Presented on the Cell Surface
[0439] Tissue samples
[0440] Tumor tissues from patients were obtained from Asterand (Detroit, MI, USA & Royston, Herts, UK), ProteoGenex Inc. (Culver City, CA, USA). Normal tissues were obtained from Asterand (Detroit, MI, USA & Royston, Herts, UK), Bio-Options Inc. (Brea, CA, USA), BioServe (Beltsville, MD, USA), Capital BioScience Inc. (Rockville, MD, USA), Geneticist Inc. (Glendale, CA, USA), Kyoto Prefectural University of Medicine (KPUM) (Kyoto, Japan), ProteoGenex Inc. (Culver City, CA, USA), Tissue Solutions Ltd (Glasgow, UK), Geneva University Hospital (Geneva, Switzerland), Heidelberg University Hospital (Heidelberg, Germany), Munich University Hospital (Munich, Germany), and Tubingen University Hospital (Tübingen, Germany).
[0441] Written informed consent was obtained from all patients before surgery or autopsy. Tissues were immediately cold-shocked after resection and stored at -70°C or below before TUMAP isolation.
[0442] Isolation of HLA peptides from tissue samples
[0443] HLA peptide libraries from frozen tissue samples were obtained from solid tissues by immunoprecipitation using HLA-A*02-specific antibody BB7.2, HLA-A, HLA-B, and HLAC-specific antibody W6 / 32, CNBr-activated agarose gel, acid treatment, and ultrafiltration according to the protocol ( Falk et al., 1991 ; Seeger et al., 1999 ) with slight modifications.
[0444] Mass spectrometry analysis
[0445] The obtained HLA peptide library was separated according to its hydrophobicity by reverse phase chromatography (nanoAcquity UPLC system, Waters), and the eluted peptides were analyzed by LTQ-velos fusion hybrid mass spectrometer (ThermoElectron) equipped with an electrospray source. The peptide library was directly loaded on an analytical fused silica microcapillary column (75 μm inner diameter x 250 mm) filled with 1.7 μm C18 reverse phase material (Waters), and a flow rate of 400 nL per minute was applied. Subsequently, the peptides were separated using a two-step 180-minute binary gradient method from 10% to 33% solvent B at a flow rate of 300 nL per minute. The gradient consisted of solvent A (water containing 0.1% formic acid) and solvent B (acetonitrile containing 0.1% formic acid). A gold-coated glass capillary (PicoTip, New Objective) was used to introduce into the nanoliter electrospray source. The LTQ-Orbitrap mass spectrometer was operated in data-dependent mode using the top 5 (TOP5) strategy. Briefly, a scan cycle was started with a full scan of high mass accuracy in the orbitrap (R = 30,000), followed by an MS / MS scan of the five most abundant precursor ions in the orbitrap (R = 7500) using dynamic exclusion of previously selected ions. Tandem mass spectra were interpreted with SEQUEST and another manual controller. The fragmentation pattern of the generated natural peptide was compared with the fragmentation pattern of a synthetic sequence-identical reference peptide to ensure the identified peptide sequence.
[0446] Label-free relative LC-MS quantification was performed by ion counting (i.e., by LC-MS feature extraction and analysis) (Mueller et al., 2007). This approach assumes that the area of the peptide's LC-MS signal is related to its abundance in the sample. The extracted features were further processed by charge state deconvolution and retention time alignment (Mueller et al., 2008; Sturm et al., 2008). Finally, all LC-MS features were cross-referenced with the sequence identification results to combine the quantitative data from different samples and tissues with the peptide presentation characteristics. The quantitative data were normalized in a two-layer manner based on the pooled data to account for technical and biological replicate variations. Therefore, each identified peptide could be associated with quantitative data, allowing relative quantification between samples and tissues. In addition, all quantitative data obtained for candidate peptides were manually checked to ensure data consistency and to verify the accuracy of the automated analysis. For each peptide, a presentation plot was calculated, which shows the sample average presentation as well as replicate variation. These features juxtapose the baseline values of head and neck squamous cell carcinoma samples with those of normal tissue samples. The presentation profiles of exemplary over-presented peptides are shown in Figure 1. The presentation scores of exemplary peptides are shown in Table 8.
[0447] Table 8: Presentation scores. This table lists HLA-A*02 peptides that are very highly over-presented on tumors compared to a range of normal tissues (+++), highly over-presented on tumors compared to a range of normal tissues (++), or over-presented on tumors compared to a range of normal tissues (+). The range of normal tissue groups considered to be relatively relevant to tumors includes: adipose tissue, adrenal glands, bile ducts, blood cells, blood vessels, bone marrow, brain, esophagus, eyes, gallbladder, head and neck, heart, kidney, large intestine, liver, lung, lymph nodes, nerves, pancreas, parathyroid, peritoneum, pituitary, pleura, skeletal muscle, skin, small intestine, spleen, stomach, thyroid, trachea, ureters, bladder.
[0448]
[0449]
[0450]
[0451] Example 2 Expression profile of genes encoding the peptides of the present invention
[0452] Over- or specific presentation of a peptide on tumor cells compared to normal cells is sufficient for its effective use in immunotherapy, and some peptides are tumor-specific despite the presence of their source protein also present in normal tissues. However, mRNA expression profiles add an additional level of safety in the selection of immunotherapy target peptides. Especially for treatment options with high safety risks, such as affinity-matured TCRs, the ideal target peptide will be derived from a protein that is unique to the tumor and not present in normal tissues.
[0453] RNA source and preparation
[0454] Surgical tissue specimens were provided as described above (see Example 1) after written informed consent was obtained from each patient. Tumor tissue specimens were snap-frozen immediately after surgery and then homogenized in liquid nitrogen with a mortar and pestle. Total RNA was prepared from these samples using TRI reagent (Ambion, Darmstadt, Germany) followed by RNeasy (QIAGEN, Hilden, Germany) cleanup; both methods were performed according to the manufacturer's protocol.
[0455] Total RNA from healthy human tissues for RNASeq experiments was obtained from:
[0456] Asterand (Detroit, MI, USA & Royston, Herts, UK), BioCat GmbH (Heidelberg, Germany), Bio-Options Inc. (Brea, CA, USA), BioServe (Beltsville, MD, USA), Capital BioScience Inc. Rockwell, MD, USA), Geneticist Inc. (Glendale, CA, USA), Istituto Nazionale Tumori "Pascale" (Naples, Italy), ProteoGenex Inc. (Culver City, CA, USA), Heidelberg University Hospital (Heidelberg, Germany). Total RNA from tumor tissues for RNASeq experiments was obtained from: Asterand (Detroit, MI, USA & Royston, Herts, UK), ProteoGenex Inc. (Culver City, CA, USA).
[0457] The quality and quantity of all RNA samples were assessed on an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 Pico LabChip kit (Agilent).
[0458] RNA-seq experiments
[0459] Gene expression analysis of RNA samples of tumors and normal tissues was performed by CeGaT (Tübingen, Germany) by next-generation sequencing technology (RNAseq). In brief, the sequencing library was prepared using the Illumina HiSeqv4 kit according to the supplier's protocol (Illumina Inc., San Diego, CA, USA), including RNA fragmentation, cDNA conversion and the addition of sequencing adapters. Libraries obtained from multiple samples were mixed in equal moles according to the manufacturer's instructions and sequenced on the Illumina HiSeq2500 sequencer to produce 50bp single-end reads. The processed reads were mapped to the human genome (GRCh38) using STAR software. According to the instructions of the ENSEMBL sequence database (Ensembl77), expression data were set at the transcription level as RPKM (reads per kilobase per million mapped reads, generated by Cufflinks software) and at the exon level (total reads, generated by Bedtools software). Exon reads were classified as exon length and calibration size to obtain RPKM values.
[0460] The expression profile of representative source genes of the present invention that are highly overexpressed in head and neck squamous cell carcinoma is shown in Figure 2. The expression scores of further representative genes are shown in Table 9.
[0461] Table 9: Expression scores. This table lists peptides for genes that are very highly overexpressed (+++) on tumors compared to a range of normal tissues, highly overexpressed (++) on tumors compared to a range of normal tissues, or overexpressed (+) on tumors compared to a range of normal tissues. This baseline score is calculated based on measurements of the following relevant normal tissues: adipose tissue, adrenal glands, arteries, bile ducts, blood cells, bone marrow, brain, cartilage, colon, esophagus, eyes, gallbladder, head and neck and salivary glands, heart, kidney, liver, lung, lymph node, pancreas, parathyroid, peripheral nerves, peritoneum, pituitary gland, pleura, rectum, skeletal muscle, skin, small intestine, spleen, stomach, thyroid, trachea, ureter, bladder, vein. If expression data for several samples of the same tissue type are obtained, the arithmetic mean of each sample is used for calculation.
[0462]
[0463]
[0464] Example 3 In vitro immunogenicity of MHC class I presented peptides
[0465] In order to obtain information about the immunogenicity of the TUMAPs of the invention, the inventors performed studies using an in vitro T cell expansion assay based on repeated stimulation with artificial antigen presenting cells (aAPCs) loaded with peptide / MHC complexes and anti-CD28 antibodies. Using this method, the inventors could show that the HLA-A*0201 restricted TUMAPs of the invention are immunogenic, indicating that these peptides are T cell epitopes against human CD8+ precursor T cells (Table 10).
[0466] In vitro priming of CD8+ T cells
[0467] For in vitro stimulation with artificial antigen-presenting cells loaded with peptide-MHC complexes (pMHC) and anti-CD28 antibodies, the inventors first isolated CD8+ T cells from healthy donors obtained from the University clinics Mannheim, Germany, using CD8 microbeads (Miltenyi Biotech, Bergisch-Gladbach, Germany) by positive selection of fresh HLA-A*02 products after leukapheresis.
[0468] PBMC and isolated CD8+ lymphocytes were cultured in T cell medium (TCM) before use, which included RPMI-Glutamax (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat-inactivated human AB serum (PAN-Biotech, Aidenbach, Germany), 100 U / ml penicillin / 100 μg / ml streptomycin (Cambrex, Cologne, Germany), 1 mM sodium pyruvate (CC Pro, Oberdorla, Germany) and 20 μg / ml gentamicin (Cambrex). At this step, 2.5 ng / ml IL-7 (PromoCell, Heidelberg, Germany) and 10 U / ml IL-2 (Novartis Pharma, Nürnberg, Germany) were also added to TCM.
[0469] Generation of pMHC / anti-CD28 coated beads, stimulation of T cells and readout were performed in a highly defined in vitro system using four different pMHC molecules per stimulation condition and 8 different pMHC molecules per readout condition.
[0470] Purified co-stimulatory mouse IgG2a anti-human CD28 antibody 9.3 (Jung et al., 1987) was chemically biotinylated using N-hydroxysuccinimide-biotin as recommended by the manufacturer (Perbio, Bonn, Germany). The beads used were 5.6 μm streptavidin-coated polystyrene particles (Bangs Laboratories, IL, USA).
[0471] The pMHC used for positive and negative control stimuli were A*0201 / MLA-001 (peptide ELAGIGILTV (SEQ ID NO: 157) modified from Melan-A / MART-1) and A*0201 / DDX5-001 (YLLPAIVHI (SEQ ID NO: 158) obtained from DDX5), respectively.
[0472] 800.000 beads / 200 μl were coated in a 96-well plate containing 4 x 12.5 ng of different biotin-pMHC, washed, and then 600 ng of biotin anti-CD28 was added in a volume of 200 μl. 1x10 6 CD8+T cells and 2x10 5Stimulation was initiated by washing the coated beads for 3 days. Afterwards, half of the culture medium was exchanged with fresh TCM supplemented with 80 U / ml IL-2 and the culture was continued at 37°C for 4 days. This stimulation cycle was performed 3 times in total. For pMHC multimer readout using 8 different pMHC molecules per condition, the two-dimensional combinatorial encoding method was used as described previously (Andersen et al., 2012) with slight modifications to include coupling to 5 different fluorescent dyes. Finally, multimer analysis was performed using Live / dead near IR dye (Invitrogen, Karlsruhe, Germany), CD8-FITC antibody clone SK1 (BD, Heidelberg, Germany) and fluorescent pMHC multimers. For analysis, a BD LSRII SORP cytometer equipped with appropriate lasers and screening programs was used. Peptide-specific cells were calculated as a percentage of total CD8+ cells. Multimer analysis results were evaluated using FlowJo software (Tree Star, Oregon, USA). In vitro loading of specific multimer+CD8+ lymphocytes is tested by comparison with negative control stimulation groups. If at least one evaluable in vitro stimulated well from a healthy donor is found to contain a specific CD8+ T cell line after in vitro stimulation (i.e., the well contains at least 1% specific multimer+CD8+ T cells and the percentage of specific multimer+ is at least 10 times the median of the negative control stimulation), the immunogenicity of a given antigen is tested.
[0473] In vitro immunogenicity of head and neck squamous cell carcinoma peptides
[0474] For the tested HLA-I class peptides, their in vitro immunogenicity can be demonstrated by the generation of peptide-specific T cell lines. Typical results of flow cytometry detection after staining of the two peptides of the present invention with TUMAP-specific multimers are shown in Figure 1. Figure 3 Other typical results of flow cytometry detection after TUMAP-specific multimer staining of the three peptides of the present invention are shown in FIG. Figure 4 The results of the 17 peptides of the present invention are summarized in Table 10A. Other results of the 17 peptides of the present invention are summarized in Table 10B.
[0475] Table 10A: In vitro immunogenicity of HLA class I peptides of the present invention
[0476] Exemplary results of in vitro immunogenicity experiments conducted by the applicant on the peptides of the present invention. <20% = +; 20%-49% = ++; 50%-69% = +++; > = 70% = ++++
[0477]
[0478] Table 10B: In vitro immunogenicity of HLA class I peptides of the present invention Exemplary results of in vitro immunogenicity experiments conducted by applicants on HLA-A*02 restricted peptides of the present invention. The results of in vitro immunogenicity experiments are shown. The percentage of positive wells and donors (others can be evaluated) is summarized as <20% = +; 20%-49% = ++; 50%-69% = +++; > = 70% = ++++
[0479]
[0480]
[0481] Example 4 Synthesis of peptide
[0482] All peptides were synthesized by standard, well-accepted solid phase peptide synthesis using the Fmoc strategy. The identity and purity of each peptide was confirmed using mass spectrometry and RP-HPLC analysis. Lyophilization (trifluoroacetate) yielded white to off-white peptides with a purity of >50%. All TUMAPs are preferably administered as trifluoroacetate or acetate, but other pharmaceutically acceptable salt forms are also possible.
[0483] Example 5 MHC binding assay
[0484] The candidate peptides for T cell therapy of the present invention are further tested for their MHC binding ability (affinity). Single peptide-MHC complexes are produced by UV-ligand exchange, wherein the UV-sensitive peptide is cleaved after UV irradiation and exchanged with the relevant peptides analyzed. Only candidate peptides that can effectively bind and stabilize the peptide-receiving MHC molecules can prevent the dissociation of the MHC complex. In order to determine the yield of the exchange reaction, an ELISA assay is performed based on the detection results of the stable MHC complex light chain (β2m). The detection is generally carried out according to the method described by Rodenko et al. (Rodenko et al., 2006).
[0485] 96-well MAXISorp plates (NUNC) were coated with 2ug / ml streptavidin in PBS at room temperature overnight, washed four times and blocked in 2% BSA in blocking buffer at 37°C for 1 hour. Folded HLA-A*02:01 / MLA-001 monomers were used as standards, covering the range of 15-500ng / ml. Peptide-MHC monomers for UV exchange reactions were diluted 100-fold in blocking buffer. Samples were incubated at 37°C for 1 hour, washed four times, incubated with 2ug / ml HRP-conjugated anti-β2m at 37°C for 1 hour, washed again, and detected with TMB solution blocked with NH2SO4. Absorption was measured at 450nm. When generating and producing antibodies or fragments thereof and / or T cell receptors or fragments thereof, candidate peptides that show high exchange yields (preferably above 50%, most preferably above 75%) are generally preferred because they show sufficient affinity for MHC molecules and can prevent the dissociation of the MHC complex.
[0486] Table 11: MHC class I binding scores. Binding of HLA class I restricted peptides to HLA-A*02:01 was categorized according to peptide exchange yield: >10% = +; >20% = ++; >50 = +++; >75% = ++++
[0487]
[0488]
[0489] In addition, this application includes but is not limited to the following: Item 1. A peptide and a pharmaceutically acceptable salt thereof, wherein the peptide comprises an amino acid sequence selected from SEQ ID No.1 to SEQ ID No.91, and a variant sequence thereof having at least 88% homology with SEQ ID No.1 to SEQ ID No.91, wherein the variant peptide binds to the major histocompatibility complex (MHC) and / or induces T cells to cross-react with the variant peptide, wherein the peptide is not a full-length polypeptide. Item 2. A peptide or variant thereof according to Item 1, wherein the total length of the peptide or variant thereof is 8 to 100 amino acids, preferably 8 to 30 amino acids, more preferably 8 to 16 amino acids, and most preferably the peptide consists of or essentially consists of the amino acid sequence of any one of SEQ ID No. 1 to SEQ ID No. 91. Item 3. A peptide or variant thereof according to Item 1 or 2, wherein the peptide is modified and / or comprises non-peptide bonds, or wherein the peptide is part of a fusion protein, in particular part of a fusion protein comprising the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). Item 4. An antibody, particularly a soluble or membrane-bound antibody, which specifically recognizes the peptide or variant thereof according to any one of Items 1 to 3, preferably the peptide or variant according to Item 1 or 2 when bound to an MHC molecule. Item 5. A T cell receptor, preferably a soluble or membrane-bound T cell receptor, which reacts with an HLA ligand, wherein the ligand has at least 75%, preferably at least 88% identity with an amino acid sequence selected from SEQ ID No.1 to SEQ ID No.91, or wherein its amino acid sequence consists of any one of SEQ ID No.1 to SEQ ID No.91. Item 6. A T cell receptor according to Item 5, wherein the T cell receptor is provided as a soluble molecule and optionally carries other effector functions, such as an immunostimulatory domain or a toxin. Item 7. An aptamer that specifically recognizes the peptide or variant thereof described in any one of Items 1 to 3, preferably the peptide or variant thereof that binds to an MHC molecule described in any one of Items 1 to 2. Item 8. A nucleic acid, or an expression receptor expressing the nucleic acid, wherein the nucleic acid encodes the peptide or variant thereof described in any one of Items 1 to 3, the antibody described in Item 4, the T cell receptor described in Item 5 or 6, or the aptamer described in Item 7, wherein the nucleic acid is optionally linked to a heterologous promoter sequence. Item 9. A recombinant host cell comprising the peptide described in any one of Items 1 to 3 and the expression vector described in Item 8, wherein the host cell is preferably selected from antigen presenting cells, such as dendritic cells, T cells or NK cells. Item 10. Use of the peptide or variant thereof described in any one of Items 1 to 3, the antibody described in Item 4, the T cell receptor described in Item 5 or 6, the aptamer described in Item 7, the nucleic acid or expression vector described in Item 8, or the host cell described in Item 9 in medicine. Item 11. A method for preparing the peptide or variant thereof described in any one of Items 1 to 3, the antibody described in Item 4, or the T cell receptor described in Item 5 or 6, the method comprising culturing the host cell described in Item 9, the host cell expressing the nucleic acid or expression vector described in Item 8, and isolating the peptide or variant thereof, antibody or T cell receptor from the host cell or its culture medium. Item 12. A method for preparing activated T lymphocytes in vitro, the method comprising contacting T cells with human class I or II MHC molecules loaded with antigens in vitro for a period of time sufficient to activate T cells in an antigen-specific manner, wherein the human class I or II MHC molecules are expressed on the surface of a suitable antigen-presenting cell or on the surface of an artificial construct that simulates an antigen-presenting cell, wherein the antigen is a peptide as described in any one of items 1 to 2. Item 13. An activated T lymphocyte prepared by the method described in item 12, which selectively recognizes a cell that presents a polypeptide containing the amino acid sequence given in any one of items 1 to 2. Item 14. A pharmaceutical composition comprising at least one active ingredient selected from the following: a) a peptide selected from SEQ ID No. 1 to SEQ ID No. 91; b) a T cell receptor reactive with the peptide and / or peptide-MHC complex described in a); c) a fusion protein comprising the peptide in a) and the 1 to 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii); d) a nucleic acid encoding any one of a) to c) or an expression vector comprising the nucleic acid; e) a host cell comprising the expression vector of d); f) activated T lymphocytes obtained by the following method, which comprises contacting T cells with the peptides of a) expressed on the surface of suitable antigen-presenting cells in vitro for a period of time sufficient to activate the T cells in an antigen-specific manner, and transferring these activated T cells into autologous or other patients; g) antibodies or soluble T cell receptors reactive with the peptides and / or peptide-MHC complexes of a), and / or cells presenting the peptides of a), which may be modified by fusion with an immunoactivating domain or a toxin; h) an aptamer that recognizes a peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 91 and / or a complex of a peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 91 and an MHC molecule; i) a conjugate or a labeled peptide or a scaffold of a) to h), and a pharmaceutically acceptable carrier, or optionally, a pharmaceutically acceptable excipient and / or a stabilizer. Item 15. Use of the peptide or variant thereof described in any one of Items 1 to 3, the antibody described in Item 4, the T cell receptor described in Item 5 or 6, the activated T lymphocyte described in Item 13, the nucleic acid or expression vector described in Item 8, or the host cell described in Item 9 in the diagnosis and / or treatment of cancer or in the preparation of anti-cancer drugs, wherein the cancer is preferably selected from head and neck squamous cell carcinoma, acute myeloid leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, bladder cancer, uterine cancer and other tumors, which overexpress proteins from which peptides of SEQ ID No. 1 to SEQ ID No. 91 can be derived. Item 16. A kit comprising: (a) a container comprising a pharmaceutical composition, which contains the peptide or variant thereof described in any one of Items 1 to 3, the antibody described in Item 4, the T cell receptor described in Item 5 or 6, the activated T lymphocyte described in Item 13, the nucleic acid or expression vector described in Item 8, or the host cell described in Item 9, in the form of a solution or lyophilized; (b) optionally, a second container containing a diluent or reconstitution fluid for the lyophilized formulation; (c) optionally, at least one peptide selected from SEQ ID No. 1 to SEQ ID No: 156, preferably SEQ ID No. 1 to SEQ ID No: 91, and (d) optionally, instructions for (i) using the solution or (ii) reconstitution and / or use of the lyophilized formulation. Item 17. A method for producing a personalized anti-cancer vaccine or compound therapy and / or cell therapy for an individual patient, the method comprising: a) Identify tumor-associated peptides (TUMAPs) presented by tumor samples from individual patients; b) comparing the peptides identified in a) to a library of peptides that have been pre-screened for immunogenicity and / or over-presentation in tumors relative to normal tissues; c) selecting at least one peptide in the library that matches a TUMAP identified in the patient; and d) producing and / or preparing a personalized vaccine or compound therapy or cell therapy based on step c). Item 18. The method according to Item 17, wherein the TUMAP is identified by the following method: a1) comparing the expression data of the tumor sample with the expression data of a normal tissue sample corresponding to the tissue type of the tumor sample to identify proteins that are overexpressed or abnormally expressed in the tumor sample; and a2) Correlating the expression data with the sequences of MHC ligands bound to MHC class I and / or class II molecules in the tumor sample to identify MHC ligands derived from proteins that are over-expressed or aberrantly expressed by the tumor. Item 19. A method according to Item 17 or 18, wherein the peptides contained in the library are identified based on the following steps: aa. Whole-genome messenger RNA (mRNA) expression analysis by highly parallel methods, such as microarray or sequencing-based expression profiling, including identification of genes overexpressed in malignant tissue compared to normal tissue; ab. selecting a peptide encoded by a gene selectively expressed or overexpressed detected in step aa, and ac. determining the induction of an in vivo T cell response by the selected peptide, including an in vitro immunogenicity assay using human T cells from a healthy donor or the patient; or ba. identifying HLA ligands from the tumor sample by mass spectrometry; bb. Genome-wide messenger RNA (mRNA) expression analysis by highly parallel methods, such as microarray or sequencing-based expression profiling, including identification of genes overexpressed in malignant tissue compared to normal tissue; bc. comparing the identified HLA ligands with the gene expression data; bd. a peptide encoded by a gene selectively expressed or overexpressed detected in step bc; be. re-detecting the TUMAPs selected by step bd that are absent or infrequently detected on tumor tissue and on healthy tissue, and determining the relevance of overexpression at the mRNA level; and bf. Determination of the induction of in vivo T cell responses by the selected peptides, including in vitro immunogenicity assays using human T cells from healthy donors or the patients described. Item 20. A method according to any one of Items 17 to 19, further comprising identifying at least one mutation that is unique to the tumor sample compared to the corresponding normal tissue of the individual patient, and selecting a peptide associated with the mutation for inclusion in a vaccine or for use in producing a cell therapy. References Abdel-Ghany,M.et al,J Biol Chem 276(2001):25438-25446 Abdelmagid,SAet al,J Cell Biochem.112(201 1):1084-1092 Adhikary,G.et al,PLoS.One.8(2013):e84324 Aguiar, R Et al, J Biol Chem 280(2005):33756-33765 Ahmed, N. et al, Biol Chem 397 (2016): 1265-1276 Ai,R.et al.,Gene Expr.11(2003):35-45 Aisa,Y.et al,Int.J Hematol.82(2005):266-269 Aizawa,S.et al,J Oral Sci.56(2014):209-214 Akbari,MRet al,Hum.Genet.129(2011):573-582 Akhtar,Ali M.et al,Proc.Natl.Acad.Sci.USA 112(2015):7743-7748 Albergaria,A.et al,Int.J Dev. 55(201 1):811-822 Allison,JPet al,Science 270(1995):932-933 Alrawi,SJet al,Anticancer Res 26(2006):107-1 19 Ammendola,M.et al,Biomed.Res Int.2014(2014):154702 Andersen,RSet al,Nat.Protoc.7(2012):891-902 Andersson,L.,Cold Spring Harb.Symp.Quant.Biol 74(2009):319-325 Andersson,L.et al.,Transcription.1(2010):144-148 Annibaldi,A.et al,PLoS.One.6(201 1):e29024 Apostolopoulou,M.et al,PLoS.One.7(2012):e33289 Appay,V.et al,Eur.J Immunol.36(2006):1805-1814 Arif,Q.et al,Arch.Pathol.Lab Med.139(2015):978-980 Attallah,A.M.et al,Tumour.Biol 36(2015):7667-7674 Baak,J.P.et al,J Clin Pathol.59(2006):1017-1028 Bachmann,S.B.et al,Mol Cancer 13(2014):125 Baglo,Y.et al,PLoS.One.8(2013):e65200 Bailey,C.M.et al.,J Cell Physiol 209(2006):617-624 Balakrishnan,A.et al.,Genes Chromosomes.Cancer 45(2006):883-892 Baluchamy,S.et al,In Vitro Cell Dev.Biol Anim 46(2010):718-725 Banchereau,J.et al,Cell 106(2001):271-274 Bao,L.et al,Cell Biol Toxicol.32(2016):419-435 Bar-Shavit,R.et al.,Methods Cell Biol 132(2016):341-358 Barach,Y.S.et al.,Trends Mol. 17(201 1):47-55 Barilli,A.et al,J Leukoc.Biol 90(2011):293-303 Barry,G.S.et al,Oncotarget.7(2016):18953-18964 Bauml,J.M.et al,Ther.Adv.Med.Oncol 8(2016):168-175 Bausch, D. et al, Clin Cancer Res 17(2011):302-309 Beatty,G.et al.,J Immunol 166(2001):2276-2282 Beggs, JD, Nature 275(1978):104-109 Benjamini,Y.et al,Journal of the Royal Statistical Society.Series B(Methodological),Vol.57(1995):289-300 Benzon,B.et al,Prostate Cancer Prostatic.Dis.(2016) Binai, NA et al., Endocrine.44(2013):496-503 Blanckaert,V.et al,Int.J Oncol 46(2015):2649-2655 Bongiovanni,L.et al,Vet.Dermatol.25(2014):138-140 Bonitsis, N. et al, Exp. 28(2006):187-193 Bottino,C.et al,Front Immunol.5(2014):56 Bouameur,JEet al.,J Invest Dermatol.134(2014):885-894 Boulter,JMet al,Protein Eng 16(2003):707-711 Boyero, L. et al, Int.J Med Sci. 10 (2013): 1 166-1173 Braumuller,H.et al.,Nature(2013) Brendle,A.et al.,Carcinogenesis 29(2008):1394-1399 Broderick,P.et al.,Cancer Res 69(2009):6633-6641 Brosens,R.P.et al,J Pathol.221(2010):411-424 Brossart,P.et al,Blood 90(1997):1594-1599 Bruckdorfer,T.et al.,Curr.Pharm.Biotechnol.5(2004):29-43 Bruna,F.et al,Stem Cell Res 18(2017):5-13 Bryan,R.T.,Philos.Trans.R Soc.Lond B Biol Sci.370(2015):20140042 Bryan,R.T.et al,J Urol.184(2010):423-431 Bu,W.et al,Oncogene 30(2011):4399-4409 Bustin,S.A.et al,DNA Cell Biol 20(2001):331-338 Buttner,S.et al,EMBO J 30(201 1):2779-2792 Cada,Z.et al.,Histol.Histopathol.24(2009):41-48 Camicia,R.et al,J Cell Sci.126(2013):1969-1980 Camicia,R.et al,Mol.Cancer 14(2015):207 Campione,E.et al,Drug Des Devel.Ther.9(2015):5843-5850 Camps,J.et al,Cancer Res 73(2013):2003-2013 Canto,I.et al,Mini.Rev Med Chem 12(2012):804-811 Card,.F.et al,Cancer Immunol Immunother.53(2004):345-357 Cazier,J.B.et al,Nat Commun.5(2014):3756 Chang,Het al,Cancer 117(2011):353-360 Chanock,SJet al,Hum.Immunol.65(2004):1211-1223 Chanthammachat,P.et al,Arch.Oral Biol 58(2013):1677-1685 Chen,J.et al,Int.J Clin Exp.Pathol.8(2015):2026-2032 Chen,L.et al,Oncotarget.(2016) Chen,Q.et al,PLoS.One.9(2014):e88386 Dog,AJet al,Breast Cancer Res Treat.155(2016):521-530 Choi,JRet al,Ann.Occup.Environ.Med 28(2016):13 Choi,YKet al,Cancer Genomics Proteomics.10(2013):265-275 Chowdhury,R.et al.,Nature 510(2014):422-426 Chuang,JJet al,Toxicol.Appl.Pharmacol.279(2014):322-330 Chung, T et al, Int. J Cancer 137(2015):776-783 Cipolat,S.et al,Elife.3(2014):e01888 Clark,D Let al.,J Anim Sci.93(2015):2546-2558 Cohen,CJet al,J Mol Recognit.16(2003a):324-332 Cohen, CJet al, J Immunol 170(2003b):4349-4361 Cohen,SNet al,Proc.Natl.Acad.Sci.USA 69(1972):2110-21 14 Coligan,JEet al.,Current Protocols in Protein Science(1995) Colombetti,S.et al.,J Immunol.176(2006):2730-2738 Corsaro,A.et al,Oncotarget.7(2016):38638-38657 DAsti,E.et al,Semin.Thromb.Hemost.40(2014):284-295 Das,M.et al,PLoS.One.8(2013):e69607 Das,M.et al,Tumour.Biol 36(2015):9987-9994 David,G.et al.,Oncogene 25(2006):7354-7360 Davies,ELet al.,Eur.J Cancer 35(1999):902-907 Delgado,APet al,Cancer Genomics Proteomics.11(2014):201-213 Deng,M.et al,J Biol Chem 284(2009):7875-7888 Deng,W.et al,Cell Physiol Biochem.35(2015):1677-1688 Deng,Y.et al.,Cancer Invest 31(2013):97-102 Dengjel,J.et al,Clin Cancer Res 12(2006):4163-4170 Denkberg,G.et al,J Immunol 171(2003):2197-2207 Depiant,D.et al,Nat Genet.42(2010):910-914 Dewar,R.et al,Arch.Pathol.Lab Med 135(201 1):422-429 do Prado,RFet al.,Oral Surg.Oral Med Oral Pathol.OralRadiol.Endod.104(2007):e40-e44 Dorn,J.et al,Oncol Lett.9(2015):418-424 Dotlic,S.et al,Appl.Immunohistochem.Mol.Morphol.22(2014):537-542 Dou,N.et al,Am.J Cancer Res 6(2016):2641-2650 Drucker,KLeth al.,BMC.Cancer 15(2015):565 Du,L.et al,Cancer Res 73(2013):2682-2694 Dubash,ADet al,J Cell Biol 202(2013):653-666 Duggan,MA,Gan To Kagaku Ryoho 29 Suppl 1(2002):176-193 Economopoulou,P.et al,Ann.Transl.Med.4(2016):173 Eichler,TEet al.,Kidney Int.90(2016):568-579 El-Rifai,W.et al,Cancer Res 62(2002):6823-6826 Elste,APet al,J Mol.Histol.41(2010):89-99 Epp,N.et al,J Cell Biol 177(2007):173-182 Er,TKet al,J Mol.Med.(Berl)(2016) Esteban-Jurado,C.et al,Eur J Hum.Genet.24(2016):1501-1505 Ettl,T.et al.,Clin Exp.Med(2016) Evangelist,MTet al,J Skin.Pathol.42(2015):824-831 Falk,K.et al,Nature 351(1991):290-296 Fan,J.et al,Clin Cancer Res 17(2011):2908-2918 Fang,WKet al,Asian Pac.J Cancer Prev.15(2014):871-876 Fang, WYet al., Acta Biochim.Biophys.Sin.(Shanghai) 37(2005):541-546 Fauci,JMet al,Gynecol.Oncol 127(2012):420-425 Fever-Montange,M.et al,Int.J Oncol 35(2009):1395-1407 Fijneman,RJet al,Clin Cancer Res 18(2012):2613-2624 Fong,L.et al.,Proc.Natl.Acad.Sci.USA 98(2001):8809-8814 French,J.et al,Histochem.J 34(2002):223-231 Frohwitter,G.et al,Oncol Lett.12(2016):107-113 Funakoshi-Tago, M., Water Resources 132(2012):1267-1272 Furstenberger,G.et al,Prostaglandins Other Lipid Mediators.82(2007):128-134 Gabrilovich,DIet al.,Night Med.2(1996):1096-1 Galoian,K.et al,Mol.Clin Oncol 3(2015):171-178 Gandhi,CRet al,Gastroenterology 148(2015):379-391 Gao,W.et al,BMC.Cancer 15(2015):367 Gao,Y.et al.,Di Yi.Jun.Yi.Da.Xue.Xue.Bao.23(2003):885-887 Gao,YBet al.,Nat Genet.46(2014):1097-1102 Gattinoni,L.et al,Nat Rev.Immunol 6(2006):383-393 Gazda,HTet al,Hum.Mutat.33(2012):1037-1044 Ge,W.et al,Nat Chem Biol 8(2012):960-962 Gelfand,R.et al,Int. 50(2017):49-65 Gemmill,RMet al,Cancer Lett.300(2011):66-78 Gieseler,F.et al,Cell Commun.Signal.11(2013):86 Giguere,A.et al.,Cancer Genet.Cytogenet.202(2010):94-100 Gnjatic,S.et al.,Proc Natl.Acad.Sci.USA 100(2003):8862-8867 Godkin,A.et al.,Int.Immunol 9(1997):905-911 Gomez-Morales,M.et al,Histopathology 63(2013):103-113 Gorski,J.J.et al,Breast Cancer Res Treat.122(2010):721-731Green,M.R.et al,Molecular Cloning,A Laboratory Manual 4th(2012)Greenfield,E.A.,Antibodies:A Laboratory Manual 2nd(2014) Grin,A.et al,Hum.Pathol.46(2015):541-548 Grosset,A.A.et al,BMC.Cancer 14(2014):801Grosset,A.A.et al,PLoS.One.11(2016):e0166731Gruber,A.D.et al.,Cancer Res 59(1999):5488-5491Gupta,S.K.et al.,Innate.Immun.19(2013):86-97Haass,N.K.et al.,Pigment CellRes 18(2005):150-159 Hammam,O.et al,J Egypt.Soc.Parasitol.44(2014):733-740 Harris,T.M.et al,Arch.Pathol.Lab Med.139(2015):494-507Hatina,J.etal.,Neoplasma 59(2012):728-736Hatta,M.et al.,J Obstet.Gynaecol.Res 30(2004):53-58Hayes,D.C.et al,Anticancer Res 26(2006):1567-1575He,C.S.et al.,CellPhysiol Biochem.40(2016):1221-1229 He,X.et al,Int.J Biol Macromol.72(2015):1081-1089Heidenreich,B.et al,Curr.Opin.Genet.Dev.24(2014):30-37 Heikinheimo,.et al,J Dent.Res 86(2007):544-549Heikinheimo,K.et al,JDent.Res 94(2015):101-1 11Herold-Mende,C.et al,Cell Tissue Res 306(2001):399-408 Higareda-Almaraz,JCet al.,BMC.Cancer 16(2016):680 Hoadley,KAet al,PLoS.Med l3(2016):el 002174Honrado,E.et al,Crit RevOncol Hematol.59(2006):27-39 Horiguchi,K.et al,Oncogene 31(2012):3190-3201Hu,J.et al,Int.J ClinExp.Pathol.8(2015):9182-9188Huang,YPet al,Biomedicine.(Taipei)6(2016):3Huang,YZet al.,Sci.Rep.4(2014):4570 Huber,ARet al.,BMC.Gastroenterol.15(2015):80 Hwang,MLet al,J Immunol.179(2007):5829-5838 Hwang,YSet al.,J Cancer Prev.20(2015):121-128 Ida-Yonemochi,H.et al.,Mod.Pathol.25(2012):784-794 lino,I.et al,Cancer Sci.104(2013):624-630 Inamura,K.et al,Lung Cancer 103(2017):44-51 Ioana,M.et al,J Gastrointestin.Liver Dis.19(2010):155-159 Iorns,E.et al.,Breast Cancer Res Treat.135(2012):79-91 Ishii,H.et al,J Biol Chem 289(2014):27386-27399 Ishimi,Y.et al,J Biochem.157(2015):561-569 Janakiram,M.et al,Discov Med 14(2012):229-236 Janakiram, M.et al, Immunotherapy 8(2016):809-819 Jiang,L.et al.,PLoS.One.9(2014):e94187 Jiang,MMet al,Zhongguo Shi Yan.Xue.Ye.Xue.Za Zhi.21(2013):821-829 Jiang,R.et al,J Biol Chem 286(2011):9127-9135 Jiang,Y.et al,Oncol Lett.10(2015):3826-3831 Johnson,RHet al.,Oncotarget.(2015) Joosse, SAet al., Clin Cancer Res 18(2012):993-1003 Jung,G.et al, USA 84(1987):4611-4615 Jurcic,V.et al,Histol.Histopathol.30(2015):945-953 Juszczynski,P.et al,Mol.Cell Biol 26(2006):5348-5359 Kakuda,DKet al,Biochim.Biophys.Acta 1414(1998):75-84 Can,T.et al,Oncology 70(2006):25-33 Kaplun,A.et al,Crit Rev Eukaryot.Gene Expr.22(2012):249-258 Kasthuri,R.S.et al,J Clin Oncol 27(2009):4834-4838 Katada,K.et al.,J Proteomics.75(2012):1803-1815 Katoh,M.,Int.J Oncol 41(2012):1913-1918 Kawakami,K.et al,Int.J Oncol(2015) Kaz,A.M.et al,Genes Chromosomes.Cancer 51(2012):384-393 Kedde,M.et al.,Cell Cycle 7(2008):899-903 Kettunen,E.et al.,Cancer Genet.Cytogenet.149(2004):98-106 Kibbe,A.H.,Handbook of Pharmaceutical Excipients rd(2000) Kim,H.J.et al,Anticancer Res 33(2013):1555-1561 Kim,K.et al.,Int.J Colorectal Dis.23(2008a):569-580 Kim,K.H.et al,Nucleic Acids Res 43(2015):7462-7479 Kim,S.W.et al.,Blood 111(2008b):1644-1653 Kim,T.W.et al.,Oncotarget.(2016) Kim,Y.H.et al,Ann.Surg.Oncol 18(201 1):2338-2347 Kinyamu,H.K.et al,Mol.Carcinog 47(2008):845-885 Kishikawa,T.et al.,Oncotarget.6(2015):8339-8352 Kitchen,M.O.et al.,Epigenetics.11(2016):237-246 Klawitter,J.et al.,Breast Cancer Res 12(2010):R16 Knudsen,K.A.et al,J Cell Biochem.95(2005):488-496 Koba,S.et al.,Am.J Dermatopathol.37(2015):e31-e36 Kobos,R.et al.,J Pathol.229(2013):743-754 Koc,E.C.et al.,Mitochondrion.24(2015):113-121 Kocaturk,B.et al,Thromb.Res 129 Suppl 1(2012):S69-S75 Kocaturk,B.et al,J Thromb.Haemost.11 Suppl 1(2013):285-293 Kohn,K.W.et al.,PLoS.One.9(2014):e99269 Kolin,D.L.et al.,Biol Chem 395(2014):1087-1093 Koringa,P.G.et al,Vet.Comp Oncol(2013) Krepischi,A.C.et al,Breast Cancer Res 14(2012):R24 Krieg,A.M.,Nat Rev.Drug Discov.5(2006):471-484 Kwok,H.F.et al,Am. 5(2015):52-71 Kwon,J.et al.,Int J Oncol 43(2013):1523-1530 Labrie,M.et al.,PLoS.One.10(2015):e0131307 Labrie,M.et al.,Oncotarget.5(2014):7705-7721 Lee,DJet al.,Cancer Biol Ther.10(2010):689-693 Lee,DMet al.,Environ.Toxicol.Pharmacol.34(2012):858-868 Lee, J Y et al, Carcinogenesis 30(2009):1528-1531 Lee, KY et al., J Med.35(2004):141-149 Leiserson, MDet al, Genome Biol 16(2015):160 Leiserson, MDet al, Genome Biol 17(2016):168 Leung,F.et al.,Cancer Epidemiol.Biomarkers Prev.25(2016):1333-1340 Leung,J.et al,Immune.Netw.14(2014):265-276 Lexander, H. et al, Anal.Quant.Cytol.Histol.27(2005):263-272 Li, J. et al, Chin Med J(Engl.) 122(2009):486-495 Li,JZet al.,Chin Med.J(Engl.)121(2008):1882-1890 Li,L.et al.,Asian Pac.J Cancer Prev.13(2012a):3265-3270 Li,T.et al,Exp.Dermatol.24(2015):342-348 Li, WQ et al, Carcinogenesis 34(2013):1536-1542 Li,X.et al,Oncogene 23(2004):1474-1480 Li,X.et al.,Biochem.Biophys.Res Commun.419(2012b):148-153 Li,Y.et al,J Cell Physiol 212(2007):675-681 Lian,M.et al,PLoS.One.8(2013):e84854 Liddy,N.et al.,Nat Med.18(2012):980-987 Lim,L.C.et al.,Pathol.Oncol Res 22(2016):169-177 Lima,L.G.et al.,Biosci.Rep.33(2013) Lin,C.S.et al,Cancer Lett.368(2015):36-45 Lin,H.S.et al.,Arch.Otolaryngol.Head Neck Surg.130(2004):311-316 Lion,M.et al,Cell Cycle 12(2013):1211-1224 Liu,C.L.et al,Eur.Rev Med Pharmacol.Sci.20(2016):4466-4473 Liu,D.Q.et al.,Sci.Rep.5(2015):1 1955 Liu,J.et al,J Biochem.148(2010):659-667 Liu,Y.et al,Oncol Rep.18(2007):943-951 Ljunggren,H.G.et al,J Exp.Med.162(1985):1745-1759 Llorente,A.et al,J Cell Sci.117(2004):5343-5351 Lo,W.Y.et al,J Proteomics.77(2012):154-166 Lonardo,F.et al,Curr.Pharm.Des 16(2010):1877-1881 Longenecker,B.M.et al,Ann N.Y.Acad.Sci.690(1993):276-291 Lonsdale,J.,Nat.Genet.45(2013):580-585 Loos,M.et al,Clin Dev.Immunol.2010(2010):683875 Low,KCet al,Trends Biochem.Sci.38(2013):426-434 Lu,JJet al,Chin J Nat Med.13(2015a):673-679 Lu,Y.et al,BMC.Mol.Biol 16(2015b):21 Lu,Y.et al,PLoS.One.8(2013):e73866 Lubben,B.et al,J Biol Chem 270(1995):11549-1 1554 Lucito,R.et al.,Cancer Biol Ther.6(2007):1592-1599 Lukas,TJet al,Proc.Natl.Acad.Sci.USA 78(1981):2791-2795 Lundblad,RL,Chemical Reagents for Protein Modification 3rd(2004) Luo, D. et al., Biochem.Biophys.Res Commun.(2016) Maass, N. et al, Acta Oncol 39(2000):931-934 Maerki,S.et al.,J Cell Biol 187(2009):791-800 Man,Y.et al,Tohoku J Exp.Med 234(2014):29-40 Mange,A.et al,J Proteomics.142(2016):114-121 Marech,I.et al,World J Gastroenterol.20(2014):8910-8920 Marioni,G.et al.,Acta Otolaryngol.129(2009):476-480 Markljung,E.et al.,PLoS.Biol 7(2009):el000256 Marshall,PAet al,J Steroid Biochem.Mol.Biol 132(2012):147-159 Martinez,O.et al,PLoS.One.5(2010):el0398 Masugi,Y.et al,Lab Invest 95(2015):308-319 Morning,SFet al.,Urol.Oncol 32(2014):309-316 Matsumoto,K.et al.,Biomed.Res 35(2014):201-206 Matsuzaka,K.et al,Bull.Tokyo Dent.Coll.45(2004):229-233 McDoniels-Silvers, A Let al, Clin Cancer Res 8(2002):1127-1138 Mei,ZZet al,J Biol Chem 291(2016):18176-18189 Melaiu,O.et al,Mutat.Res 771(2015):6-12 Meschenmoser,K.et al,In Vivo 27(2013):431-442 Meslin, F. et al, Cancer Res 67(2007):10910-10919 Messina,M.et al,Blood 123(2014):2378-2388 Meziere, C. et al, J Immunol 159(1997):3230-3237 Min,L.et al.,Histopathology 67(2015):677-688 Misago, N. et al, J Dermatol. 43 (2016): 439-442 Mitchell,SMet al,BMC.Cancer 14(2014):54 Mlacki,M.et al,PLoS.One.9(2014):e89247 Morgan,PRet al,EurJ Cancer B Oral Oncol 30B(1994):160-166 Morgan, RA et al, Science 314(2006):126-129 Mori,M.et al,Transplantation 64(1997):1017-1027 Morris,LGet al,Nat Genet.45(2013):253-261 Morris, M et al., Oncogene 30(201 1):1390-1401 Mortara, L. et al, Clin Cancer Res. 12 (2006): 3435-3443 Moskvina,LVet al,Arkh.Patol.72(2010):58-61 Mountzios,G.et al,Ann.Oncol 25(2014):1889-1900 Mueller,LNet al,J Proteome.Res 7(2008):51-61 Mueller,LNet al.,Proteomics.7(2007):3470-3480 Mumberg,D.et al,Proc.Natl.Acad.Sci.USA 96(1999):8633-8638 Muramatsu,T.et al,Oral Oncol 39(2003):199-203 Mussai,F.et al,Blood 125(2015):2386-2396 Myklebust, MP et al, Br. J Cancer 106(2012):756-762 Naeem,ASet al,Cell Death.Differ.22(2015):2123-2132 Nagappan,A.et al.,BMC.Biochem.14(2013):24 Nagata,M.et al,PLoS.One.9(2014):e93164 Narayanan,BA,Curr.Cancer Drug Targets.6(2006):711-727 Narisawa,Y.et al,J Dermatol.42(2015):445-452 National Cancer Institute,(5-6-2015),www.cancer.gov Natsuga,K.et al.,J Invest Dermatol.(2015) Natsuga,.et al,J Invest Dermatol.136(2016):99-106 Neumann,M.et al,Blood 121(2013):4749-4752 North,JPet al,Am.J Surg.Pathol.39(2015):1347-1356 Novak,B.et al,Naunyn Schmiedebergs Arch.Pharmacol.384(2011):583-602 Nygren,MCet al,Front Biosci.(Elite.Ed)3(201 1):989-993 Oehler,VGet al.,Blood 114(2009):3292-3298 Oh,HRet al,Cell Oncol(Dordr.)37(2014):455-461 Oi,N.et al,Oncogene 34(2015):2660-2671 Oikonomopoulou,K.et al,Biol Chem 391(2010):299-310 Ormanns,S.et al,Br.J Cancer 113(2015):1460-1466 Otsubo,T.et al.,Cancer Med 4(2015):415-425 Palacios,J.et al,Pathobiology 75(2008):85-94 Papagerakis, S. et al, Hum.Pathol.34(2003):565-572 Paparella,MLet al,J Oral Pathol.Med 44(2015):801-809 Paredes,J.et al,Breast Cancer Res 9(2007):214 Paredes,J.et al.,Biochim.Biophys.Acta 1826(2012):297-31 1 Park,JYet al,Oncotarget.6(2015a):5342-5353 Park,YHet al,Int.J Cancer 136(2015b):1976-1984 Pereira,PMet al,Org.Biomol.Chem.12(2014):1804-1811 Perrin,C.et al,Am.J Dermatopathol.33(2011):131-139 Persson,F.et al,Cancer Lett.260(2008):37-47 Pickering, CRet al., Clin Cancer Res 20(2014):6582-6592 Pierce,A.et al,Mol.Cell Proteomics.7(2008):853-863 Pigullo,S.et al,Pediatr.Blood Cancer 52(2009):376-378 Pinheiro,J.et al.,nlme:Linear and Nonlinear Mixed Effects Models(http: / / CRAN.R- project.org / packe=nlme) (2015) Piura,B.et al,Harefuah 144(2005):261-5,303,302 Plebanski,M.et al.,Eur.J Immunol 25(1995):1783-1787 Poligone,B.et al,J Invest Dermatol.135(2015):869-876 Polotskaia,A.et al.,Proc.Natl.Acad.Sci.U.S.A 112(2015):E1220-E1229 Pondugula,S.et al,Mol.Cell Biol 29(2009):4891-4905 Porta,C.et al,Virology 202(1994):949-955 Preisz,K.et al.,Orv.Hetil.148(2007):979-983 Probst,C.et al,Clin Chim 410(2009):13-18 Qiu,S.et al,Cancer Sci.(2016) Qu,T.et al,Mol.Med Rep.14(2016):5041-5048 Rafhar,T.et al,Cancer Res 71(201 1):1356-1361 Ramakrishna,S.et al.,PLoS.One.7(2012):e37772 Ramakrishna,S.et al,J Biol Chem 286(2011):10505-10514 Ramani,D.et al,Clin Nutr.33(2014):14-22 Ramani,V.C.et al,BMC.Cancer 8(2008):373 Ramena,G.et al.,PLoS.One.11(2016):e0147489 Rammensee,H.et al.,Immunogenetics 50(1999):213-219 Rashid,R.et al,Mol.Cell 21(2006):249-260 Rastelli,F.et al,Tumori 96(2010):875-888 Ratovitski,E.A.,FEBS Lett.587(2013):3581-3586 RefSeq,The NCBI handbook[Internet],Chapter 18,(2002),http: / / www.ncbi.nlm.nih.gov / books / NBK21091 / Remmelink,M.et al,Histopathology 58(201 1):543-556 Resende,C.et al,Helicobacter.16 Suppl 1(2011):38-44 Reyes,C.et al,Appl.Immunohistochem.Mol.Morphol.21(2013):283-286 Ribeiro,A.S.et al.,Front Oncol 4(2014):371 Riker,A.I.et al.,BMC.Med Genomics 1(2008):13 Rini,B.I.et al,Cancer 107(2006):67-74 Rock,K.L.et al,Science 249(1990):918-921 Rohan,S.et al,Clin Cancer Res 12(2006):6937-6945 Rohrbeck,A.et al.,PLoS.One.4(2009):e7315 Rooney, M et al., Cell 160(2015):48-61 Rotmann,A.et al,Biochem.J 395(2006):1 17-123 Rotty,JDet al,J Cell Biol 197(2012):381-389 Ruf,W.,Thromb.Res 130 Suppl 1(2012):S84-S87 Ruf,W.et al,J Thromb.Haemost.9 Suppl 1(201 1):306-315 Rui,X.et al.,Int.J Clin Exp.Pathol.8(2015):5435-5442 Saaber,F.et al,Pathol.Res Pract.211(2015):208-213 Sabeti,S.et al,Indian J Dermatol.58(2013):331-336 Safadi,RAet al,Oral Surg.Oral Med.Oral Pathol.Oral Radiol.121(2016):402-411 Sager,R.et al,Cun-.Top.Microbiol.Immunol.213(Pt 1)(1996):51-64 Saiki,RKet al.,Science 239(1988):487-491 Salas, S. et al, Int.J Cancer 125(2009):851-860 Saletta,F.et al,BBA.Clin 1(2014):59-77 Sanchez-Palencia, A. et al, Int.J Cancer 129(2011):355-364 Sasaki,Y.et al,Cancer Biol Ther.13(2012):1512-1521 Sato,T.et al,Oncogene 33(2014):2215-2224 Sauer,H.et al,Free Radic.Biol Med 27(1999):1276-1283 Sawada,.et al.,J Oral Sci.58(2016):325-331 Schmitt-Graeff,A.et al,Histopathology 51(2007):87-97 Schrader,CHet al.,Mol.Cancer 14(2015):107 Schulten,R.et al,Naunyn Schmiedebergs Arch.Phannacol.385(2012):969-979 Schumann,H.et al.,Br J Dermatol.167(2012):929-936 Scola,N.et al,Br.J Dermatol.167(2012):591-597 Seal,S.et al,Cancer Res 63(2003):8596-8599 Sedda,S.et al,World J Gastroenterol.20(2014):11977-1 1984 Seeger,FHet al,Immunogenetics 49(1999):571-576 Seishima,M.et al.,Arch.Dermatol.140(2004):1500-1503 Sellheyer,K.,J Cutan.Pathol.42(2015):90-101 Sharifi,N.et al,Prostate 67(2007):301-311 Shen,M.et al,Environ.Mol.Mutagen 50(2009):285-290 Shen,X.et al,Tumor.Biol 36(2015):7133-7142 Sheng,S.,Front Biosci.9(2004):2733-2745 Sherman,F.et al.,Laboratory Course Manual for Methods in YeastGenetics(1986) Shi,L.et al,BMC.Cancer 16(2016):815 Shim,J.H.et al,Cancer Prev.Res(Phila)3(2010):670-679 Shimbo,T.et al,PLoS.One.5(2010):el0566 Shinmura,K.et al.,Dis.Markers 2014(2014):619273 Shruthi,D.K.et al,J Oral Maxillofac.Pathol.18(2014):365-371 Sidiropoulos,K.G.et al,Mol.Oncol 10(2016):993-1007 Silveira,A.C.et al,Cancer Lett.276(2009):32-37 Singh-Jasuja,H.et al.,Cancer Immunol.Immunother.53(2004):187-195 Sinha,N.et al.,Oral Oncol 49(2013):854-862 Sivanathan,L.et al,Prostate 74(2014):537-546 Sizemore,G.M.et al,J Biol Chem 289(2014):24102-241 13 Skipworth,R.J.et al.,Int.J Oncol 36(2010):973-982 Slaga,T.J.et al,Prog.Clin Biol Res 391(1995):1-20 Small,E.J.et al.,J Clin Oncol.24(2006):3089-3094 Smith,.T.et al,Mol.Cell Proteomics.11(2012):1815-1828 Sobolik-Delmaire,T.et al,Cell Commun.Adhes.14(2007):99-109 Solus,J.F.et al,Int.J Surg.Pathol.24(2016):29-36 Somasekharan,S.P.et al., 208(2015):913-929 Song,B.et al,Exp.Ther.Med 12(2016):2455-2468 Soreide,K.et al,J Pathol.209(2006):147-156 Southgate,J.et al,Histol.Histopathol.14(1999):657-664 Sturm,M.et al,BMC.Bioinformatics.9(2008):163 Sun,B.C.et al.,Zhonghua Yi.Xue.Za Zhi.86(2006):1808-1812 Sun,L.et al,Mol.Med Rep.12(2015a):4266-4272 Sun,N.K.et al,Oncotarget.6(2015b):27065-27082 Sun,S.et al,Gene 584(2016):90-96 Suzuki,A.et al.,Cancer Sci.99(2008):986-994 Swatler,J.et al.,Postepy Hig.Med Dosw.(Online.)70(2016):25-42 Swoboda,R.K.et al.,Cancer Res 67(2007):3555-3559 Tai,G.et al.,PLoS.One.8(2013):e81 167 Taintor,A.R.et al,J Am.Acad.Dermatol.56(2007):S73-S76 Tamir,A.et al,J Ovarian.Res 7(2014):109 Tamm-Rosenstein,K.et al.,PLoS.One.8(2013):e68907 Tang,B.et al.,Oncotarget.6(2015a):12723-12739 Tang,H.B.et al.,Zhonghua Yi.Xue.Za Zhi.88(2008):1553-1556 Tang,X.H.et al,Oncotarget.6(2015b):24424-24435 Taniguchi,T.et al,Nat Med 9(2003):568-574 Taoka,Y.et al.,Biomed.Res 36(2015):253-261 Tauber,S.et al,Mol.Cancer 9(2010):200 Teles,Alves,I et al,Oncogene 34(2015):568-577 Tennenbaum,T.et al,J Investig.Dermatol.Symp.Proc.1(1996):157-161 Teo,C.R.et al.,Cell Signal.28(2016):1479-1488 Terada,T.,Int.J Clin Exp.Pathol.5(2012):596-600 Teufel,R.et al,Cell Mol Life Sci.62(2005):1755-1762 Tian,S.Y.et al.,Int.J Clin Exp.Pathol.7(2014):3752-3762 Timar,J.et al,Clin Exp.Metastasis 27(2010):371-387 Tomlinson,R.L.et al,Mol.Biol Cell 19(2008):3793-3800 Tonoike,Y.et al,BMC.Cell Biol 12(201 1):41 Tran,E.et al,Science 344(2014):641-645 Trojandt,S.et al,Hum.Immunol.77(2016):1223-1231 Tsuji,ABet al.,Biochem.Biophys.Res Commun.333(2005):1370-1377 Tsutsui,M.et al.,Int.J Oncol 47(2015):867-874 Ueda,S.et al,Cancer Res 64(2004):5672-5676 Vadie,N.et al,RNA.Biol 12(2015):893-899 Vakrakou, A. et al, Biol Chem 395 (2014): 1 105-11 17 Valletta,D.et al,Carcinogenesis 35(2014):1407-1415 Vanaja, DK et al., Cancer Res 63(2003):3877-3882 Vasca,V.et al,Oncol Lett.8(2014):2501-2504 Vieira,AFet al,Mol.Cancer 14(2015):178 Vigneswaran,N.et al,Oral Maxillofac.Surg.Clin North Am.26(2014):123-141 Vliet-Gregg, PA et al., Virology 478(2015):50-60 Volkmer,JPet al,Proc.Natl.Acad.Sci.USA 109(2012):2078-2083 Walia,V.et al,Cancer Res 69(2009):6624-6632 Walia,V.et al,Oncogene 31(2012):2237-2246 Walter,S.et al.,J Immunol 171(2003):4974-4978 Walter,S.et al.,Nat Med.18(2012):1254-1261 Wang,J.et al.,Br.J Dermatol.153(2005):558-564 Wang,L.et al,J Cutan.Pathol.42(2015a):361-367 Wang,L.et al,Int.J Cancer 134(2014a):2764-2771 Wang,L.et al.,Tumour.Biol 37(2016a):14939-14947 Wang,M.et al,Exp.Dermatol.23(2014b):636-638 Wang,S.et al,Cytokine 86(2016b):110-1 18 Wang,X.et al,Oncotarget.7(2016c):22911-22927 Wang,X.et al,Proc.Natl.Acad.Sci.U.S.A 110(2013):15997-16002 Wang,X.et al,Mol.Cell Biol 27(2007):3098-3108 Wang,X.et al.,Eur.J Pharmacol.768(2015b):1 16-122 Wang,X.et al,Sci.Rep.6(2016d):19006 Wang,X.et al,Int.J Biol Markers 29(2014c):el50-el59 Wang,Z.S.et al,Oncotarget.7(2016e):44266-44276 Ward,A.M.et al.,R A.Biol 8(201 1):1173-1 186 Watanabe,T.et al.,Cancer Cell Int.10(2010):2 Wheler,J.J.et al,BMC.Cancer 15(2015):442 Willcox,B.E.et al.,Protein Sci.8(1999):2418-2423 Willers,I.M.et al,Biochim.Biophys.Acta 1807(2011):543-551 Williams,L.M.et al,Aquat.Toxicol.180(2016):141-154 Willis,S.et al.,Meta Gene 4(2015):129-141 Winslow,S.et al,Mol.Cancer 12(2013):156 Witte,D.et al,J Clin Med 5(2016) Wojtalewicz,N.et al.,PLoS.One.9(2014):e90461 Wojtukiewicz,M.Z.et al,Cancer Metastasis Rev 34(2015):775-796 Wong,M.P.et al.,Pathology 40(2008):61 1-616 World Health Organization,(2014),http: / / www.who.int / en / Wreesmann,V.B.et al,ORL J Otorhinolaryngol.Relat Spec.69(2007):218-225 Wu,S.et al,Oncotarget.(2016) Xi,Y.et al,Monoclon.Antib.Immunodiagn.Immunother.34(2015):346-353 Xie,C.et al.,Sci.Rep.6(2016a):27528 Xie,X.et al,Obesity.(Silver.Spring)24(2016b):389-397 Xin,Z.et al,Virchows Arch.465(2014):35-47 Xu,C.et al,PLoS.Genet.9(2013):el003169 Xu,X.et al,Proteomics.10(2010):1374-1390 Xue,LY et al.,Zhonghua Zhong.Liu Za Zhi.32(2010):838-844 Yadav,R.et al,J Neurochem.133(2015):857-869 Yamaguchi,T.et al,Exp.Dermatol.22(2013):840-842 Yamazaki,K.,Ultrastruct.Pathol.31(2007):209-219 Yang, C. et al, Tumor.Biol (2015) Yang,F.et al.,Biomed.Rep.4(2016a):681-686 Yang,HYet al,J Proteomics.75(2012a):3639-3653 Yang, J. et al, Curr. Opin. Oncol 25 (2013): 398-406 Yang,L.et al,Carcinogenesis 33(2012b):1863-1870 Yang, L. et al, J Biol Chem 291(2016b):3905-3917 Ye,Z.et al.,Cell Physiol Biochem.39(2016):1568-1580 Yermachenko,A.et al,Gene 590(2016):85-89 Yi,KHet al,ImmunoLRev 229(2009):145-151 Yi,Y.et al,Mol.Cytogenet.2(2009):18 Yong,A.A.et al.,Australas.J Dermatol.54(2013):241-250 Yongjun Zhang,M.M.et al,J Cancer Res Ther.9(2013):660-663 Yu,X.J.et al,EBioMedicine 2(2015a):583-590 Yu,Y.et al,ACS Appl.Mater.Interfaces.7(2015b):4401-4405 Yu,Y.et al.,PLoS.One.8(2013):e83943 Yun,C.W.et al.,Anticancer Res 36(2016):4449-4458 Zaremba,S.et al,Cancer Res.57(1997):4570-4577 Zdrojewicz,Z.et al,Postepy Hig.Med Dosw.(Online.)68(2014):393-403 Zekri,A.R.et al,Asian Pac.J Cancer Prev.16(2015):3543-3549 Zhang,H.et al.,Oncotarget.6(2015):17039-17053 Zhang,Q.et al.,Endocrinology 143(2002):4788-4796 Zhang,S.et al.,J Mol.Histol.45(2014a):283-292 Zhang,W.et al,Tumori 100(2014b):338-345 Zhang,Y.et al.,PLoS.One.7(2012):e30188 Zhao,L.H.et al,Genet.Mol.Res 14(2015):5417-5426 Zhao,LJet al,Chin Med.J(Engl.)126(2013):4260-4264 Zhao,S.et al.,Clin Cancer Res 23(2017):311-319 Zheng,G.et al.,FEBS J 277(2010):4506-4518 Zhou,L.et al,Int.J Cancer 135(2014):2329-2337 Zhou,P.et al,Eur.J Cancer Prev.21(2012):231-240 Zhou,X.et al.,Oncotarget.7(2016):67196-6721 1 Zhu,X.et al.,J Dermatol.34(2007):503-51 1 Zhu,Y.et al,Mol.Biol Cell 15(2004):81-90 Ziari,K.et al,Biologicals 43(2015):181-185 Ziegler,A.et al,Cancer Lett.326(2012):1-7 Zimmermann,J.et al.,J Dtsch.Dermatol.Ges.8(2010):598-606 Zubor,P.et al,Mol.Biol.Rep.42(2015):977-988
Claims
1. A peptide or a pharmaceutically acceptable salt thereof, the peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 2 and 4 to 91, wherein the total length of the peptide is up to 16 amino acids.
2. A nucleic acid encoding the peptide according to claim 1.
3. A recombinant host cell comprising the peptide according to claim 1 or the nucleic acid according to claim 2.
4. A method for preparing the peptide according to claim 1, characterized in that: The method comprises: culturing the recombinant host cell according to claim 3, and isolating the peptide from the host cell or its culture medium.
5. A method for preparing activated T lymphocytes in vitro, the method comprising contacting T cells with human class I or II MHC molecules loaded with antigens for a period of time in vitro sufficient to activate the T cells in an antigen-specific manner, wherein the human class I or II MHC molecules are expressed on the surface of a suitable antigen-presenting cell or on the surface of an artificial construct that simulates an antigen-presenting cell, wherein the antigen is a peptide according to claim 1.
6. An activated T lymphocyte produced by the method of claim 5, wherein the activated T lymphocyte selectively recognizes a cell presenting the peptide of claim 1.
7. A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of the peptide or pharmaceutically acceptable salt thereof according to claim 1, the nucleic acid according to claim 2, the recombinant host cell according to claim 3 or the activated T lymphocyte according to claim 6.
8. Use of the peptide or pharmaceutically acceptable salt thereof according to claim 1, the nucleic acid according to claim 2, the recombinant host cell according to claim 3 or the activated T lymphocyte according to claim 6 in the preparation of a medicament for diagnosing, preventing and / or treating cancer.
9. A kit comprising: (a) a container comprising a pharmaceutical composition, the pharmaceutical composition comprising the peptide or a pharmaceutically acceptable salt thereof according to claim 1, the nucleic acid according to claim 2, the recombinant host cell according to claim 3 or the activated T lymphocyte according to claim 6, in the form of a solution or a lyophilized product; (b) optionally, a second container comprising a diluent or reconstitution fluid for the lyophilized formulation; (c) optionally, at least one other peptide selected from the group consisting of SEQ ID NOs: 1 to 101; (d) optionally, one or more of (i) a buffer, (ii) a diluent, (iii) a filter, (iv) a needle, (v) a syringe, or (vi) an adjuvant.
10. An in vitro method for providing data for diagnosing cancer in a sample, the sample comprising cells from a subject, the method comprising: (a) adding antibodies or T cell receptors to a tissue sample of the subject, and (b) detecting the binding of the antibody or the T cell receptor to cells from the tissue sample from the subject, thereby identifying the presentation of the tumor-associated peptide of claim 1 on cells from the tissue sample from the subject, wherein the antibody or T cell receptor specifically recognizes (i) the peptide according to claim 1 or (ii) the peptide when bound to an MHC molecule.
Citation Information
Patent Citations
Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
EP1760088B1
T cell receptor display
US20100113300A1
Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US20130096016A1
T cell receptor fusions and conjugates and methods of use thereof
US20130115191A1
Solid phase anti-C3 assay for detection of immune complexes
US4342566A
Cited By
Small peptide for preventing and treating colon cancer and application thereof
CN121378411A
